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ABSTRACT OF THE DISSERTATION 
 
OMCP Mediated Cowpox Virulence and its Dependence on the Immune Receptors 
NKG2D and FCRL5. 
 
By 
Michel M. Sun 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology  
Washington University in Saint Louis, 2016 
Associate Professor Anthony R. French, Chair  
 
Viruses with large DNA genomes, such as cowpox virus, encode many open-reading 
frames involved in the modulation of the host immune system, facilitating escape from 
immune detection or downregulation of specific aspects of the host immune response.  
Investigation of virally-encoded immunoevasins has been instrumental in understanding 
host-pathogen interactions.  Here, we focus on the cowpox virus immunoevasin 
Orthopoxvirus MHC Class I-like Protein (OMCP) and demonstrate for the first time that 
OMCP facilitates cowpox virus virulence in vivo.  We have previously documented that 
OMCP binds the activating receptor NKG2D on NK cells as well as the orphan receptor 
FCRL5 on innate B cells.  By using NKG2D-deficient, FCRL5-deficient, and wild type 
mice, as well as recombinant cowpox viruses lacking OMCP or expressing a mutated 
form of OMCP that does not bind NKG2D, we were able to delineate the impact of 
OMCP targeting of each receptor.  We found that OMCP’s virulence in vivo could 
 xiv
largely be attributed to blocking NKG2D-mediated NK cell responses with no apparent 
effect due to binding to FCRL5 bearing innate B cells.  Interestingly, the delay in weight 
recovery observed in mice surviving WT cowpox compared to OMCP-deficient cowpox 
infection was not observed in NKG2D-deficient mice and was abrogated in WT mice by 
the depletion of NK cells on day 8 post-infection.  Additionally, we show that monomeric 
OMCP has a low affinity for FCRL5, although OMCP tetramers bind FCRL5 bearing 
cells well.  We further demonstrate that the OMCP binding interfaces for NKG2D and 
FCRL5 are distinct, raising the possibility that the low affinity binding to FCRL5 may be 
overcome by multivalent presentation of OMCP through clustering of OMCP complexes 
on cells expressing NKG2D.  This work delineates the impact of OMCP targeting of 
NKG2D and FCRL5 on cowpox virus virulence in vivo and highlights the importance of 
NKG2D-mediated control of orthopoxviruses.  
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 CHAPTER 1: Introduction   
Orthopoxvirus is a genus of poxviruses that includes several members with the capacity 
to infect humans, the best known of which is variola virus (VARV). Humans are the only 
host for variola virus, which causes smallpox, a highly contagious and often fatal 
infectious disease.  Other notable members include vaccinia virus (VACV), which was 
used in the worldwide eradication of smallpox, and the zoonotic cowpox virus (CPXV) 
and monkeypox virus (MPXV) both of which can infect man. Humans can become 
incidentally infected through contact with rodent reservoirs, as in the case of cowpox 
virus or monkeypox virus infection. During recent decades, there have been increasing 
reports of human monkeypox outbreaks in Africa and North America [1, 2], illustrating 
that these zoonoses are important emerging health threats, especially in this era of 
increasing encroachment on animal reservoir habitats, expanding foreign travel, and 
importation of exotic animal species. Monkeypox virus was involved in a large multi-
state outbreak linked to importation of prairie dogs in 2003. In total, 71 cases of 
monkeypox were reported in 5 states within a 1 month span, emphasizing that 
orthopoxviruses are capable of large scale, epidemiologically relevant outbreaks. 
Additionally, the cessation of routine childhood vaccination for smallpox, has rendered 
the population susceptible to possible bioterrorism attacks with smallpox, a Category A 
biological warfare pathogen. This constant threat to the unvaccinated and increasingly 
immunosuppressed population provides additional incentive for the study of 
orthopoxviruses and their interaction with human hosts. Our study seeks to better 
understand the mechanism of poxvirus immune evasion, with specific focus on the role 
of OMCP, a viral protein secreted by cowpox and monkeypox virus. Here we investigate 
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the role of viral OMCP on immune function in mice, the natural reservoir for these 
poxviruses, during both intraperitoneal and intranasal infection. We demonstrate that 
OMCP is involved in inhibition of NKG2D mediated NK cell killing in vivo, which may be 
critical for poxvirus clearance following infection.   
 
Previous Evaluation of OMCP 
Poxviruses have very large DNA genomes, allowing them to carry many accessory 
genes that are not required for viral replication and assembly. Many of these genes are 
involved in the manipulation of the immune system, facilitating escape of immune 
detection or downregulation of the immune response [3]. Members of the mammalian 
MHC Class I superfamily (MHCISF) in particular have been shown to be common 
targets for viral subversion. Many viral antagonists of the MHCISF, including viral 
NKG2D ligands, are known or predicted to adopt a class I-like fold themselves [4]. 
However, these viral antagonists have very low sequence homology to mammalian 
MHC Class I molecules, and fail to align with simple BLAST analysis. Faced with this 
problem, a structurally-constrained hidden Markov model was designed to search viral 
genomes for previously uncharacterized class I-like members that may serve as novel 
viral immunoevasins.  Once identified these immunoevasions could be used to probe 
pathways important in host defense [4]. Using this hidden Markov model (trained with 
class-I like sequences and constrained by crystallographic data), the orthopoxvirus 
protein OMCP (also known as CPXV018 or V018) was identified as a viral protein with a 
putative class I-like fold and therefore predicted to be involved in immune evasion. 
OMCP variants are encoded by both CPXV and MPXV. The form isolated from the 
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CPXV-Brighton Red strain will be referred to as OMCPbr, and that isolated from the 
MPXV-Zaire 1979 strain referred to as OMCPmpx. (The majority of the work described 
here is performed using OMCPbr, hence OMCP will refer to OMCPbr unless otherwise 
noted. For experiments involving receptors, both human and murine proteins were 
initially tested. Data reported will be with murine proteins unless specifically noted.) 
 
OMCP is secreted from infected cells [4]. Investigating whether OMCP recognized the 
NKG2D receptor was of particular interest, due to its putative MHC class I-like structure 
(proposed to be similar to the α1 and α2 domains of classical MHC class I), and 
because inhibition of NKG2D and its endogenous ligands is a common immune evasion 
strategy used by herpesviruses [5]. Subsequent crystal structure determination 
confirmed the MHC class I-like nature of OMCP (Fig 1). Upon examination, it was found 
that OMCP indeed recognizes both mouse and human NKG2D with high affinity, and is 
effective at inhibiting NKG2D dependent NK cell cytotoxicity by chromium release assay 
[4]. Thus, OMCP high-affinity binding to NKG2D prevents NK cell recognition of host 
stress ligands normally upregulated during viral infections.  
 
OMCP is a unique viral immunoevasin, in that it is the only known NKG2D antagonist 
from poxviruses. Previously identified NKG2D antagonists from HCMV and MCMV act 
by specifically inhibiting expression of some of the 8 human NKG2D ligands or 9 murine 
NKG2D ligands [6]. OMCP may therefore be a more efficient NKG2D antagonist, as it is 
directed toward the receptor itself, rather than suppressing expression of the host 
derived ligands. Crystallographic evidence suggests that OMCP binds orthogonally 
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across the NKG2D binding site in a way that at least partially overlaps with the binding 
of endogenous NKG2D ligands (Lazear et al, submitted). Notably, all other known 
NKG2D antagonists are surface expressed molecules, making OMCP the only known 
antagonist that is actively secreted from infected cells. Therefore, we hypothesize that 
secreted OMCP acts in a paracrine fashion around orthopoxvirus infected cells to 
saturate NKG2D receptors on approaching NK cell effectors and preventing NKG2D-
dependent killing.  
 
Given that OMCP is actively secreted into the inflammatory milieu, it is possible that it 
has additional actions on other host immune cells distinct from its inhibitory activity on 
NK cell mediated killing. When murine splenocytes and human PBMCs were tested for 
binding to OMCP, it was found that F4/80+ monocytes/macrophages and innate B cells 
(CD21hi CD23+/lo splenic marginal zone B cells and CD5+ peritoneal B-1a B cells) 
displayed significant OMCP binding in both mouse and humans (Fig 2) [7]. Because B 
cells do not express NKG2D, this observation suggested that additional receptors on B 
cells and macrophages are also capable of binding to OMCP. To identify these putative 
receptors, a retroviral cDNA library was constructed using a WEHI-231 B cell line with 
high surface expression of an OMCP binding receptor. This library was transduced into 
an OMCP receptor negative C1498 cell line, and repeated flow cytometric enrichment 
with OMCP tetramers was used to sort for OMCP staining cells. Genomic DNA was 
extracted from OMCP tetramer positive clones, retroviral inserts were amplified and 
sequenced, and FCRL5 was subsequently identified as the receptor responsible for 
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OMCP binding on innate B cells [8]. Binding of OMCP was validated by demonstrating 
binding to FCRL5 receptor transduced Ba/F3 cell lines (Fig 3) 
The FCRL5 receptor 
FCRL5 is a member of the Fc receptor-like family, a group of poorly characterized 
receptors that consist of Ig domains homologous to classical Fc receptor family 
members but do not bind immunoglobulin. Many FCRL’s, including FCRL5 are orphan 
receptors with unidentified endogenous ligands and unknown function. The contribution 
of FCRL5 to immunity has not been reported, and how the impact of FCRL5 is modified 
by OMCP binding remains unknown.  In addition, the role of innate B cells in antiviral 
immunity and host immunity in general, is unclear and poorly understood.  
 
The ligand for FCRL5 has not been identified, and the function of the receptor is 
complicated by the fact that it contains both a non-canonical ITAM and two canonical 
ITIMs in its cytoplasmic region [9]. The current paradigm is that FCRL5 has the potential 
to serve as an inhibitory co-receptor on mature B cells. The FCRL5 -/- mouse is 
available, but its phenotype has not been published. Consistent with the idea that 
OMCP may be targeting FCRL5 to give the virus a survival advantage, we expected 
that the FCRL5 -/- mouse will have a survival advantage compared to WT mouse when 
both are infected with OMCP-sufficient CPX, since the FCRL5 -/- is capable of avoiding 
one aspect of viral subterfuge that is likely to be detrimental to the host. However, 
FCRL5 -/- may have a disadvantage compared to WT when both are infected with 
OMCP-deficient CPX, since B cells in the FCRL5 -/- are lacking a possible immune 
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modulating receptor that in the situation without immunevasion targeting is deleterious 
to the cell.  
 
Despite significant effort by our laboratory to identify a role for OMCP binding to FCRL5 
on innate B cell function, no in vitro or in vivo effect has been established. OMCP 
incubation does not affect BCR-induced calcium mobilization in WEHI-231 cells 
stimulated with anti-IgM F(ab’)2, nor does soluble OMCP downregulate cell surface 
FCRL5 [7].  Additionally, no impact was identified on anti-CPX IgM production early 
during CPX infection. Interestingly, the OMCP-FCRL5 interaction was restricted to mice 
and not conserved with human FCRL analogs [7].  
 
We thoroughly investigated OMCP binding to NKG2D and the FCRL5 receptors. We 
present extensive evidence of OMCP targeting of NKG2D on NK cells and FCRL5 on 
innate B cells and its effects on cowpox virulence in vivo in Chapter 2. Here we 
demonstrate that OMCP has significant inhibitory effect on NKG2D receptors that 
accounts for the majority of OMCP’s virulence following cowpox infection. However, we 
find no evidence that OMCP binding to FCRL5 on innate B cells has an effect on murine 
survival or weight loss in vivo. Chapter 3 investigates a unique hypothesis of OMCP 
receptor crosslinking. Although we demonstrate here that OMCP crosslinking is 
plausible, we have not found conclusive data to confirm redirected NK cell killing. Finally, 
Chapter 4 offers future directions for continuation of this cowpox OMCP project. A 
discourse on problems we have encountered during our investigation of the OMCP 
binding receptor on macrophages is presented in Appendix 1.  
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Figures:      
 
 
Figure 1: CPX OMCP is an MHC Class I-Like protein 
The 2.25 Å resolution crystal structure of Brighton Red OMCP reveals an MHC class I 
like structure similar to known NKG2D ligands. Ribbon diagram of CPXV OMCP. 
Secondary structure elements are noted, S for beta strands and H for helix. The α1/α2 
portions of the platform domain are indicated in cyan and magenta, respectively. PDB 
ID = 4FFE 
Figure from Lazear et al. J. Virology 2013 [10] 
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Figure 2: OMCP binds to NK cells, innate B cells, and macrophages/monocytes in 
murine and human cells.  
Primary murine splenocytes or peritoneal lavage cells, or human PBMCs were stained 
for appropriate cell markers and binding to DIII tetramers (black) or OMCP tetramers 
(red). Figure taken from experiments presented in [4] and [8] 
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Figure 3: CPX OMCP binds to cells transduced with NKG2D and FCRL5 receptors 
 Untransduced parental Ba/F3 cells or cells retrovirally transduced for stable expression 
of the murine NKG2D receptor or FCRL5 receptor were stained with APC labeled 
OMCP tetramers (green), D132R tetramers (red), or control DIII tetramers (gray 
shaded).  
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 CHAPTER 2: OMCP virulence in vivo   
Introduction:  
Viral immunoevasins have proven to be powerful tools for probing host-pathogen 
interactions, revealing cellular pathways that viruses exploit and identifying components 
of host defense integral for control of a specific virus.  We previously described the 
immunoevasin Orthopoxvirus MHC Class I-like Protein (OMCP) secreted by cowpox 
virus (CPXV) and monkeypoxvirus [4].  OMCP acts as a competitive antagonist of 
NKG2D, preventing interactions with cellular stress ligands and inhibiting in vitro NK 
cell-mediated cytolysis [4].  OMCP was also found to engage the orphan receptor 
FCRL5 on splenic marginal zone (MZ) and peritoneal B-1 B cells, but the functional 
consequences of this interaction remain unknown [8].  
 
OMCP is the only known NKG2D antagonist produced by poxviruses.  In contrast to 
previously identified NKG2D antagonists encoded by human and murine 
cytomegaloviruses which act by specifically inhibiting surface expression of one or more 
of the 8 human or 9 murine NKG2D ligands [11, 12], OMCP is secreted from infected 
cells.  We hypothesize that secreted OMCP acts in vivo in a paracrine fashion around 
orthopoxvirus infected cells, saturating NKG2D receptors on approaching NK cell 
effectors and preventing NKG2D-dependent killing of virally infected cells.  The recent 
crystal structure of OMCP bound to NKG2D demonstrates a novel orientation of OMCP 
within the NKG2D binding site that allows for both higher shape complementarity and 
greater buried surface area (E. Lazear et al, submitted), resulting in a higher affinity of 
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OMCP for the NKG2D receptor than the affinity of endogenous NKG2D ligands [4].  
This high-affinity binding of soluble OMCP may facilitate more efficient NKG2D 
antagonism by blocking NKG2D binding to multiple different NKG2D ligands.   
 
OMCP tetramers also bind to innate B cells and macrophages in an NKG2D-
independent manner [8].  Although the binding of OMCP to macrophages remains 
poorly characterized, we have previously identified that FCRL5 is the receptor 
responsible for OMCP binding to innate B cells [8].  The Fc receptor-like (FCRL) family 
consists of receptors that encode Ig domains homologous to classical Fc receptor family 
members but not thought to bind immunoglobulin [13]. A recent report suggests that two 
human FCRL members may bind IgA and certain subtypes of IgG [14], although there 
has been no evidence of immunoglobulin binding in other human FCRL family members 
or any of the mouse FCRL family members.  The endogenous ligands of the FCRL 
family members are unknown, with the exception of human FCRL6 which binds HLA-
DR, an MHC class II molecule [15].  The role of FCRL5 in host immunity and the impact 
of OMCP binding on FCRL5-mediated responses remain incompletely understood.  
 
In this manuscript, we investigate the contributions of the immunoevasin OMCP on 
CPXV virulence in vivo.  We isolate the effects of the binding interactions of OMCP to 
either NKG2D or FCRL5 receptors in vivo using NKG2D-deficient and FCRL5-deficient 
mice, as well as recombinant CPXV lacking OMCP expression or expressing a mutant 
OMCP that selectively does not bind NKG2D.  Using these unique tools, we 
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demonstrate OMCP’s role as a CPXV immunoevasin in vivo and the importance of 
NKG2D-mediated responses to host defense against CPXV.  
 
Experimental Methods: 
Cell lines and mice.   
The generation of Ba/F3 transductants expressing NKG2D and FCRL5 was previously 
described [4, 8].  C57BL/6 (B6) mice were obtained from the National Cancer Institute 
(Charles River, MA).  NKG2D-deficient mice on a B6 background were a kind gift from 
Bojan Polic (University of Rijeka, Croatia) [16], and FCRL5-deficient mice on a B6 
background were obtained from Riccardo Dalla Favera (Columbia University).  Mice 
were maintained under specific pathogen–free conditions and used between 8 and 12 
weeks of age.  All experiments were conducted in accordance with institutional 
guidelines for animal care and use based on the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health.  The protocol was approved by 
the Animal Studies Committee at Washington University (#20110104).  Female mice 
utilized in survival studies were observed daily after infection for 28 days and moribund 
mice were euthanized per institutional guidelines.   
 
CPXV and infection of mice.   
Brighton Red strain CPXV was obtained from the ATCC and propagated in BS-C-1 cells.  
Virus was purified from infected BS-C-1 cell lysates by centrifugation through a 36% 
sucrose gradient.  The titer of the viral stock was determined using a standard plaque 
assay on BS-C-1 cells [17, 18].  Intraperitoneal i.p. infections were done at a dose of 
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2x106 pfu CPXV/mouse unless otherwise indicated.  For intranasal infections, mice 
were first anesthetized i.p. with ketamine/xylazine short acting sedative.  Mice were 
infected with the appropriate innoculum of virus in a 50µL volume intranasally.  All i.n. 
infections were done at a dose of 2.5x104 pfu CPXV/mouse unless otherwise indicated.  
 
Generation of recombinant cowpox viruses.  
Recombinant virus lacking expression of OMCP (ΔV018) and its revertant were 
produced by transient dominant selection [19, 20].  A PCR product encoding the VACV 
p7.5 5’ UTR and promoter was amplified and spliced to another PCR product encoding 
the E. coli gpt sequence.  The final product was cloned into plasmid pUC19 to create 
pUC19 p7.5 gpt. OMCP was then amplified in two fragments in order to insert two 
tandem early termination codons.  This product was cloned into pUC19 7.5 gpt to create 
pUC19 p7.5 gpt OMCPSTOP.  The revertant plasmid pUC19 p7.5 gpt OMCP was 
generated by excising the OMCPSTOP sequence and replacing it with wild-type OMCP.  
OMCP D132R mutant CPXV was generated in a similar manner with primers to insert a 
point mutation at D132.  The mutated D132R construct was also spliced to E. coli gpt 
and cloned for transient dominant selection.  
 
Confluent CV-1 cells were then infected with CPXV (for CPXV ΔV018 or D132R 
generation) or CPXV ΔV018 (for revertant generation) at an MOI of 0.5.  Two hours 
post-infection, the cells were transfected with pUC19 p7.5 gpt OMCPSTOP for CPXV 
ΔV018, pUC19 p7.5 gpt OMCP-D132R for D132R generation, or pUC19 p7.5 gpt 
OMCP for revertant generation using Lipofectamine2000.  The infected/transfected cells 
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were lysed after 48 hours, and gpt+ viruses were selected by infecting confluent B-SC-1 
cells with the transfected virus stock in gpt selection medium (DMEM, 2% FCS, 25 
μg/mL mycophenolic acid, 250 μg/mL xanthine, and 15 μg/mL hypoxanthine).  Gpt+ 
viral plaques underwent two further rounds of selection in gpt selection media and two 
subsequent rounds of purification in non-selective media.  Finally, plaques were tested 
for their ability to grow in both selective and non-selective media.  Plaques that grew 
only in non-selective media (indicating loss of the gpt marker) were picked and 
underwent a total of five plaque purifications.  Virus stocks were subsequently 
propagated in B-SC-1 cells and titered following standard protocols using B-SC-1 cells 
[18]. 
 
Protein, Antibodies, and Flow cytometry.  
Recombinant OMCP, D132R OMCP, and West Nile Virus glycoprotein domain III (DIII) 
were produced and biotinylated as previously reported [4, 21].  APC labeled tetramers 
were made fresh by incubating biotinylated OMCP protein with APC-streptavidin in a 4:1 
molar ratio, incubating for 10 min at room temp, and used for staining cells.  APC 
streptavidin, PE anti-F4/80 (BM8),  APC eFlour 780 anti-CD3 (145-2C11), eFlour 450 
anti-CD19 (1D3) were purchased from eBioscience (San Diego, CA).  FITC anti-CD23 
(B3B4), FITC CD19 (1D3), PE anti-NK1.1 (PK136), PE-Cy7 anti-GR1 (1A8), V500 anti-
B220 (RA3-6B2), and BV510 anti-CD21 (7G6) were from BD Biosciences (San Jose, 
CA).  FITC anti-CD5 (53-7.3) was from Biolegend (San Diego, CA).  Single cell 
suspensions of splenocytes and isolation of peritoneal cells were performed using 
standard protocols [22, 23].  To block nonspecific binding of antibodies to FcRs, cells 
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were incubated in 2.4G2 (anti-FcγRII/III) supernatants (hybridoma from ATCC) prior to 
staining with labeled Abs. For protein bridging experiments, APC labeled NKG2D 
tetramers were preincubated with unlabeled OMCP monomer or DIII control monomer 
in a 2 or 4 monomer:1 tetramer molar ratio. Tetramers were preincubated for 20 min on 
ice prior to staining of single cell suspensions. 7AAD (CalBiochem) was used on all 
samples for dead cell exclusion.  Data was collected on a FACScan flow cytometer (BD 
Pharmingen) with DxP multicolor upgrade (Cytek Development, Fremont, CA) and 
FlowJo CE software (TreeStar, Ashland, OR) or FACSCalibur flow cytometer (BD 
Biosciences) with CellQuest collection software (BD Biosciences).  Data analysis was 
performed using FlowJo software (TreeStar).  Identification of cells is as follows: splenic 
NK cells (NK1.1+, CD3-), T cells (NK1.1-, CD3+), follicular B cells (CD19+, CD21 lo. 
CD23+), marginal zone B cells (CD19+, CD21+, CD23-) peritoneal B1-a (CD19+, 
CD5+), B1-b (CD19+, CD5-) B cells, macrophages (F4/80+, GR1lo), and granulocytes 
(F4/80-, GR1hi).   
 
Plaque assay. 
Tissues harvested from mice were weighed and collected in tubes containing 1mL of 
DMEM and stored at -80oC until processing.  Frozen organs wee homogenized using 
glass dounce homogenizers and collected in 1mL of DMEM.  The tissue homogenate 
was serially diluted in D2.5 media (DMEM, 2.5% FBS, 1% L-glutamine, 1% penicillin-
streptomycin, 1% non-essential amino acids) and used in standard plaque assays on 
BS-C-1 cells [17].  Each organ was titered on 5x105 BS-C-1 cells plated in wells of 6 
well plates in duplicate.  Infected cell cultures were maintained in D2.5 media at 37oC, 
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5% CO2 for 48 hours.  Cells were stained at 48 hours post infection using a crystal violet 
solution and plaques were counted.  Viral titers were calculated from a minimum of 3 
dilutions done in duplicate.  
 
NK cell depletion. 
Mice were depleted of NK cells 8 days p.i. with 100 μg of purified anti-NK1.1 antibody 
(PK136; BioXcel). Controls were given 100 μg of an isotype matched irrelevant antibody 
(MAR18.5; BioXcel). The antibodies were diluted in sterile PBS immediately prior to 
administration, and a 300 μL volume injected intraperitoneally per mouse. Mice were 
monitored daily for weight loss and survival until 28 days p.i.  
 
Cloning, expression, and purification of FCRL5. 
The mature FCRL5 coding sequence was cloned into the AgeI and KpnI sites of the 
pHL-Avitag3 vector [24]. FCRL5-6His-birA plasmid was transiently transfected into 293F 
cells (Life Technologies) using PEI and the supernatant was collected on day 3 and day 
6.  Supernatants were supplemented with 10 mM imidazole and 0.02% sodium azide 
and purified via Ni-NTA Superflow resin (Qiagen).  Protein was bulk eluted with 250 mM 
imidazole, concentrated, and further purified over a Superdex 200 column (16/60; GE 
Healthcare Life Sciences).  The pooled FCRL5 fractions were then site-specifically 
biotinylated via the C-terminal birA tag according to the manufacturers specifications 
(Avidity).  OMCP was purified as previously described [10]. 
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Surface plasmon resonance (SPR). 
A Biacore T100 instrument (GE Healthcare Life Sciences) was used to assess the 
binding of OMCP and the conformationally-specific FCRL5 antibody, 9D10 [25]. All 
experiments were carried out at a flow rate of 50 μl/min, 25°C, and in running buffer 
containing 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% Triton X-100. 
CM5 chips (GE Healthcare Life Sciences)  with immobilized neutravidin were made as 
previously described [26].  500 RUs of biotinylated FCRL5 were coupled to the surface 
of the chip and then 100 nM OMCP or 9D10 were injected across the chip.  
 
Statistical analysis. 
Data analysis was done with Microsoft Excel and GraphPad Prism (GraphPad Software, 
La Jolla, CA).  Unless otherwise noted, unpaired, two-tailed t tests were used to 
determine statistically significant differences.  Error bars in the figures represent SDs 
from the mean value.  The Log-rank (Mantel-Cox) test was used in the comparison of all 
Kaplan Meier survival curves.  
 
Results: 
CPXV lacking OMCP is significantly attenuated in vivo.   
To facilitate our investigation of the role of OMCP in vivo during CPXV infection, we 
generated an OMCP-deficient (ΔV018) CPXV that does not produce OMCP using a 
transient dominant selection strategy.  Multi-step growth curves of the WT CPXV, 
OMCP-deficient CPXV, and a revertant CPXV demonstrated nearly identical replication 
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growth kinetics (Fig. 4), indicating that OMCP is dispensable for viral growth or 
replication in vitro.  
 
Using WT and OMCP-deficient CPXV, we investigated the impact of OMCP during 
systemic CPXV infection (via the intraperitoneal (i.p.) route) in WT B6 mice.  Survival of 
WT mice infected with WT CPXV demonstrated a dose dependence with an LD50 value 
of 0.91x106 pfu/mouse (Fig. 5A).  Comparison of the survival of WT mice infected i.p. 
with OMCP-deficient CPXV (Fig. 5B) revealed substantially greater survival in the mice 
infected with OMCP-deficient CPXV than with WT CPX.  Indeed, the LD50 value of 
1.64x106 pfu/mouse for mice infected with OMCP-deficient CPXV demonstrated that 
CPXV lacking OMCP is substantially attenuated in vivo compared to WT CPXV.  Kaplan 
Meier survival curves of WT mice infected with the OMCP revertant CPXV (at 0.6x106 
and 2x106pfu CPXV/mouse) correlate well with the survival observed following infection 
with WT CPXV (Fig. 5C), demonstrating that the decreased virulence observed during 
infection with OMCP-deficient CPXV reflects the absence of OMCP.  Together, these 
results establish for the first time that OMCP facilitates CPXV virulence in vivo.  
 
D132R OMCP mutant displays selective loss of NKG2D binding while retaining 
binding to FCRL5 ex vivo on primary cells.   
To isolate the effect of OMCP binding to NKG2D from that of binding to FCRL5, we 
generated OMCP with a point mutation, D132R, that abrogates binding to NKG2D but 
retains binding to FCRL5 on stably transduced cells in vitro as well as in SPR studies  
(E. Lazear et al, submitted.)  We also generated a recombinant CPXV that expressed 
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the mutant D132R OMCP, using a transient dominant selection strategy.  Multi-step 
growth curve of D132R CPXV demonstrated identical replication growth kinetics to WT 
CPXV (Fig. 4).   
 
We subsequently evaluated the ability of the selectively deficient D132R OMCP mutant 
to bind to primary cells isolated from WT, NKG2D-deficient, and FCRL5-deficient mice.  
Wild type OMCP tetramers bind to NKG2D bearing NK cells and FCRL5 expressing 
peritoneal B1-a B cells, and splenic MZ B cells, but not T cells or splenic follicular B 
cells (Fig. 6A, top panel).  Peritoneal B1-b B cells demonstrated similar staining patterns 
as peritoneal B1-a B cells (data not shown).  When OMCP tetramers were used to stain 
cells from NKG2D-deficient mice, OMCP binding to NK cells was completely abrogated, 
demonstrating that OMCP binding to NK cells is entirely through NKG2D.  However, 
binding to FCRL5 expressing B cells was retained, confirming that OMCP interactions 
with innate B cells is NKG2D-independent (Fig. 6A, middle panel).  WT OMCP tetramer 
staining on cells from FCRL5-deficient mice showed loss of binding to peritoneal B1-a B 
cells and splenic MZ B cells, with retained binding to NK cells (Fig. 6A, bottom panel).  
The D132R OMCP tetramer demonstrated complete loss of binding to NK cells from WT 
and FCRL5-deficient mice, yet retained normal binding to FCRL5 bearing peritoneal B1-
a B cells and splenic MZ B cells from WT and NKG2D-deficient mice (Fig. 6B, top and 
middle panels).  As expected, the FCRL5 binding was eliminated on MZ B cells from 
FCRL5-deficient mice (Fig. 6B, bottom panel).  These ex vivo studies with primary cells 
from WT, NKG2D-deficient, and FCRL5-deficient mice confirm that the D132R OMCP 
mutant has a selective deficiency in binding to NKG2D but retains binding to FCRL5. 
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NKG2D mediates all of the virulence of OMCP during intranasal CPXV infection.  
We subsequently investigated the impact of OMCP binding in vivo to NKG2D and 
FCRL5 during CPXV infection.  Cowpox and its close relatives variola virus, vaccinia 
virus, and monekeypox can be spread via contact and aerosol transmission [27]; 
therefore, we choose to study the role of OMCP during acute intranasal i.n. infection.  
Using our series of WT OMCP expressing CPXV, OMCP-deficient CPXV (ΔV018), and 
D132R OMCP mutant expressing CPXV in combination with WT, NKG2D-deficient, and 
FCRL5-deficient mice, we were able to delineate the impact of OMCP on NKG2D and 
FCRL5 expressing cells during CPXV infection in vivo.  This unique set of tools allowed 
us to probe the influence of an orthopoxvirus immunoevasion in vivo at a level of detail 
that has not previously been possible. 
 
Mice were infected i.n. with 2.5x104 pfu/mouse of WT, OMCP-deficient, or D132R CPXV 
virus.  Infection with WT CPXV resulted in similar mortality in WT, NKG2D-deficient, and 
FCRL5-deficient mice (Fig. 7 solid lines).  However, a strong survival phenotype was 
unmasked when mice were infected with the OMCP-deficient CPXV (Fig. 7, dashed 
lines).  The complete loss of OMCP rendered CPXV severely attenuated in WT and 
FCRL5-deficient mice, while OMCP-deficient CPXV infection in NKG2D-deficient mice 
remained similarly lethal as WT CPXV.  These results illustrated that under normal 
circumstances (i.e., WT CPXV infection in WT mice), OMCP is able to effectively 
abrogate activation through the NKG2D receptor, rendering WT CPXV as lethal in WT 
mice as it is in NKG2D-deficient mice. Mice infected with the D132R CPXV (which 
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produces OMCP selectively incapable of binding to and inhibiting NKG2D) phenocopied 
the mortality of mice infected with a complete OMCP-deficient CPXV (Fig. 7, dotted 
lines).  Despite the fact that OMCP has multiple binding partners, this finding strongly 
implicated binding to NKG2D in mediating the virulence of OMCP during CPXV infection.  
The similar mortality observed in NKG2D-deficient mice following infection with D132R 
or WT CPXV also demonstrated the internal consistency of our infection model since 
there is no NKG2D receptor available in the NKG2D-deficient mice for WT OMCP to 
inhibit.  The survival studies in NKG2D-deficient mice revealed no significant differences 
in survival following infection with any of the 3 strains of CPXV (Fig. 7B), supporting the 
conclusion that OMCP’s impact following i.n. CPXV virus infection is mediated entirely 
through NKG2D.  The survival observed in the FCRL5-deficient mice following infection 
with each of the strains of CPXV closely mimicked that seen in WT mice (Figs. 7C vs 
7A), indicating that there is no significant role of the FCRL5 receptor on survival 
following this route of infection.  Despite the striking differences in survival, no 
significant differences were observed in the lung viral titers in WT mice infected 
intranasally with WT or OMCP-deficient CPXV (Fig. 7D).  The significant attenuation of 
OMCP-deficient CPXV and the D132R CPXV infection in WT and FCRL5-deficient mice 
demonstrated the critical importance of NKG2D blockade during WT CPXV infection, 
and strongly implicates OMCP binding to NKG2D as the primary virulence effect of this 
viral immunoevasin following acute i.n. infection.  
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Delayed weight phenotype is absent in NKG2D-deficient mice and abrogated in 
mice depleted of NK cells. 
We assessed daily weights as an additional measure of OMCP virulence during i.n. 
CPXV infection.  Analysis of weight-loss in WT, NKG2D-deficient, and FCRL5-deficient 
mice during infection with WT, OMCP-deficient, and D132R cowpox viruses generally 
supported the conclusions drawn from the i.n. survival studies.  Mice infected with the 
less virulent OMCP-deficient CPXV or D132R CPXV lost less weight and surviving mice 
regained weight faster than their counterparts infected with WT CPXV, emphasizing the 
viral virulence attenuation when OMCP is absent or unable to bind to NKG2D (Fig. 8).  
However, in contrast to the prolonged weight-loss observed in surviving WT and 
FCRL5-deficient mice infected with WT CPXV (compared to OMCP-deficient and 
D132R CPXV; Fig. 8A & C), weight loss in surviving NKG2D-deficient mice infected with 
WT CPXV paralleled the weight loss observed in NKG2D-deficient mice infected with 
the less virulent OMCP-deficient or D132R CPXV (Fig. 8B), consistent with their similar 
mortality rates in NKG2D-deficient mice.  Interestingly, WT mice that were depleted of 
NK cells on day 8 p.i. regained weight faster during recovery from WT CPXV infection 
than control mice (Fig. 8D), phenocopying the weight gain observed in surviving WT 
mice infected with OMCP-deficient or D132R CPXV.  These experiments suggested 
that the NKG2D receptor on NK cells was responsible for the paradoxical delayed 
weight recovery phenotype observed in the presence of OMCP that is capable of 
binding to NKG2D receptors.   
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Low affinity binding of OMCP to FCRL5 can be overcome by multimerization with 
NKG2D on NK cells. 
We hypothesized that the impact of NK cell expressed NKG2D on the paradoxical 
delayed weight recovery phenotype observed in WT mice infected with WT CPXV could 
reflect OMCP redirecting NK cell-mediated cytolysis by bridging NK cells and innate B 
cells or macrophages.  The binding interface utilized by OMCP to interact with NKG2D 
has been recently been described (E. Lazear et al, submitted), but the OMCP binding 
sites for FCRL5 and the as yet unidentified receptor on macrophages/monocytes have 
not been characterized.  Therefore, to investigate the plausibility of our bridging 
hypothesis, we formally evaluated whether the OMCP binding interfaces for NKG2D 
and FCRL5 were distinct and independent.  Using fluorescently labeled NKG2D 
tetramers, we demonstrated that NKG2D did not bind to FCRL5 transductants or a 
monocyte cell line.  However, preincubation of the labelled NKG2D tetramers with 
monomeric OMCP resulted in fluorescence specifically associated with FCRL5 
expressing cells and monocyte cells, demonstrating that OMCP can simultaneously 
bind to NKG2D and FCRL5 (or NKG2D and monocytes/macrophages) using different 
binding interfaces (Fig. 9A),  In contrast, preincubation of the NKG2D tetramers with 
irrelevant protein did not result in NKG2D tetramers interactions with either the FCRL5 
transductants or the monocyte cell line, and no OMCP-preincubated NKG2D tetramers 
were detected on NKG2D transfectants, due to competition for the single NKG2D 
binding site on the OMCP intermediary.  These results indicated that OMCP is capable 
of binding to NKG2D and FCRL5 (or NKG2D and macrophages/monocytes) 
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simultaneously, potentially acting as a bridging ligand between NK cells and innate B 
cells (or monocytes/macrophages).   
 
We have previously reported that OMCP tetramers bind to FCRL5 transductants, innate 
B cells, and macrophages in an NKG2D-independent manner [8].  Given the lack of 
observable in vivo survival phenotype in the FCRL5-deficient mice during CPXV 
infection, we further analyzed the binding of monomeric OMCP to FCRL5.  A647-
labeled OMCP monomer staining demonstrated that OMCP monomers bind strongly to 
NKG2D but have a much lower affinity for FCRL5 (Fig. 9B).  Additional validation by 
SPR confirmed that any binding of monomeric OMCP to FCRL5 receptors was below 
the sub-micromolar detection limit of SPR (Fig. 9C).  These results suggest that OMCP, 
which is secreted as a monomer in vivo [10], is unlikely to effectively bind FCRL5 in the 
absence of NKG2D multimerization (Fig. 9A).  However, multivalent presentation of 
OMCP may be achievable on cells expressing NKG2D, which may display OMCP for 
high avidity binding to FCRL5 expressing B cells and/or macrophages. 
 
NKG2D binding plays a critical role in mediating OMCP’s virulence following 
systemic intraperitoneal infection but NKG2D independent mechanisms also exist.   
We also investigated the impact of OMCP binding in vivo to NKG2D and FCRL5 during 
systemic CPX infection.  Using our series of WT OMCP expressing CPX, OMCP-
deficient CPX (ΔV018), and D132R OMCP mutant expressing CPX viruses in 
combination with WT, NKG2D-deficient, and FCRL5-deficient mice, we were able to 
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delineate the impact of OMCP on NKG2D and FCRL5 expressing cells during CPX 
infection in vivo.   
 
WT mice were infected with 2x106 pfu/mouse of WT, OMCP-deficient, and D132R CPX 
virus. WT CPX infection in WT, NKG2D-deficient, and FCRL5-deficient mice was 
similarly lethal (Fig. 10 solid lines). However, as with intranasal infection, a strong 
survival phenotype was unmasked when the mice were infected with the D132R 
expressing CPX virus (Fig. 10, dotted lines). D132R CPX was severely attenuated in 
WT and FCRL5-deficient mice, while D132R CPX infection in NKG2D-deficient mice 
phenocopied  WT CPX infection in NKG2D-deficient mice. This strongly indicated that 
under normal circumstances (WT CPX in WT mice), OMCP is able to completely inhibit 
activation through the NKG2D receptor, rendering WT CPX as lethal in WT mice as it is 
in NKG2D-deficient mice. The effect of OMCP is uncovered with the D132R mutation 
that renders OMCP incapable of inhibiting NKG2D. The importance of NKG2D blockade 
is evidenced by the fact that D132R CPX infection in WT and FCRL5-deficient mice is 
severely attenuated. D132R CPX in NKG2D-deficient mice has similar mortality as WT 
CPX infection in those mice (Fig. 10B dotted vs solid lines), demonstrating our infection 
model is internally consistent, as in this strain there is no NKG2D receptor available for 
inhibition.  
  
Unexpectedly, we noted that infection with the complete OMCP-deficient virus was less 
virulent than WT CPX, but more virulent than D132R CPX in WT mice (Fig. 10A, 
dashed line).  This indicates that although the overall effect of OMCP is to promote CPX 
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virulence, there are some NKG2D independent effects of OMCP that is paradoxically 
beneficial to the host. The fact that the absence of the NKG2D receptor in NKG2D-
deficient mice does not eliminate the difference in survival observed following infection 
with  WT and OMCP-deficient CPX (Fig 10B solid vs dashed) also supports the 
presence of NKG2D-independent effects of OMCP following i.p. infection. 
 
The survival observed in the FCRL5-deficient mice following i.p. infection with each of 
the strains of CPX virus closely mimics that seen in WT mice (Figs. 10C vs 10A), 
indicating that we uncovered no significant role of the FCRL5 receptor on survival 
following this route of infection.  The difference in mortality observed following i.p. 
infection with the D132R mutant virus compared with the OMCP-deficient virus in both 
WT and FCRL5-deficient mice, suggested that OMCP may have NKG2D- and FCRL5-
independent effects that are paradoxically beneficial to the host.  However, the large 
survival difference between WT CPX and both OMCP-deficient CPX and D132R CPX in 
WT and FCRL5-deficient mice strongly implicates OMCP binding to NKG2D in providing 
the primary virulence effect of this viral immunoevasin following i.p. infection.  
 
The conclusions derived from the survival curves were further evaluated by 
determination of splenic and hepatic viral titers at day 6 p.i. (Fig. 11).  There was 
approximately a 1 log difference in the median splenic and hepatic viral titers between 
WT mice and NKG2D-deficient mice infected with WT CPX.  In WT mice, infection with 
OMCP-deficient CPX and D132R CPX resulted in lower splenic viral titers than infection 
with WT CPX, consistent with the increased survival observed in WT mice infected with 
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OMCP-deficient and D132R CPX.  Furthermore, the median splenic titers in WT mice 
infected with OMCP-deficient CPX virus were similar to the splenic titers observed in 
NKG2D-deficient mice following infection with WT CPX, consistent with the survival 
results.  However, the splenic titers did not completely correlate with the survival data.  
For example, similar splenic titers were observed in WT mice infected with OMCP-
deficient and D132R CPX, despite the increased survival observed in the WT mice 
infected with D132R.  The hepatic titers as a whole correlated less well with the survival 
data, suggesting that hepatic titers may not be a primary factor influencing death in this 
model.  Mice inoculated with CPX i.p. have been shown to sustain viral infection in a 
range of cell types and organs in the peritoneal cavity, including the liver, spleen, 
pancreas, uterus, ovary, and adipose tissue [27].  Migration of CPX infected peritoneal 
macrophages into the thoracic cavity is thought to bring virus to the diaphragm, 
mediastinum, and pulmonary lymph nodes [27].  This diffuse viral dissemination during 
systemic infection appears to contribute to a multifactoral cause of death, consistent 
with only modest correlation with individual organ titers.  
 
Discussion: 
Viral evasion of NKG2D recognition is integral for the avoidance of innate host defense 
mechanisms, as evidenced by the many members of the herpesvirus family that have 
evolved proteins to inhibit expression of a number of NKG2D ligands [28-31].  In 
contrast to herpesvirus immunoevasins that target individual NKG2D ligands, CPXV 
utilizes a novel approach of directly targeting the NKG2D receptor using a soluble MHC 
class I-like immunoevasin.  This high-affinity, soluble decoy (OMCP) can theoretically 
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completely inhibit NKG2D activation by blocking receptor engagement with any of the 
NKG2D stress ligands upregulated during viral infection, facilitating CPXV escape from 
immune detection.  
 
After extensive characterization of CPXV OMCP in vivo using novel mutant viruses and 
genetically modified mice, we have shown that the majority of OMCP’s effect on host 
survival can be attributed directly to NKG2D receptor antagonism.  In both the intranasal 
and intraperitoneal routes of infection, NKG2D binding appears to be the main 
determinant of OMCP-mediated CPXV virulence.  Unexpectedly, we did not detect 
evidence of a direct impact of OMCP interaction with FCRL5 on survival during CPXV 
infection.  
 
The finding that NKG2D antagonism is the primary contributor to OMCP-mediated 
virulence during CPXV infection is not unexpected.  OMCP has a highly conserved 
MHC class I like structure and binds murine and human NKG2D with a higher affinity 
than endogenous NKG2D ligands [4, 10].  Furthermore, OMCP has also been shown to 
competitively block host NKG2D ligand engagement in vitro, suggesting that OMCP 
binding can successfully inhibit NKG2D activation [4, 10].  Indeed, we have shown that 
soluble OMCP is sufficient to block in vitro NKG2D-mediated NK cell killing of target 
cells [4].  Therefore, we hypothesized that secreted OMCP from CPXV infected cells 
creates a gradient of local high concentration of OMCP around infected cells, sufficient 
to competitively block the interaction of the NKG2D receptor on incoming NK cell 
effectors with stress ligands induced on virally infected cells, thus preventing NK cell 
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recognition and killing.  The results of our in vivo studies support this hypothesis and 
suggest that NKG2D blockade is important to CPXV virulence.  Interestingly, NKG2D 
has also been implicated in resistance to a related orthopoxvirus, ectromelia [32], 
suggesting that the NKG2D receptor is essential for innate defense to the extended 
orthopoxvirus family.  
 
We unexpectedly observed that surviving NKG2D-deficient mice infected intranasally 
with WT CPXV regained lost-weight faster than WT and FCRL5-deficient mice late 
during infection (>10 days p.i.).  One consideration in explaining this observation is that 
NKG2D is upregulated on CD8+ T cells during many viral infections [33, 34].  However, 
we have not observed NKG2D upregulation on CD8 T cells during CPXV, and a recent 
study demonstrated that two CPVX-encoded immunoevasins (CPX012 and CPX203) 
neutralized CD8 effector cell responses [35].  Furthermore, WT mice depleted of NK 
cells day 8 p.i. similarly regained weight faster during the recovery period (Fig. 8D), 
implicating NKG2D on NK cells in mediating this process.  Indeed, the weight gain in the 
surviving NKG2D-deficient mice or NK cell depleted mice infected with WT CPXV 
mirrored that of their counterparts infected with OMCP-deficient or D132R virus.  One 
potential explanation for this observation (i.e., OMCP binding to NKG2D bearing NK 
cells paradoxically delaying murine weight gain during CPXV recovery) is that OMCP 
may be acting as a bridging ligand facilitating interactions between NKG2D-bearing NK 
cells and innate B cells (or monocytes/macrophages) and potentially redirecting NK cell 
lysis against these cells.  Indeed, FCRL5 expressing cells (and 
monocytes/macrophages) were labeled by fluorescent NKG2D tetramers only in the 
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presence of an OMCP bridge (Fig. 9A), demonstrating that the OMCP binding sites are 
independent.  The observation that monomeric OMCP binds FCRL5 with low affinity 
(Fig. 9B) and requires multivalent interactions for sustained binding (Figs. 9A & B) may 
partially explain the lack of survival phenotype we observed during infection in the 
FCRL5-deficient mice.  However, we demonstrate that OMCP is capable of strong 
binding to FCRL5 when complexed with tetrameric NKG2D (Fig. 9A), a scenario that 
simulates OMCP presentation on NKG2D receptor bearing NK cells.  Furthermore, we 
have recently reported that artificially cell-associated OMCP (using a cell line 
transfected with OMCP attached to a Thy1.1 transmembrane domain [4]) resulted in 
efficient NK cell-mediated cytolysis of the OMCP bearing target cell (E. Lazear et al., 
submitted).  Given that we observe delayed weight gain in FCRL5-deficient mice 
infected with WT cowpox (Fig. 8C), we favor the hypothesis that OMCP is facilitating the 
redirection of NK cell-mediated responses toward monocytes/macrophages resulting in 
slower weight gain in surviving mice late during CPXV infection.  However, confirmation 
of this intriguing bridging hypothesis will require additional future studies. 
 
We did not detect any impact of OMCP binding to FCRL5 on survival during CPXV 
infection.  However, it is possible that OMCP binding to FCRL5 mediates other 
processes that do not directly affect survival or weight loss during acute CPXV infection.  
FCRL5 is a poorly characterized innate B cell receptor known to modulate BCR 
signaling [9, 36, 37].  It is expressed on innate splenic marginal zone and peritoneal B1 
B cells, subsets of innate B cells with unique developmental lineages [38-40] and 
specialized roles in the initial stages of humoral defense [41-44].  Despite significant 
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investigation, our laboratory has not identified an in vitro impact of OMCP binding to 
FCRL5 on innate B cell function or an in vivo effect on survival, weight loss, or viral 
titers.  
 
Taken together, these findings demonstrated the importance of the CPXV 
immunoevasin OMCP in contributing to the in vivo virulence of CPXV.  The majority of 
OMCP’s effect can be attributed to binding to NKG2D, and our studies found minimal 
contributions of OMCP binding to FCRL5 on survival or weight loss.  We identified a 
paradoxical delayed weight gain associated with binding of OMCP to NKG2D on NK 
cells following intranasal CPXV infection, and have begun to investigate the possibility 
of OMCP functioning as a bridging ligand between NK cells and FCRL5-bearing cells or 
macrophages.  We have also provided initial evidence that NKG2D-mediated 
multimerization of OMCP may help overcome the relatively low affinity of monomeric 
OMCP for FCRL5. This work highlights the importance of NKG2D receptor blockade in 
vivo during CPXV infection and will inform future studies of the host innate immune 
response to epidemiologically relevant orthopoxviruses. 
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Figures:  
 
 
Figure 4:  ΔV018 virus and D132R virus do not have a growth defect in vitro.   
Multi-step growth curves for WT CPX, ΔV018, D132R, and revertant viruses show that 
all four cowpox virus strains have similar replication kinetics in a multi-step growth curve. 
B-SC-1 cells were infected at an MOI of 0.01 with the indicated viruses.  Infected cells 
were harvested at the indicated time points and freeze-thawed three times.  Lysates 
were tittered by plaque assay on B-SC-1 monolayers. Results are representative of 
three experiments done in duplicate.  
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Figure 5:  Cowpox virus lacking OMCP is significantly attenuated in vivo.   
WT CPX (A) is more virulent than ΔV018 CPX (B), as evidenced by increased lethality 
at all tested doses.  The Revertant CPX control (C) phenocopies WT CPX as is 
expected. 8-12 week old female WT B6 mice were infected with 2x106 (solid line), 1x106 
(dashed line), or 0.6x106 (dotted line) of the indicated CPX strain, and survival was 
assessed daily for 28 days.  Data are aggregated from two-seven independent 
experiments with 5-10 mice per group. 
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Figure 6:  WT OMCP binds to NKG2D expressing NK cells and FCRL5 expressing B1 
B cells, while D132R OMCP mutant displays selective loss of NKG2D binding with 
retained FCRL5 binding.   
 APC labeled OMCP tetramers (solid line) were used to stain splenic NK cells (NK1.1+, 
CD3-), splenic T cells (NK1.1-, CD3+), peritoneal B1-a B cells (CD19+, CD5+), splenic 
marginal zone B cells (CD19+, CD21+, CD23-), and splenic follicular B cells (CD19+, 
CD21+. CD23+).. Peritoneal B1-b (CD19+, CD5-) B cells (not shown) stain similar to 
B1-a cells.  Staining with APC labeled WNV DIII tetramer control shown in gray 
histograms.  (A) OMCP tetramer binds selectively to WT NK cells, peritoneal B1-a B 
cells, and MZ B cells.  The NKG2D-deficient mice lose OMCP binding to NK cells while 
retaining binding to B1-a B cells and MZ B cells.  Conversely, the FCRL5-deficient mice 
lose OMCP binding to B1-a B cells and MZ B cells with retained binding to NK cells. 
Representative results from four independent experiments.  (B) OMCP tetramer with the 
D132R mutation loses binding to NKG2D while retaining binding to FCRL5 expressing 
cells.  The D132R mutant has lost binding to NK cells in WT mice, but it has 
undiminished binding to peritoneal B1-a B cells and splenic MZ B cells.  Peritoneal B1-a 
B cell and splenic MZ B cell staining is lost only in FCRL5-deficient mice. 
Representative results from three independent experiments. 
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Figure 7:  NKG2D mediates all of the virulence of OMCP during intranasal CPXV 
infection.   
WT CPXV (solid line), ΔV018 CPXV (dashed line) and D132R OMCP CPXV (dotted 
line) infected via the intranasal route differentially influence survival in (A) WT B6, (B) 
NKG2D-deficient, and (C) FCRL5-deficient mice.  Kaplan-Meier analysis shows survival 
of female mice following intranasal infection with 2.5x104 pfu of the designated CPXV 
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strain.  The data are aggregated from two to four independent experiments.  The Log-
rank (Mantel-Cox) test was used in the comparison of all Kaplan Meier survival curves. 
NS not significant, **p<0.01 ***p<0.001 (D) Female WT B6 mice were infected 
intranasally with 2.5x104 pfu of WT or ΔV018 CPXV.  Lungs were harvested on the 
indicated day post infection and tittered by standard plaque assay on BSC-1 cells. Line 
represents the median value.   
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Figure 8: Mice infected with WT CPXV intranasally lose more weight and regain weight 
slower than mice infected with the less virulent  ΔV018 CPXV or D132R CPX .  
  
(A) WT B6, (B) NKG2D-deficient, and (C) FCRL5-deficient mice were intranasally 
infected with 2.5x104 pfu of WT CPXV (solid line), ΔV018 CPXV (dashed line) and 
D132R CPXV (dotted line) and weighed daily.  Weights were plotted as percent of initial 
body mass.  The data are aggregated from two to three independent experiments with 
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4-10 mice per group.   (D) Weights of WT mice infected with WT CPXV (2x104 
pfu/mouse) depleted of NK cells (PK136) or injected with an isotype control Ab 
(MAR18.5) on day 8 p.i. were monitored over the course of infection.  The data are 
aggregated from 2 independent experiments with 8-16 mice per group.   
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Figure 9: Low affinity binding of OMCP to FCRL5 can be overcome by multimerization 
with NKG2D on NK cells  
 (A) Untransduced parental Ba/F3 cells and cells transduced to express the murine 
NKG2D receptor and murine FCRL5 receptor, as well as a human Thp1 monocyte cell 
line were used to test OMCP binding in the presence of human NKG2D. Cells were 
stained with either APC labeled control DIII tetramer (line 1), APC labeled human 
NKG2D tetramer (line 2), APC labeled human NKG2D tetramer preincubated with DIII 
control (line 3) or APC labeled human NKG2D tetramer preincubated with OMCP (line 
4).  Representative results from two independent experiments. (B) Parental Ba/F3 cells 
and cells transduced with the murine NKG2D and murine FCRL5 receptor were tested 
for binding to APC labeled DIII control (line 1), fluorescent APC labeled OMCP 
tetramers (line 2) or A647 labeled OMCP monomers (line 3). Representative results 
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from two independent experiments. (C) Purified OMCP monomer or an anti-FCRL5 
conformational antibody (9D10) were injected over flow cells containing immobilized 
murine FCRL5. Binding is detected as an increase in signal.
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Figure 10: NKG2D binding accounts for the majority of OMCP’s virulence during 
intraperitoneal infection.   
 WT CPX (solid line), ΔV018 CPX (dashed line) and D132R expressing CPX (dotted 
line) infected via the intraperitoneal route differentially impact survival in (A) WT B6, (B) 
NKG2D-deficeint, and (C) FCRL5-deficient mice. Kaplan-Meier analysis shows survival 
of female mice following intraperitoneal infection with 2x106 pfu of the designated CPX 
strain.  Data are aggregated from three to five independent experiments with 4-10 mice 
per group.  The Log-rank (Mantel-Cox) test was used in the comparison of all Kaplan 
Meier survival curves. NS not significant, **p<0.01, ****p<0.0001 
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Figure 11: Splenic viral titers during CPX infection in intraperitoneally infected mice. 
   
Female WT B6 mice (black) or NKG2D mice (white) were infected with 2x106 pfu of WT 
CPX (circles), ΔV018 CPX (squares), or D132R CPX (triangles).  Spleens were 
harvested on day 6 p.i., and titered by standard plaque assay on BSC-1 cells.  Line 
represents the median value.  Data are aggregated from four independent experiments 
with 4-5 mice per group. 
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Figure 12: Intraperitoneal survival curves at 3 doses.  
WT CPX, ΔV018 CPX, D132R expressing CPX, or revertant CPX infected via the 
intraperitoneal route differentially impact survival in WT B6, NKG2D-deficeint, and 
FCRL5-deficient mice. Kaplan-Meier analysis shows survival of female mice following 
intraperitoneal infection with 0.6 x106 pfu (dotted line), 1 x106 pfu (dashed line), or 2x106 
pfu (solid line) of the designated CPX strain.  Data are aggregated from greater than 10 
independent experiments with 4-10 mice per group.     
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Figure 13: Intranasal survival curves at 2-3 doses.  
WT CPX, ΔV018 CPX, D132R expressing CPX, or revertant CPX infected via the 
intranasal route differentially impact survival in WT B6, NKG2D-deficeint, and FCRL5-
deficient mice. Kaplan-Meier analysis shows survival of female mice following intranasal 
infection with 2.5 x104 pfu (dotted line), 5 x104 pfu (dashed line), or 7.5 x104 pfu (solid 
line) of the designated CPX strain.  Data are aggregated from greater than 10 
independent experiments with 4-10 mice per group 
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CHAPTER 3: Assessment of OMCP crosslinking  
Introduction:  
OMCP blocked with recombinant NKG2D does not bind NK cells but retains the ability 
to bind to B cells and macrophages [4], suggesting that OMCP binds to NKG2D and the 
other receptors via distinct binding sites on separate interfaces. This observation raised 
the hypothesis that OMCP may act during viral infection to link NK cells and B cells or 
macrophages together via simultaneous binding to these independent receptors. If this 
is the case, it may be possible that OMCP serves to divert NK cell lysis away from CPX 
infected cells (that are actively secreting OMCP to protect infected cells from NKG2D 
recognition), and redirect NK cell lysis towards innate B cells or macrophages that 
constitutively express an OMCP binding receptor. We wished to address whether 
OMCP held on a cell surface by FCRL5 or a macrophage receptor would act as a 
pseudo-NKG2D stress ligand and be sufficient to activate NKG2D mediated NK cell 
killing.  
 
During a typical viral infection, infected cells experience “cellular stress,” resulting in 
induction of a number of MHC class I like surface glycoproteins (MICA, MICB, ULBP 
family, and Rae1 family in humans; H60, Mult1, and Rae1 family in mice [45]). NK cells 
expressing the NKG2D receptor use this as a surveillance mechanism to identify cells 
that have been perturbed by pathogen infection, tumorigenesis, heat shock, or similar 
stresses. Engagement of NKG2D by stress ligands on virally infected cells results in 
subsequent killing of these target cells. We have previously determined that soluble 
 48
OMCP blocks NKG2D mediated killing because soluble monomeric OMCP is unable to 
crosslink and activate NKG2D. We now wished to test whether immobilized OMCP held 
on a cell surface is sufficient to induce NKG2D signaling and stimulate NK cell killing 
(Fig 14).  Yac-1 targets, a murine T cell lymphoma line highly sensitive to NK cell killing 
due to low or no surface expression of MHC class I, were used as a positive control in 
all assays.  Surface bound OMCP was expressed using an OMCP-Thy1.1 fusion, but 
similar surface presentation of OMCP in vivo could be envisioned for a cell presenting 
OMCP bound via the surface receptors FCRL5 or FcRI. Our experiment demonstrated 
that Ba/F3 cells that had OMCP presented on the cell surface were killed to a 
comparable extent as cells expressing the canonical NKG2D ligands Mult1 and Rae1δ 
(Fig 14). This gave support that redirected NK cell lysis towards OMCP presenting cells 
is possible. A series of NK cell killing assays were performed to further test this 
hypothesis.  
 
Experimental Methods:  
In vitro Killing Assay  
NK cell effectors: Splenocytes were harvested from naïve B6 mouse, and incubated in 
200 U IL-2 overnight to activate NK cells for effective killing. Splenocytes were washed 
with R10 x2, counted, resuspended at 2x107 c/mL, and plated with target cells at 
defined E:T ratios.  
 
PBMC effectors: Fresh blood is drawn from a healthy donor the day of the experiment. 
Blood is diluted 1:1 with room temperature HBSS. The blood/HBSS mixture is added 
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slowly over a ficoll layer at a 2:1 blood mix:ficoll ratio. The cells are spun over a ficoll 
gradient at 2500 rpm for 30 min at 25oC with no brake. The mononuclear cell layer is 
isolated and washed with R10 x2. Cells are counted, then resuspended at 2x107 c/mL 
and plated with target cells.   
 
Target cells: Ba/F3 or Yac-1 target cells are CFSE labeled fresh the day of the 
experiment. Cells are washed and resuspended in PBS at 3 x106 c/ml. 0.5 uM CFSE 
diluted in PBS is added in a 1:1 ratio, and cells are incubated at 37oC for 8 min. The 
Cells are then washed with R10 and incubated with fresh R10 at 37oC for 20 min. 
Target cells are then counted, resuspended at 5x105 c/mL and plated with target cells at 
defined E:T ratios.  
 
Targets and effectors are plated at E:T ratios of 10:1, 20:1, and 40:1 in triplicate in 96 
well plates. Cells are incubated at 37oC, 5% CO2 for 4 hours. Cells are then harvested 
and killing percentage determined by flow cytometry with the dead cell exclusion dye 
7AAD. 7AAD is a fluorescent cell viability stain that intercalates into dsDNA, but does 
not readily pass intact cell membranes. Dead cells stain positive for 7AAD  
 
Killing is analyzed by gating on CFSE+ target cells and determining percent of 7AAD+ 
(killed) targets. Values are normalized to the percentage of dead cells at baseline in 
target only control wells. Percent killed is calculated as = (% dead with splenocytes - % 
dead at baseline) / (% live at baseline)   
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OMCP incubations: Killing assays testing OMCP killing were performed in several ways. 
1.) Effector cells (splenocytes or PBMCs) were incubated with 20 ug OMCP monomer 
at 37oC for 30 min prior to plating. Cells were then washed x1 with R10, counted, and 
plated with target cells that were not preincubated with OMCP. 2.) Target cells were 
incubated with 20 ug OMCP monomer at 37oC for 30 min. Cells were then washed x1 
with R10, counted, and plated with effector cells that were not preincubated with OMCP. 
3.) Both Effector cells and Target cells were incubated with 20 ug OMCP monomer, and 
cells were counted and plated together. 4.) Effector cells and Target cells were not 
preincubated with OMCP, but rather plated normally, then free OMCP monomer was 
added to the media prior to the full 4 hour incubation. Serial dilutions of 10 ug, 5 ug, 
2.5ug, 1.25ug, 0.625ug, 0.3125ug, 0.156ug, and 0.78ug OMCP were added to the 
effector and target cell wells. All experiments were performed at E:T ratios of 10:1, 20:1, 
and 40:1 in triplicate, with the exception of the serial dilutions of free OMCP, which were 
performed at 20:1 in triplicate.  
 
Combined CD107a and IFNγ Degranulation Assay  
Splenocytes are harvested, washed, counted, and plated in wells of a 24 well plate. 10 
ug, 5 ug, or 2.5 ug of monomeric or tetrameric OMCP is added to the media, or no 
protein control. Cells stimulated with plate bound anti-NK1.1, plate bound anti-NKG2D, 
or a cytokine cocktail (10 ng/mL IL-12, 50 ng/mL IL-18, 10 ng/mL IL-15) were included 
as positive controls. A647-CD107a antibody is added to each well, and cells are 
incubated for 1 hour at 37oC, 5% CO2. After 1 hour, Golgiplug and GolgiStop (monensin 
and brefeldin A) are added to each well, and the cells are incubated for a further 6 hours 
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at 37oC 5% CO2. Cells are then harvested and stained for additional cell surface 
markers, incubate 30 min at 4oC in the dark. Intracellular staining for IFNγ is performed 
using BD CytoFix/CytoPerm solution with 2uL of PE-IFNγ per sample. Cells are then 
analyzed by flow cytometry for intensity of A647-CD107a and PE-IFNγ. 
 
Results:  
Multimeric OMCP is not sufficient to activate NK cells through NKG2D 
Our proposed OMCP bridging and NK cell redirecting hypothesis would require OMCP 
to sufficiently activate NK cells through the NKG2D receptor to trigger NK cell mediated 
killing. We have previously shown that soluble monomeric OMCP does not cause 
NKG2D receptor downregulation or activation, and rather soluble monomeric OMCP 
binding to the NKG2D receptor is inhibitory. Here, we sought to test whether multimeric 
OMCP is sufficient for activation through NKG2D. NK cells were enriched using Miltenyi 
negative selection kits and incubated with either monomeric OMCP or tetrameric OMCP 
for 7 hours (initial 1 hour incubation, then 6 hours after addition of monensin & brefeldin 
A). Cells stimulated with plate bound anti-NK1.1, plate bound anti-NKG2D, or a cytokine 
cocktail (10 ng/mL IL-12, 50 ng/mL IL-18, 10 ng/mL IL-15) were included as controls. 
We did not observe any activation of NK cells using tetrameric OMCP, as determined by 
IFNγ or CD107a staining (Fig 15). Additionally, there was no upregulation of the 
activation markers CD69 or CD71 using multimeric OMCP (data not shown). These 
results suggest that soluble tetrameric OMCP is not sufficient to cluster NKG2D and 
activate NK cells in vitro, however it remained possible that OMCP on a cell surface 
may allow enough crosslinking for signaling. 
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 NK cell Killing Assays 
We developed a killing assay to further test the possibility of OMCP acting as a bridging 
ligand to activate NKG2D. Splenocytes harvested from naïve B6 mice were incubated 
overnight in 1000 U/mL IL-2 to prime NK cells for more effective killing. Ba/F3 
transgenic targets or Yac-1 positive controls were then CFSE labeled, and incubated 
with IL-2 activated splenocytes for 4 hours at several E:T ratios (40:1, 20:1, 10:1). Cells 
were harvested after 4 hours, and dead cells identified with 7AAD cell viability stain to 
determine percentage of target cells killed. Untransduced Ba/F3 targets were used as a 
negative control. Control experiments were performed to confirm that soluble OMCP 
can block killing of BaF/Mult1 in this system, as was previously established.  
 A series of experiments were performed to assess the possibility of OMCP bridging 
between NKG2D and FCRL5 receptors. For these killing assays, OMCP was titrated in 
an attempt to achieve optimal effect. Too little protein would have no effect, whereas too 
much protein would saturate both the NKG2D and FCRL5 receptors, preventing 
crosslinking. Therefore we expected that a bridging effect resulting in increased target 
killing would be seen at some optimal concentration of OMCP. A range of protein 
concentrations were tested for each experiment to accommodate this fact. Additionally, 
scenarios were tested in which only NK effectors were preincubated with OMCP, only 
FCRL5 expressing targets were preincubated with OMCP, or both effectors and targets 
were preincubated with OMCP to identify any combination that would allow us to see 
increased killing in the presence of OMCP.  
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OMCP does not redirect killing towards FCRL5 expressing targets 
Killing assays were performed with two independent BaF/FCRL5 transductants (Fig 16 
and 17), a C1498/FCRL5 transductant (data not shown), and the WEHI231 cell line (Fig 
18). Assays with each cell line were performed 1-2 times, with two independently 
produced lots of OMCP protein. In all cases, addition of OMCP did not result in 
increased killing at any of the tested doses (Fig 16, 18). If anything, there is a slight 
downward trend in killing at high OMCP concentrations, suggesting that OMCP is 
functioning only as a high affinity inhibitor of NKG2D.  Despite extensive investigation, 
these results provide no clear evidence to support the hypothesis that OMCP functions 
by “bridging” NKG2D+ NK cells and FCRL5+ B cells thereby facilitating NK cell killing. 
 
OMCP does not redirect killing towards mouse BMDMs 
All experiments thus far have suggested that OMCP does not crosslink NK cells and B 
cells to result in activation and redirected lysis of B cells by NK cells. Subsequent 
assays were performed to test the possibility of OMCP crosslinking of NKG2D and the 
putative macrophage receptor. Our initial experiment used primary bone marrow 
derived macrophages (BMDMs) obtained through long term culture of WT bone marrow 
cells in M-CSF. BMDMs have previously been shown to bind to OMCP tetramers in the 
unstimulated state. We incubated WT BMDM targets with IL-2 activated splenocyte 
effectors, however our assay showed no evidence of receptor bridging (Fig 19). In fact, 
BMDMs appeared to be highly resistant to killing. It may be possible that other 
macrophage or monocyte subtypes would be more optimal for these killing assays. 
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Further experiments using primary mouse macrophage or human monocyte derived 
macrophage targets can also be performed to confirm these findings.  
 
Future Experiments: 
The most likely reasons we were not able to see OMCP crosslinking of these separate 
receptors are due to low affinity binding or short half-lives of interaction. A bridging 
effect is only possible if OMCP binding to NKG2D and OMCP binding to FCRL5 or the 
macrophage receptor are both stable for long enough to allow bridging to occur followed 
by clustering of receptors and initiation of downstream activating signals. The OMCP-
murine NKG2D interaction has a short half life on the order of seconds (koff  = 1.8 x 10−2 
s−1), while OMCP’s interaction with human NKG2D has a strikingly longer half life on the 
order of minutes (koff = 1.23 × 10−4 s−1) [4]. Given this difference, we plan to repeat these 
bridging killing assays using human PBMCs and human monocyte targets. 
 
We plan to use the Thp1 cell line as the human monocyte target. Thp1 is a human 
monocyte cell line derived from an acute monocytic leukemia patient. These cells have 
previously been shown to stain positive for OMCP tetramer binding, and were the cell 
line used in our immunoprecipitation pull-down approach to try to identify the OMCP 
binding receptor on macrophages and monocytes (Appendix 1).  
 
Due to the magnitude of our experiment, we plan to use human PBMCs obtained from a 
leukocyte reduction system (LRS) chamber, rather than PBMCs from fresh blood as our 
effector cells. Leukocyte reduction is the removal of white blood cells from blood or 
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blood components used for blood transfusion. The leukocytes are separated by size 
using counterflow centrifugation elutriation and are trapped in the LRS chamber. These 
LRS cones are a source of viable human white blood cells that can be used in research 
applications. We will ficoll purify cells obtained from the LRS chambers, then freeze the 
cells with 10% DMSO in smaller aliquots for use.  
 
In our killing assay, we will use CFSE labeled human Thp1 cells as targets and frozen 
human PBMCs from an LRS cone source as effectors. Effectors will not be preactivated. 
OMCP should have a higher binding affinity and longer half life with human NKG2D as 
compared to murine NKG2D. However, OMCP binding kinetics to the human or mouse 
macrophage receptor have not been determined. Our results will show if there is any 
effect of OMCP on Thp1 cell killing by human PBMC effectors under any of the 
conditions tested (effectors preincubated with OMCP, targets preincubated with OMCP, 
both effectors and targets preincubated with OMCP, and titration of OMCP directly in 
wells with effectors and targets).  
 
Discussion:  
We have extensively investigated the possibility of OMCP crosslinking of NKG2D 
bearing NK cells with FCRL5 expressing cells. Killing assays performed with two 
independent BaF/FCRL5 transductants, a C1498/FCRL5 transductant, and the 
WEHI231 cell line targets did not show increased killing in the presence of soluble 
OMCP under any contition. Additionally, we did not see any evidence of increased 
killing with murine splenocytes against murine BMDMs. This might suggest that soluble 
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OMCP is not sufficient to crosslink NKG2D bearing cells and FCRL5 or macrophage 
receptor bearing cells.  
 
However, we have yet to thoroughly test human PBMC effectors against human cell line 
targets. We might expect better success using human PBMCs, due to the higher affinity 
of human NKG2D for cowpox OMCP. We plan to investigate killing of human PBMCs 
against the Thp1 monocyte cell line first, as we consider it more likely that OMCP may 
be acting on monocytes in preference to FCRL5 bearing innate B cells.   
 
The binding affinities and kinetics of OMCP-FCRL5 and the unidentified macrophage 
receptor have yet to be determined by SPR. Once these values are obtained, a 
theoretical half life for the bridged species can be calculated, and the feasibility of such 
a species occurring at high enough a density to result in clustering and crosslinking of 
the NKG2D receptor can be assessed. Given our lack of success in validating this 
hypothesis with killing assay data using murine splenocytes with an array of cell lines 
expressing FCRL5 or macrophage cell line targets, we suspect that crosslinking and 
activation of NK cells in this manner is unlikely in vivo. However, crosslinking of human 
NK cells has yet to be determined.  
 
Alternatively, cell bound OMCP may not be sufficient to activate through the NKG2D 
receptor, but may be able to activate through FCRL5 or the macrophage receptor if 
those receptors have a lower threshold for activation. Similar experiments can be 
performed to look at receptor activation on macrophages using tetrameric OMCP, plate 
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bound OMCP, or BaF/OMCP-Thy1.1 to crosslink receptors on macrophages. We can 
also incubate BaF/OMCP-Thy1.1 cells with receptor expressing macrophages and 
assay for phagocytic and ADCC activity against BaF/OMCP-Thy1.1 targets. Finally, 
NKG2D expressing NK cells could be incubated with BMDMs in a range of OMCP 
concentrations similar to the previous experiment, instead assaying for phagocytosis of 
NK cell targets rather than NK cell mediated killing. Unfortunately similar experiments 
investigating FCRL5 activation will be complicated by the lack of knowledge of FCRL5’s 
endogenous function. Although the hypothesis of macrophage or FCRL5 activation via 
OMCP binding is possible, it suffers from the same requirement for the sustained 
existence of an NKG2D-OMCP-macrophage receptor bridged species that may be only 
present transiently in vivo.  
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Figures:  
 
Figure 14: Cell surface OMCP is sufficient to crosslink NKG2D and stimulate NK cell 
killing.  
Splenocytes harvested from naïve B6 mice were incubated in 1000 U/mL IL-2 overnight 
to activate NK cells for effective killing. Yac-1 or Ba/F3 transgenic targets were CFSE 
labeled and incubated with IL-2 activated splenocytes at 10:1, 20:1, and 40:1 
effector:target ratios for 4 hours at 37oC, 5% CO2. Cells were harvested after 4 hours 
and percentage of CFSE+ dead cells identified using 7AAD cell viability stain.   Yac-1 
targets are a positive control; untransduced Ba/F3 targets are negative control. Note 
that BaF/OMCP-Thy1.1 cells show comparable killing to BaF/Rae1δ and BaF/Mult1 
cells that express known NKG2D ligands on the surface.  
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Figure 15: Tetrameric OMCP is not sufficient to activate NKG2D.  
Negatively enriched NK cells were incubated with several doses of monomeric or 
tetrameric OMCP for 7 hours, with addition of golgiplug & golgistop after the first hour. 
Cells were stained for CD107a and intracellular IFNγ  
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Figure 16: Representative killing assay with BaF/FCRL5-His transductants.  
Target cells, IL-2 activated splenocytes, or both were incubated with a saturating 
amount of OMCP (20ug), washed, then plated together for a 4 hour killing assay (top 
panel). Alternatively, known concentrations of OMCP (10ug to 0 ug) were titrated in with 
targets and splenocytes (bottom panel). At no dose of OMCP did we observe increased 
NK mediated killing. Killing assay with each cell line was performed 1-2 times with two 
batches of OMCP protein. 
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Figure 17: Representative killing assay with an independently generated BaF/FCRL5-
FLAG transductant.  
Target cells, IL-2 activated splenocytes, or both were incubated with a saturating 
amount of OMCP (20ug), washed, then plated together for a 4 hour killing assay (top 
panel). Alternatively, known concentrations of OMCP (10ug to 0 ug) were titrated in with 
targets and splenocytes (not shown). At no dose of OMCP did we observe increased 
NK mediated killing. Killing assay was performed once. 
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Figure 18: Representative killing assay with the OMCP binding, FCRL5 expressing 
WEHI231 cell line.  
Target cells, IL-2 activated splenocytes, or both were incubated with a saturating 
amount of OMCP (20ug), washed, then plated together for a 4 hour killing assay (top 
panel). Alternatively, known concentrations of OMCP (10ug to 0 ug) were titrated in with 
targets and splenocytes (bottom panel). At no dose of OMCP did we observe increased 
NK mediated killing. Killing assay was performed 1-2 times with two batches of OMCP 
protein. 
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Figure 19: Representative killing assay with BMDMs cultured from WT B6 mouse bone 
marrow to test OMCP crosslinking of macrophage targets.  
Target cells, IL-2 activated splenocytes, or both were incubated with a saturating 
amount of OMCP (20ug), washed, then plated together for a 4 hour killing assay. 
Alternatively, known concentrations of OMCP (10ug to 0 ug) were titrated in with targets 
and splenocytes (not shown). At no dose of OMCP did we observe increased NK 
mediated killing. Killing assay was performed once.  
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CHAPTER 4: Future Experiments   NKG2D binding activity 
Previous work has clarified the role of OMCP on NKG2D expressing NK cells both in 
vitro [4], and in vivo (Sun M., manuscript submitted). Data indicating OMCP’s 
importance as an NKG2D antagonist in the context of viral infection is conclusive, and 
work on this avenue is finalized.  
 
FCRL5 binding activity 
Despite extensive investigation, we have not identified a clear role for OMCP binding to 
the immune receptor FCRL5 on innate B cells. In vivo data indicates that FCRL5-/- mice 
respond identically to CPX infection as wildtype C57BL/6 mice via all routes of infection 
tested, suggesting that OMCP binding to FCRL5 is not crucial for survival, weight loss, 
or organ titers. Any effect of OMCP binding to FCRL5 is therefore likely to have minimal 
impact on CPX virulence. Additionally, FCRL5 is an orphan receptor, and its 
endogenous ligand is unknown. As such, the regulation and endogenous activity of this 
receptor is not clear. I therefore propose that follow-up of FCRL5 binding activity be 
postponed secondary to investigation of OMCP’s macrophage binding activity, which 
may be more relevant biologically as well as easier to probe with assays on known 
macrophage functions.  
 
It is possible that OMCP may also bind to FCRLA and FCRLB, intracellular FCRL family 
members that have three domains homologous to the domains responsible for OMCP 
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binding to FCRL5.  However, we thought this was unlikely, since OMCP has been 
definitively shown to be secreted in large numbers from a virally infected cell, and is 
more likely to be acting on cell surface receptors of immune cells as they approach the 
infected cell. Additionally, due to the presence of the signal peptide, directing OMCP to 
the secretory pathway of the ER, OMCP produced within infected cells does not have 
an opportunity to interact with cytoplasmic receptors such as FCRLA and FCRLB. For 
these reasons, OMCP binding to intracellular FCRL family members was not evaluated. 
However, more extensive investigation of FCRL receptor binding may be pursued if 
desired.  
 
Macrophage binding activity 
Definitive identification of an OMCP binding receptor on macrophages has yet to be 
determined. Macrophages are an extremely important cell subset involved in many 
facets of innate immunity. Their primary roles include phagocytosis of pathogens, 
processing of antigen, and acting as specialized antigen presenting cells to stimulate T 
cells and other immune cells. In addition to their endocytic and phagocytotic activity, 
they are also responsible for producing oxidative bursts which create reactive oxygen or 
reactive nitrogen species to destroy pathogens directly. Furthermore, they can secrete a 
variety of cytokines and chemokines to alter the overall inflammatory milieu [46]. 
Macrophages are not homogenous, and distinct populations of macrophages with 
different roles in host defense, wound healing, and immune regulation have been 
described [47-49].  
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Initial attempts to identify a change in macrophage activity in the presence of OMCP 
were unsuccessful. These experiments involved measuring TNF production by ELISA, 
nitric oxide production using the colorimetric Greiss reagent assay, induction of iNOS by 
ELISA, assay for reactive oxygen species using DCF fluorescence, and a bulk 
phagocytosis assay by ingestion of fluorescently labeled E. coli particles (data not 
shown). No difference was seen in the presence of OMCP in this broad panel of assays. 
 
Attempts to identify the receptor responsible for OMCP binding to macrophages were 
performed using an immunoprecipitation approach where tagged OMCP was incubated 
with human Thp1 cell lysate. The initial protein of interest identified in this method was 
the high affinity Fc receptor FcRI. Although subsequent experiments have called this 
particular hit into question (see Appendix 1), this immunoprecipitation pull-down coupled 
with mass spec identification approach can be repeated to identify additional putative 
receptor binding partners. Other methods to identify the putative macrophage receptor 
might include a cDNA library approach using total RNA from Thp1 cells or BMDMs 
similar to the approach used to identify FCRL5. The BMDM cDNA library would be 
amplified and cloned into plasmids for expression into C1498 cells. Transduced cells 
can then be sorted for high OMCP tetramer staining, subject to limit dilution cloning and 
genomic DNA extraction to identify OMCP tetramer positive clones.  
 
Identification of the receptor responsible for OMCP binding on macrophages would 
make characterization of OMCP’s impact on macrophage function more tractable. 
However, gross macrophage function assays can be performed in the absence of an 
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identified receptor, as macrophage functions are fairly limited in scope and well 
established functional assays exist.  
 
We hypothesize that OMCP inhibits a function performed through activation of a 
macrophage receptor, analogous to its inhibition of NKG2D mediated killing.  
Macrophages are highly adept at recognizing and internalizing foreign material including 
complement or antibody opsonized pathogens. Following internalization of an 
opsonized pathogen, foreign peptides are presented to T cells via standard processing 
and presentation pathways. Macrophages can also mediate ADCC  
during processes such as in vivo tumor rejection [50], and antibody therapy [51]. 
Therefore, we propose to focus on a few of the main activities performed by 
macrophages, namely phagocytosis and antigen presentation.  
 
Combined Phagocytosis & ADCC assay by flow: To further probe the effect of OMCP 
on macrophage function, we would like to assay for phagocytosis and ADCC activity by 
flow cytometry. In this experiment, Raji cells, a Burkitt’s lymphoma cell line, will be 
CFSE labeled and opsonized with a panel of antibodies that have the rituximab variable 
region (anti-CD20) fused to various mouse (mIgG1, mIgG2a, mIgA) and human (huIgG1, 
huIgG2, huIgG3, huIgG4) constant regions (Invivogen). This panel will be a helpful tool 
in identifying effects of OMCP that may be isotype or FcR specific. The rituximab 
variable region is identical within this panel of mAbs and is very well characterized. We 
can then analyze antibody mediated phagocytosis and ADCC by bone marrow 
macrophages. The CFSE labeled Raji cells will be opsonized, then incubated with 
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BMDMs for up to 72 hours in the presence or absence of OMCP or a control protein. 
Following incubation, BMDMs will be labeled with PE-CD115, and cells will be analyzed 
by flow cytometry with the dead cell exclusion dye 7AAD. On analysis, PE-CD115 cells 
represent macrophages, CFSE+ cells represent Raji cells, while the PE-CD115+ 
CFSE+ double positive cells will represent cells that have been phagocytosed or 
surface bound doublets, as has previously been published [52]. Additionally, Raji cells 
that are killed externally by ADCC will be identified as the CFSE+ 7AAD+ subset. The 
percent phagocytosed and the percent killed will be obtained for each condition in the 
presence or absence of OMCP. An unopsonized sample will be included to ensure that 
cell death is due to antibody mediated phagocytosis or ADCC rather than another 
nonspecific process.  
 
Rituximab is used clinically to treat Burkitt’s lymphoma, so use of rituximab antibodies to 
opsonize CD20+ Raji cells should work well. Rituximab is known to mediate ADCC in 
monoclonal antibody mediated cancer therapy [51, 53] via macrophages and 
neutrophils [50]. Our planned assay is adapted from the flow cytometic imaging and 
quantification of ADCC that was introduced by Helguera et al. [52] using the anti-CD20 
antibody rituximab to target CFSE labeled Ramos human Burkitt’s lymphoma cells to 
labeled human monocyte effectors. The protocol is straightforward, and no problems 
are expected in adapting it for our use. Antibody mediated phagocytosis has readily 
been observed using similar flow cytometric and plate reader based readouts using 
fluorescently labeled bacteria or particles [54, 55]. One caveat with using large Raji B 
cells, however, is that complete phagocytosis of a Raji cell will likely be a rare event, 
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and one macrophage would be expected to ingest at most one or two cells. Compared 
to other macrophage phagocytosis assays using much smaller bacteria or yeast 
particles that show high percentage of double positive phagocytosed cells, the 
percentage of double positive cells using opsonized Raji cells will likely be closer to the 
1.5-2% seen in [52]. However, the advantages of using a panel of rituximab antibodies 
of different isotypes outweigh the anticipated decrease in absolute phagocytosis 
numbers when using the larger CD20+ B cell lines.  
 
A preliminary phagocytosis and ADCC experiment was completed to assess the 
feasibility of this experiment as proposed (Fig 20). In this experiment using naïve 
BMDMs and unopsonized Raji cells, we observed approximately 0.5% of double 
positive phagocytosed cells and approximately 2% externally killed Raji cells. Activation 
of BMDMs with LPS and/or IFNγ or opsonization of Raji target cells would be expected 
to increase the phagocytosis and ADCC percentage.  
  Fc mediated RBC phagocytosis: An alternative phagocytosis assay will be performed 
using more easily phagocytosed RBCs. This assay can be adapted for either flow 
cytometry or fluorescent plate reader. Human RBCs from healthy donors will be FITC 
labeled and opsonized with mouse anti-human RBC antibodies. The opsonized RBCs 
will be incubated with unlabeled mouse BMDMs in the presence or absence of OMCP.  
At various time points, the extracellular fluorescence of uningested RBCs will be 
quenched with trypan blue allowing phagocytosed cells to be assessed with a 
fluorescent plate reader. Alternatively, we can use human D+ RBCs from an Rh+ donor, 
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FITC label, and opsonize with human anti-D mAbs and incubate with unlabeled human 
PBMCs in the presence or absence of OMCP to test the effect in both mouse and 
human.  
 
The adherence and rosetting of these opsonized RITC labeled RBCs around Fc bearing 
macrophages will concurrently be examined by fluorescence microscopy. Macrophages 
will be labeled a complementary color to facilitate identification of cells. We would 
expect to see numerous RBCs in rosette formation around each macrophage. In the 
presence of OMCP, the rosetting might be expected to be disturbed, with fewer RBCs 
clustering per macrophage. The numbers of RBCs attached to each macrophage may 
be quantified and analyzed.  
 
We can readily obtain human polyclonal anti-D from pooled donors that is the standard 
treatment for Rh- mothers [56, 57]. Both phagocytosis and ADCC have been determined 
to be among the mechanisms for anti-D antibody mediated clearance of D+ RBCs [58], 
suggesting that the use of anti-D antibodies in our RBC phagocytosis assays should 
result in adequate ingestion of donor RBCs. We may expect to see reduced 
phagocytosis in the presence of OMCP, as shown by reduced fluorescence intensity of 
macrophages after quenching. Adapting a phagocytosis experiment for analysis by 
plate reader is advantageous because the faster readout allows more control over time, 
so the kinetics of phagocytosis in the presence and absence of OMCP can be parsed 
out more thoroughly.  
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Antigen presentation to T cells: Human RBCs (or alternatively sheep RBCs) will be 
covalently labeled with ovalbumin [59]. The RBC-OVA will then be opsonized with 
mouse anti-human RBC IgG and incubated with mouse BMDMs in the presence or 
absence of OMCP as described previously. After incubation for various times to allow 
for adequate internalization of the RBC-OVA, the BMDMs will be washed to remove 
uninternalized RBCs. The BMDMs will then be incubated with OVA-specific T cells, and 
antigen presentation will be assessed by assaying for T cell proliferation by thymidine 
incorporation, CFSE dilution, or IL-2 production (by ELISA).  
 
RBCs are easily conjugated to small haptens or proteins, so the production of RBC-
OVA is not expected to be difficult. We choose to use RBC-OVA rather than 
unconjugated RBCs in these antigen presentation assays due to the fact that OVA-
specific T cells are readily available and will allow a more specific readout. If 
phagocytosis experiments suggest a reduction in RBC internalization in the presence of 
OMCP, then it would follow that fewer peptides will be presented to T cells, resulting in 
less IL-2 production and less T cell proliferation. If the previous phagocytosis 
experiments are inconclusive or suggest no difference in phagocytic ability, it is still 
possible that internalized OMCP alters signaling in some way to reduce antigen 
presentation. Based on the function that OMCP has on NKG2D, we hypothesize that 
OMCP blocks activation of macrophages through an activating receptor, and expect that 
all downstream effects such as internalization and antigen presentation will be reduced.  
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It is possible that the outlined approaches will not delineate a functional consequence of 
OMCP binding to macrophages. We will then pursue tests of other macrophage 
functions including cytokine production, reactive oxygen production, and related 
activities. A negative outcome could suggest that OMCP binding to macrophages may 
be simply an epiphenomenon of NKG2D or FCRL5 binding. However, we postulate that 
OMCP is independently targeting NKG2D, FCRL5, and a macrophage receptor, and 
possibly has unique functional effects on each receptor.  
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Figures:   
 
Figure 20: Phagocytosis & ADCC assay Gating Scheme.  
 Anticipated gating scheme using CFSE labeled Raji cells and CD115 labeled primary 
BMDMs. PE-CD115 cells represent macrophages, CFSE+ cells represent Raji cells, 
while the PE-CD115+ CFSE+ double positive cells (population A) will represent cells 
that have been phagocytosed or surface bound doublets, as has previously been 
published [52]. Additionally, Raji cells that are killed externally by ADCC will be 
identified as the CFSE+ 7AAD+ subset (population B). 
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 APPENDIX 1: Investigation of FcRI as a putative OMCP binding receptor  
Introduction:  
The FCRL5 receptor is not expressed on macrophages, and although activated murine 
macrophages have been reported to express NKG2D [60], experimental evidence 
showed that preincubation with anti-NKG2D antibodies or the recombinant NKG2D 
ligand MULT1 does not inhibit OMCP tetramer binding to monocytes/macrophages, 
suggesting that macrophages express an additional receptor distinct from both FCRL5 
and NKG2D [7]. An immunoprecipitation pull down method was used to identify FcRI 
(CD64) as a putative OMCP-binding receptor expressed on macrophages.  An OMCP-
human IgG(Fc) fusion protein and a Mult1-human IgG(Fc) control were generated and 
used to pull down protein lysate from a human monocyte cell line previously shown to 
bind OMCP (Thp1 cells). Mass spectrometry sequencing results identified FcRI as a 
receptor of interest. OMCP binding to FcRI was initially confirmed by OMCP tetramer 
staining to stable BaF/human FcRI transductants. Specificity of the interaction was 
validated by blockade with anti-FcRI polyclonal antibodies, anti-FcRI F(ab’)2 fragments, 
and cold OMCP tetramers (Fig 21). OMCP binding was also confirmed on BaF/mouse 
FcRI transductants (Fig 22).  
 
The high affinity FcRI receptor 
FcRI is part of a large family of Fc receptors that contains both activating and inhibitory 
members that have different affinities for the various subclasses of immunoglobulins. 
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FcRI is the only high affinity IgG receptor (with near nanomolar affinity for IgG 
subclasses). It is constitutively expressed on monocytes and macrophages, and it is 
inducible on activated granulocytes by IFNγ [61]. Macrophages express all classes of 
activating Fcγ receptors, and there is significant redundancy between the functions of 
these receptors, as all activating Fc receptors use the same ITAM bearing gamma 
signaling chain [61]. However, there is evidence that the FcRI alpha chain can elicit 
functions independently of the gamma chain, making it possible that FcRI may have 
unique functions that can not be compensated for by the other activating Fc receptors 
present on macrophages [62].  
 
Fc receptors bind antibodies at their invariant Fc region, allowing cells bearing Fc 
receptors to bind to opsonized pathogens, immune complexes, or in some cases 
monomeric Ig. FcRI is the highest affinity IgG receptor that preferentially binds mouse 
IgG2a and IgG2b (or human IgG1 and IgG3) [63, 64]. The high affinity interaction 
between FcRI and serum IgG is also unique among Fcγ receptors. FcγRI’s affinity for 
IgG is higher than the concentration of IgG in serum (20 nM for mouse FcRI binding to 
mouse IgG2a [65]; 15-40 nM for human FcRI binding to human IgG1, IgG3, IgG4 [66]), 
making FcRI capable of binding monomeric serum IgG. The receptor is thought to be 
prearmed with IgG similar to mast cell FcεRI with IgE [61].  
 
The high affinity IgG receptor FcRI is known to facilitate phagocytosis and antibody 
dependent cellular cytotoxicity. But the involvement of macrophages and monocytes 
and the role of FcRI in particular in orthopoxvirus infections has not been well 
 78
established, although macrophage dependent clearance of ectromelia [67] and vaccinia 
[68] viruses has previously been observed.   
 
It is proposed that FcRI in an unactivated state functions as a type of scavenger 
receptor, constantly sampling extracellular antigens as the receptor-IgG complex gets 
internalized and recycled back to the surface. However, at sites of inflammation, 
cytokine production promotes de novo synthesis of FcγRI and accelerates the recycling 
process, allowing macrophages to internalize more antigen in an inflammatory area [61]. 
Following internalization of an opsonized pathogen, foreign peptides are presented via 
standard processing and presentation pathways. Another process involving Fc 
receptors is antibody dependent cell mediated cytotoxicity (ADCC). ADCC is classically 
thought of as being mediated by FcRIII receptors on NK cells, where engagement of 
FcRIII by an opsonized target stimulates release of cytotoxic granules.  ADCC has also 
been shown to be mediated by macrophages during processes such as in vivo tumor 
rejection [50], and antibody therapy [51] where lysis of cells is thought to involve release 
of the cytotoxic mediators TNF-α and IL-1 [69, 70]. 
 
Phenotype of FcRI-/- knockout mouse and human mutations 
The FcRI -/- mouse has been generated independently by two separate labs, both of 
which described a range of defects involving impaired endocytosis of monomeric IgG, 
phagocytosis of immune complexes, chemokine release, macrophage based ADCC, 
reduced hypersensitivity responses, immune complex dependent antigen presentation 
to primed T cells, and impaired protection from bacterial infection [71, 72]. In contrast, 
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no defects were appreciated in leukocytes isolated from a human family with a 
premature stop mutation in human FcRI [73, 74]. Their monocytes were able to bind 
and phagocytose aggregated human IgG and coated human RBCs normally through 
redundancy with FcRII. This situation illustrates the problem that OMCP inhibition of 
FcRI may be masked by the functions of other Fc receptors on macrophages. However, 
the virus has targeted a receptor that is quite unique in its high affinity nature of binding, 
so it is unlikely that targeted functions of FcRI can be completely compensated for by 
other Fc receptors.  If this is the case, then we expected that the FcRI -/- mouse may 
exhibit an equal or increased survival advantage compared to WT mouse when both are 
infected with OMCP-sufficient cowpox, while the FcRI -/- mouse may be more 
susceptible to infection than WT mouse due to loss of a critical immune receptor when 
both are infected with OMCP-deficient cowpox.  
 
The initial discovery that viral OMCP specifically targets FcRI on immune cells was 
investigated. Given the near nanomolar affinity that FcRI has for serum IgG, it would be 
important to determine whether OMCP has a binding affinity that can successfully 
compete with IgG or immune complexes. Alternatively, we considered OMCP may have 
been acting as a non-competitive inhibitor on a site other than the IgG binding site. 
OMCP may also function by stabilizing either activated or unactivated forms of the 
receptor or disrupting interactions between the alpha and gamma signaling chain of 
FcγRI.  
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Experimental Methods:  
Immunoprecipitation pull down/mass spec analysis 
FcRI was identified as a putative OMCP-binding receptor through an 
immunoprecipitation pull down method. An OMCP-human IgG(Fc) fusion protein and a 
Mult1-human IgG(Fc) control were generated and incubated with Thp1 (human 
monocyte cell line) cell lysates and pulled down with Protein G beads. The beads were 
then reduced and run on SDS-PAGE gel, and a unique band in the OMCP-hu IgG(Fc) 
fusion protein lane was identified, cut out, and sent for mass spectrometry sequencing, 
which identified FcRI as a receptor of interest.  
 
FcR cloning 
The FcRI gene was cloned out of the human Thp1 cell line and M-CSF conditioned 
mouse BMDMs and ligated into the pMX-IRES-GFP vector. PLAT-E retroviral 
packaging cells were transfected with human or mouse FcRI expressing plasmids, and 
grown to allow packaging of the plasmid material into retroviruses with the Moloney 
murine leukemia virus capsid. This retroviral supernatant was then used to transduce 
BaF/3 cells. Stable incorporation of the pMX-IRES-GFP insert was selected for by 
FACS sorting for GFP positive BaF/3 cells, and expression of FcRI was confirmed by 
antibody staining.  
 
We have also completed cloning of all of the murine and human Fc receptors for 
transduction into BaF3 cell lines. Total RNA was isolated from cultured mouse BMDMs 
or fresh human PBMCs, and reverse transcribed into total cellular cDNA. Sequences for 
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mouse FcγRIIb, FcγRIII, and FcγRIV and human FcγRIIa and FcγRIIIa were amplified, 
restriction digested, and ligated into pMX-IRES-GFP vectors for transformation into 
ultracompetent cells as described above for FcRI. Plasmids were grown for 
transfection into PLAT-E retroviral packaging cells for stable transduction of BaF3 cells. 
Fc receptor transduced BaF3 cell lines were then used to further evaluate OMCP 
tetramer binding. 
 
Recombinant protein expression and tetramerization 
Recombinant BirA tagged OMCP was expressed in bacterial cells, refolded from 
inclusion bodies, and purified by size exclusion chromatography. A biotin ligase reaction 
was performed to site-specifically biotinylate the OMCP protein at the BirA tag, followed 
by another size exclusion chromatography purification. Biotinylated OMCP was 
tetramerized fresh before each staining experiment by incubation with APC labeled 
streptavidin at a 4:1 molar ratio for 10 min at RT and used for cell staining same day. 
 
OMCP tetramer binding by flow cytometry  
The appropriate cell lines or primary cells for each experiment are stained with 400ng of 
OMCP tetramer, D132R tetramer, DIII control tetramer, or streptavidin control for 1 hour 
on ice, in the dark. Tetramers are fluorescently labeled by binding biotinylated protein 
with APC-streptavidin in a 4:1 molar ratio. All tetramers are made fresh for each 
experiment. In blockade experiments, the designated protein or antibody blockade is 
incubated with cells first for 1 hour on ice in the dark, followed by an additional 1 hour 
incubation with labeled tetramers. Following staining, cells are washed with sorting 
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buffer x3 to remove unbound tetramer. Data was collected on a FACSCalibur, and 
analyzed using FlowJo software (TreeStar, Ashland, OR).  
 
In vitro generation of murine bone marrow derived macrophages 
Male or female 8 week old mice were sacrificed by CO2 euthanasia. The long bones 
(tibia and femur) of the hind leg are harvested and cleaned of muscle and tendons. The 
ends of each bone are snipped open to access bone marrow. Marrow is flushed or 
centrifuged out of the bone, and resuspended in DMEM with 20% L929 cell supernatant, 
10% FBS, 1% L-glutamine, 1% Na pyruvate, 1% P/S. Marrow from one mouse (4 
bones) can be plated in 5x 10 cm tissue culture petri dishes. Incubate at 37oC, 5% CO2 
for 7 days. On Day 5, add fresh L929 supplemented media. BMDMs ready for use 
between day 7-day 14. Note – L929 cell line produces murine M-CSF. Supernatant from 
L929 cells in log phase growth is filtered and used for BMDM media. L929 supernatant 
can be replaced with recombinant murine M-CSF.    
 
Mutant D132R OMCP protein expression  
Initial binding assays have identified the D132 residue of OMCP as integral for NKG2D 
binding. To create a mutant that has exclusively lost NKG2D binding, we sought to 
introduce a positively charged arginine to disrupt interactions. Primers were designed 
for a SOE reaction to introduce D132R mutation into VO18 sequence.  The product was 
ligated into p7.5gpt plasmid and transformed into competent cells with selective media, 
followed by mini-prep and sequencing (PNACL) to verify presence of mutation. BSC-1 
cells were infected with cowpox, then transfected with D132R plasmid under gpt 
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selective pressure. Plaques were picked and plaque purified twice in gpt selective 
media, then twice in non-selective media. Viral stock was grown and sequenced to 
confirm presence of the D132R mutation. 
 
Mutant CPX virus generation 
An OMCP deficient cowpox virus (V018-/- CPX) was generated using a transient domain 
selection strategy to introduce mutations into the virus genome. Two tandem stop 
codons were inserted in the OMCP open reading frame, resulting in loss of functional 
OMCP with minimal impact on other genes [7]. The virus was propagated in BSC-1 cells, 
purified through sucrose gradient, titered, and used for i.p. mouse infections at 0.61x106 
pfu/mouse and 1.93x106 pfu/mouse. We have established that cowpox virus deficient in 
OMCP has decreased virulence as determined by lethality in WT C57BL/6 mice. 
 
Results: 
Initial Identification of FcRI 
An immunoprecipitation pull down method was used to initially identify FcRI (CD64) as 
a putative OMCP-binding receptor expressed on macrophages. Here, an OMCP-human 
IgG(Fc) fusion protein and a Mult1-human IgG(Fc) control were generated and 
incubated with Thp1 (human monocyte cell line) cell lysate and pulled down with Protein 
G beads. The beads were then reduced and run on an SDS-PAGE gel, and a unique 
band in the OMCP-hu IgG(Fc) fusion protein lane was identified, cut out, and sent for 
mass spec sequencing. Sequencing results identified FcRI (CD64) as a receptor of 
interest.  
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OMCP binding to FcRI was confirmed by OMCP tetramer staining to stable BaF/human 
FcRI transductants, as well as murine bone marrow derived macrophages (BMDMs) 
(Fig 22). OMCP tetramers do not bind untransduced Ba/F3 cells, and an irrelevant WNV 
DIII protein was used as a negative control in all staining experiments. Specificity of the 
interaction was validated by blockade with anti-huFcRI polyclonal antibodies and cold 
OMCP tetramers on BaF/huFcRI transductants (Fig 21). We found that preincubation 
of cells with cold OMCP tetramers (Fig 21C) or anti-huFcRI F(ab)2 fragments (Fig 21D) 
greatly decreased labeled OMCP tetramer binding, supporting our initial hypothesis that 
OMCP specifically targets the FcRI receptor on macrophages and monoctyes. We 
believed this experiment addressed the possibility that the OMCP-Fc used in our initial 
pull down was binding to FcRI via its Fc, as our purified OMCP protein should not have 
contained Fc binding domains.  
 
Characterization of FcRI binding 
We showed that cells that express the human FcRI receptor had a correspondingly 
high level of OMCP tetramer binding, although BaF cells transduced with murine FcRI 
appeared to have lower affinity binding. Inconsistently, we saw that OMCP binding was 
strong on murine BMDMs, despite the apparent low binding on the BaF/muFcRI cell 
line (Fig 22). This may have suggested additional factors responsible for OMCP binding 
on primary murine macrophages. To determine whether NKG2D binding may be playing 
a role, we tested binding of the D132R mutant on cells expressing NKG2D, FCRL5, or 
FcRI. As expected, the D132R mutant lost all binding to NKG2D expressing cells, with 
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no decreased binding to the FCRL5 expressing cells (BaF/FCRL5 or WEHI cells) (Fig 
23). Additionally, there was no reduced binding of the D132R mutant to BaF/huFcRI 
cells. However, binding of D132R was reduced, but not completely abrogated on murine 
BMDMs (Fig 23). This finding was inconsistent with previous published results that 
showed no reduction in OMCP binding when murine macrophages are preincubated 
with anti-NKG2D antibodies [8].  
 
Further experiments showed repeatable dose dependent OMCP tetramer binding to 
murine BMDMs and human CD14+ monocytes isolated from fresh PBMCs (Fig 24).  
Bone marrow derived macrophages (BMDMs) exhibit high FcRI expression in the 
unactivated state, with a 3 fold increase in expression after overnight stimulation with 
interferon gamma (IFNγ) and bacterial lipopolysaccharide (LPS) (data not shown).  
OMCP tetramers demonstrated robust binding to WT BMDMs even in the unactivated 
state (Fig 24). Here we demonstrate that OMCP tetramers from the Brighton Red strain 
of CPX bind both human PBMCs and murine primary BMDMs.  
 
OMCP retains binding to FcRI ko BMDMs 
After initially confirming binding to mouse bone marrow derived macrophages (BMDMs), 
human PBMCs, as well as specific binding to BaF/muFcγRI and BaF/huFcγRI 
transductants, we obtained FcγRI -/- mice for our studies. Unexpectedly, we found that 
OMCP tetramer binding was retained on FcγRI -/- BMDMs, with no apparent reduction in 
staining intensity (Fig 25). This has been repeated with BMDMs from multiple FcγRI -/- 
mice, and lack of expression of FcRI on their cells has been confirmed. Additionally, 
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although anti-FcγRI polyclonal F(ab’)2 blockade is sufficient to block OMCP tetramer 
staining on BaF/FcγRI transductants, it is not sufficient to block OMCP binding on WT 
mouse BMDMs or human CD14+ monocytes (Fig 26). Additional blockade using the 
anti-FcγRI polyclonal F(ab’)2 fragments with 2.4G2 sup (anti-FcγRII/FcγRIII 
monoclonal) showed no reduction in OMCP tetramer binding compared to unblocked 
controls. This data may implicate other murine FcRs or some unrelated receptor as 
being responsible for OMCP binding on FcγRI ko BMDMs.  
 
It is possible that OMCP binds to multiple Fc receptors. This is not a novel strategy in 
poxviruses, as the immunoevasin CrmD has been demonstrated to promiscuously bind 
all tested Fc receptors (M. Epperson, unpublished data). Based on anti-FcγRI and 
2.4G2 blocking data, as well as analysis of expression patterns of each of the Fc 
receptors in mouse, we suspected OMCP may be binding to both FcγRI and FcγRIV on 
murine macrophages. The FcγRI and FcγRIV receptors are both gamma chain 
dependent activating Fc receptors that display selectivity for the most potent mouse IgG 
subclasses, IgG2a and IgG2b [75]. FcγRI is uniquely expressed on monocytes, 
macrophages, and a subset of monocyte derived DCs [76], while FcγRIV expression is 
detected on monocytes, macrophages, neutrophils, and DCs, but notably not T cells, B 
cells or NK cells [77], consistent with earlier results in our laboratory. Although FcγRI is 
the high affinity IgG receptor, FcγRIV has an intermediate affinity (3x107 M-1) for IgG2a 
and IgG2b, and there is convincing evidence that FcγRIV plays a central role in IgG2a 
and IgG2b activity [75-77].  
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Possible OMCP binding to multiple FcRs 
We subsequently tested OMCP binding to all murine and human Fc receptors (mFcγRI, 
mFcγRIIb, mFcγRIII, mFcγRIV, huFcγRI, huFcγRIIa, huFcγRIIIa). We have cloned all of 
the murine and human Fc receptors for transduction into Ba/F3 cell lines. Total RNA 
was isolated from M-CSF cultured mouse BMDMs or fresh human PBMCs, and reverse 
transcribed into total cellular cDNA. Sequences for mouse FcγRIIb, FcγRIII, and FcγRIV 
and human FcγRIIa and FcγRIIIa have been amplified, restriction digested, and ligated 
into pMX-IRES-GFP vectors for transformation into ultracompetent cells. Plasmids were 
grown for transfection into PLAT-E retroviral packaging cells for stable transduction of 
Ba/F3 cells. Fc receptor transduced Ba/F3 cell lines were then be used to further 
evaluate OMCP tetramer binding.  
 
When we tested OMCP binding to Ba/F3 cells expressing mouse FcγRIIb, FcγRIII, and 
FcγRIV and human FcγRIIa and FcγRIIIa, we saw that in addition to binding to mouse 
FcγRI and human FcγRI, we saw consistent binding to murine FcγRII (CD32) (Fig 27). 
We did not see binding of OMCP tetramers to any of the other murine and human FcRs. 
Contrary to our initial hypothesis, we did not see OMCP binding to mouse FcγRIV. We 
noted that OMCP binding to FcγRIIb strangely showed a pattern of multiple peaks, 
which was inconsistent with the uniform expression of the FcγRIIb receptor as 
determined by staining using the 2.4G2 (anti-FcγRII/FcγRIII) antibody (Fig 28). This 
unexpected pattern is repeatable, but remains unexplained.  
 
 88
These experiments in aggregate suggested that OMCP may bind to additional Fc 
receptors, namely murine FcγRIIb, which may explain the retained tetramer binding in 
the FcγRI ko mouse BMDM cells. However, there were several abnormalities observed 
in this data, which complicates the interpretation of these findings. For example, OMCP 
binding to FcγRIIb is inconsistent with our previous observations that combined anti-
mFcRI  and anti-mFcRIIb blockade does not block OMCP binding to WT BMDMs 
(data not shown).  
 
OMCP binding to BMDMs does not require Dap10, Dap12, or FcRγ 
To further investigate possible OMCP binding to Fc receptors, we tested OMCP binding 
to BMDMs derived from FcR gamma chain ko mice and Dap10/Dap12 double ko mice. 
The FcRγ-/- mice do not express the activating Fc receptors FcεRI, FcγRIII, FcγRIV that 
require the signaling gamma chain for surface expression. Although the FcR gamma 
chain ko mice has been reported to have 1/5 the normal level of FcγRI expression, the 
residual FcRs were found to be deficient in activity [71]. Dap10 and Dap12 are signaling 
adaptors are required for expression of numerous immune receptors, including NKG2D, 
Ly49D, and Ly49H on NK cells; Clec5a, Trem1, and Trem2 on macrophages; Siglec-H, 
pDC-Trem, and DlgR1 on myeloid cells, as well as many other important receptors [78]. 
Contrary to expectations, we found that OMCP binding to murine BMDMs did not 
appear to require expression of any of the adaptor molecules Dap10, Dap12, or FcRγ 
(Fig 29). Strangely, there was no reduction in OMCP binding to FcRγ -/- BMDM, despite 
our evidence of OMCP binding to mFcγRI and mFcγRII.  This inconsistency might 
indicate that OMCP is binding a receptor that is completely FcRγ independent, ruling 
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out all of the known Fc receptors. If true, the binding observed to BaF/mFcγRI, 
BaF/mFcγRII, and BaF/huFcγRI may be artifactual.  
 
OMCP does not bind human FcγRI by SPR 
Independent analysis performed by Eric Lazear (Fremont Lab) demonstrated that 
OMCP monomer indeed does not bind to human FcγRI by SPR (data not shown).  
Controls demonstrated strong OMCP binding to mNKG2D, and strong IgG2c binding to 
FcγRI as expected. This independent assessment strengthens the idea that presumed 
OMCP binding to FcγRI was in fact artifactual.  
 
New batches of OMCP protein does not bind FcγRI 
Additional experiments using new batches of inclusion body derived OMCP protein that 
was refolded and purified at later times did not reproduce our initial findings (Fig 30). 
Also, binding assays using mammalian derived OMCP produced from 293F cells did not 
show FcγRI or any FcR binding (Fig 31). We performed two additional IP-mass spec 
pulldowns with biotinylated OMCP (instead of OMCP-Fc fusion protein) on lysate from 
RAW264.7 and IC21 mouse macrophage cell lines (instead of the human Thp1 
monocyte cell line). These experiments did not pull down any FcRs, and no promising 
hits were identified (data not shown).  These later experiments are all consistent, and 
strongly imply that our initial conclusions were incorrect, and may be attributed to 
contaminated protein stocks.  
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Summary of evidence that OMCP may not bind to FcγRI  
Following the initial positive results suggesting OMCP binding to the high affinity Fc 
receptor FcRI, came a series of disappointing results that subsequently shed doubt on 
our initial conclusions.   
 OMCP still binds to FcRI-/- BMDMs.  
 Anti-mFcRI polyclonal blockade does not block OMCP binding to WT BMDMs. 
 Combined anti-mFcRI and anti-mFcRIIb blockade does not block OMCP 
binding to WT BMDMs.  
 Most recent batch of inclusion body derived OMCP does not replicate binding to 
BaF/huFcRI, BaF/mFcRI or BaF/mFcRIIb by flow cytometry. Staining with old 
OMCP in parallel with most recent OMCP batch demonstrated binding in the old 
batch of protein only.  
 Mammalian 293F derived fully glycosylated OMCP does not bind to BaF/huFcRI, 
BaF/mFcRI or BaF/mFcRIIb by flow cytometry or SPR. 
 Independent SPR analysis suggests OMCP does not bind any mouse or human 
FcRs 
 Two subsequent IP-mass spec pulldowns with biotinylated OMCP (instead of 
OMCP-Fc fusion protein) on lysate from RAW264.7 and IC21 mouse 
macrophage cell lines did not pull down any FcRs.   
 
Together, these independent results suggest that the original strong binding of OMCP to 
FcRI may have been an artifact.  
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Discussion:   
The viral immunoevasin Orthopoxvirus MHC Class I-like Protein (OMCP) binds with 
high affinity to the NK cell activating receptor, NKG2D. OMCP acts as a competitive 
antagonist of NKG2D, preventing interactions with cellular stress ligands and inhibiting 
NK killing. OMCP also engages the orphan receptor FCRL5 on splenic marginal zone 
and peritoneal B-1a B cells, but the functional consequence of this interaction is 
unknown. We had evidence that implicated the high affinity IgG receptor FcRI (CD64) 
on macrophages as a putative third receptor for OMCP. However this finding has 
recently been called into question.    
 
Original hypotheses 
Our initial hypothesis was that OMCP acts as a competitive inhibitor, blocking IgG 
binding to FcRI and subsequent macrophage activation. This would require a very high 
(at least nanomolar) affinity to the receptor to overcome the high affinity that FcRI has 
for monomeric IgG and even higher affinity for immune complexes. A high nanomolar to 
picomolar binding affinity is plausible, as OMCP has previously been demonstrated to 
have a KD of 37 ± 6 nM for muNKG2D, and KD of 168 ± 33 pM for huNKG2D [4]. 
Alternatively, OMCP might act as a noncompetitive inhibitor at a site unique from the 
IgG binding site. In this event, OMCP may have inhibitory effects on the receptor with a 
more modest binding affinity. Another possibility was that OMCP is acting within 
infected cells and binding FcRI internally, possibly when both molecules are 
synthesized in the ER and golgi, before the receptor has opportunity to get transported 
to the cell surface to bind free IgG. In this scenario, OMCP has the chance to bind FcRI 
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in infected cells without competing with its endogenous ligand, IgG. Poxviruses have 
been demonstrated to preferentially infect monocytes/macrophages, B cells, and DCs 
[79], suggesting that intracellular binding is a plausible possibility.  
 
An additional hypothesis that we initially pursued is the possibility that OMCP was 
selectively targeting FcRI and crossreacting with FCRL5 due to homology, or vice 
versa. Comparison of affinity and avidity data for the FCRL5 receptor and FcRI 
receptor with OMCP would be useful in determining if OMCP is truly targeting one 
receptor and only incidentally binding the other. We might expect to see higher affinity 
binding to the targeted receptor compared to the incidental receptor.  
 
Structural similarity between FCRL5 and FcRI  
Classical Fc receptors have not been reported to bind NKG2D ligands.  Additionally 
FCRL5 and other Fc-like receptors have not been reported to bind other NKG2D ligands 
[7]. However, we expected that these binding interactions were unique to viral OMCP, 
and did not originally consider these distinct binding partners unusual. In fact, it 
appeared appropriate that OMCP would bind to two receptors in closely related families 
that were composed of similar immunoglobulin domains.  
 
FCRL5 is the largest of the FCRL family of proteins, consisting of 5 extracellular Ig 
domains, a transmembrane domain, and a cytoplasmic domain with a noncanonical 
ITAM and two canonical ITIMs (Fig 32) [80]. To determine which domains of FCRL5 
were responsible for OMCP binding, a series of domain truncation mutants of FCRL5 
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fused to the GPI linked Thy1.1 were previously created. A library of each individual 
domain and combinations of consecutive domains were generated and tested for 
OMCP tetramer binding. These experiments demonstrated that domains 1, 2, and 3 
were necessary and sufficient for OMCP binding, while domains 4 and 5 were 
superfluous (Fig 33) [8].  
 
The FcRI α chain consists of 3 ligand binding Ig domains, a transmembrane domain, 
and a cytoplasmic domain that associates with the ITAM bearing FcR γ chain for 
signaling (Fig 32) [61]. Interestingly, FcRI is the only classical IgG receptor with 3 Ig 
domains (all others have only 2 domains) [66, 81], and the 3 Ig domains of FcRI share 
significant homology to the 3 N-terminal Ig domains of FCRL5 that were identified as 
necessary for OMCP tetramer binding.  The full length FcRI has approximately 24% 
amino acid identity compared to full length FCRL5, and each Ig domain has 28-32% 
amino acid identity between receptors [82]. The homology between two receptors raised 
the possibility that OMCP is targeting one of these closely related receptors, and is 
binding the other incidentally. This seemed likely given the high homology between the 
3 Ig domains that compose FcγRI and the N-terminal 3 Ig domains in FCRL5 (Fig 32).  
 
Furthermore, the closely related monkeypox version of OMCP (OMCPmpx), although 
capable of binding to BaF/NKG2D, does not bind BaF/mouse FCRL5 [7]. The homology 
between mouse FCRL5 and FcRI (Fig 32), as well as the unexpected lack of 
conservation of OMCPbr-FCRL interaction in the human species and between OMCP 
from different orthopoxvirus species prompted the initial hypothesis that viral OMCP 
 94
may be specifically targeting FcRI, and incidentally binding mouse FCRL5. This might 
suggest that OMCP has two specific targets – NKG2D on NK cells and a receptor on 
monocytes and macrophages – rather than three targets. These extensive structural 
similarities also seemed to validate our initial pull down of FcγRI as a putative OMCP 
binding macrophage receptor, since a protein would be more likely to bind to members 
of related families with moderate to high sequence homology.  
 
However, in retrospect, the structural similarities between FCRL5 and FcγRI may simply 
be coincidental. Although we originally interpreted this as theoretical validation for our 
pull-down of FcγRI, it is very likely that the use of an Fc fusion protein was responsible 
for the identification of an FcR. The relationship between the FcR and FCRL families 
may have been due to chance, but unfortunately misguided our investigations.  
 
Problems with Identification of FcRI 
The putative OMCP binding receptor on macrophages was initially identified using an 
immunoprecipitation-mass spec approach, where an OMCP-huIgG(Fc) fusion protein or 
Mult1-huIgG(Fc) control was incubated with lysate from a human Thp1 cell line and 
pulled down with Protein G beads. Binding to FcRI was validated using labeled OMCP 
tetramers (with no Fc) on Ba/F3 cells transduced with human FcRI, mouse FcRI, and 
primary mouse BMDMs. This binding could be specifically blocked with cold OMCP 
tetramers and anti FcRI F(ab)2 fragments. OMCP was also subsequently shown to 
bind to mouse FcRIIb transduced Ba/F3 cells, but none of the other mouse or human 
FcRs. 
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The fact that a high affinity Fc receptor was pulled down by an IgG(Fc) fusion protein 
initially generated concern. This result may have been due to binding of the FcR directly 
to the IgG domain, rather than the OMCP domain of the fusion protein. However, this 
should have been controlled for with the Mult1-human IgG(Fc) control that was 
generated in parallel with the OMCP fusion protein. In retrospect, it is possible that the 
Mult1 fusion protein had misfolded IgG domains that rendered it incapable of pulling 
down the FcR, whereas the OMCP-IgG fusion protein was successfully folded and 
presented. The Mult1 fusion protein was never tested for proper folding, whereas the 
OMCP protein was only tested for NKG2D binding ability.  
 
When later IP-mass spec pulldowns were performed, we used biotinylated OMCP as 
bait instead of an OMCP-Fc fusion protein, to attempt to minimize the role of the Fc 
domain. We incubated biotinylated OMCP with lysate from RAW264.7 and IC21 mouse 
macrophage cell lines instead of the human Thp1 monocyte cell line used in our first 
experiment. These later pull downs did not identify any FcRs as potential binding 
partners for OMCP. This again suggests that the use of the OMCP-Fc fusion protein in 
our initial pull down was responsible for our erroneous FcR identification.   
 
Possible explanations for protein binding artifacts 
In order to rule out artifact binding due to the presence of the IgG domain in the OMCP-
IgG fusion protein, subsequent binding experiments were performed with what was 
thought to be pure refolded OMCP. These subsequent experiments with OMCP binding 
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suggested true binding to FcRI, including successful blockade with anti-FcRI 
antibodies. In retrospect, it is possible that our initial stocks of OMCP were 
contaminated with small amounts of the OMCP-IgG fusion protein that strongly bound to 
FcRs. This may be plausible, as batches of inclusion body derived OMCP protein 
produced years later, as well as batches of OMCP protein produced independently in 
mammalian 293F cells did not replicate the initial FcR binding phenotype. However, this 
explanation is not completely satisfactory, as any OMCP-IgG fusion protein contaminant 
present should not have been biotinylated, and therefore should not have generated 
productive fluorescently labeled tetramers when incubated with APC-streptavidin.  
 
Other possibilities to explain this incongruous binding artifact include contamination, 
misfolding of protein, degradation of protein, or the creation of higher order oligomers. 
Artifactual binding may have been due to a contaminating protein that interacts with 
OMCP-b. For example an OMCP-Fc fusion protein contaminant could oligimerize with 
OMCP-b through OMCP-OMCP dimer or multimer formation. Although OMCP has been 
determined to be secreted as a monomer, OMCP was crystallized as a trimer in the 
asymmetric unit. If strong OMCP-OMCP interactions are possible in solution, this would 
allow FcR binding to the Fc fusion protein, while remaining labeled by APC-streptavidin 
interactions with the biotinylated OMCP partner, however this interaction is highly 
unlikely.  
 
Another more likely possibility may be contamination with a biotinylated protein that is 
inappropriately binding FcR bearing cells and capable of being labeled by APC-
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streptavidin independently of OMCP-b. An example of this type of contaminant could be 
a biotinylated full length antibody that may have been used as a primary antibody for 
other experiments in the lab. These biotinylated antibody reagents are commonplace 
and used by all members of the lab, and it is possible that despite meticulous care, 
contamination of protein stocks may have occurred. Given the simplicity of this 
explanation, we think that contamination of our OMCP-b stocks with biotinylated 
antibody is possible. Contamination with biotinylated antibody would also explain the 
observation that binding was specifically blocked with anti-FcRI antibodies.  
 
Alternatively, inappropriate binding may be due to misfolded OMCP-b protein in the 
initial protein batches. When protein is overexpressed in E. coli, aggregation of partially 
folded protein in inclusion bodies results. Our protein purification protocol used standard 
arginine refolding methods to solubilize and slowly refold the overexpressed OMCP. It is 
possible that some misfolded OMCP remained that had inappropriate FcR binding.  
 
Another possibility is that our OMCP batches contained degradation products that 
bound to FcRs erroneously. There may have been a mix of full length and degraded 
OMCP in our initial protein batches. This may be possible if bacterial proteases were 
not purified out appropriately. We consider this unlikely, as all protein batches were 
purified by size exclusion chromatography and purity confirmed by SDS-PAGE gel. 
Additionally, abnormal binding due to degradation product formation would be expected 
to increase over time, whereas we observed abnormal FcR binding with fresh batches 
of protein, and there did not appear to be a change in FcR binding intensity over time.  
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One final consideration is that higher order oligomers may have been involved in 
inappropriate FcR association. OMCP may have formed covalent or noncovalent 
interactions with other molecules of full lenth/degraded/misfolded OMCP. These larger 
complex oligomers would have properties that differ from monomeric OMCP, and may 
abnormally bind to FcRs.  
 
Reviewing our results in aggregate, we are inclined to believe that binding of OMCP to 
FcγRI does not truly occur, and our pursuit to identify a receptor responsible for OMCP 
binding to macrophages was unsuccessful. Recent evidence from several independent 
sources calls into question our original hypothesis that OMCP binds to FcRs. All OMCP 
binding seen previously may be artifact of misfolded/contaminated/otherwise altered 
OMCP-b. However, OMCP may indeed be binding to a receptor on macrophages, as 
that observation has been consistent across many years, but that receptor remains to 
be identified.  
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Figure 21: OMCP tetramer blockade and anti-FcRI blockade on BaF/huFcRI cells 
 (A) stable BaF/huFcγRI transductants were stained with PE anti-FcγRI (green line), 
isotype control (black line), or left unstained (gray shading) (B) BaF/huFcγRI 
transductants were stained with OMCP tetramers labeled with APC (100, 50, 10, or 1 ng 
titration, red lines), WNV-DIII control tetramer labeled with APC (10 ng and 1 ng, blue 
lines) or streptavidin-APC alone (gray shading). (C) BaF/huFcγRI transductants were 
pre-incubated with 5000 ng of cold OMCP-neutravidin tetramers (red line) or DIII-
neutravidin control tetramers (blue line), then stained with 10 ng of OMCP-APC labeled 
tetramers. BaF/huFcγRI stained with 10 ng OMCP tetramers without blockade shown in 
red shading, control stained with 10 ng DIII tetramers in blue shading. (D) BaF/huFcγRI 
cells preincubated with polyclonal anti-FcγRI F(ab’)2 antibody mix (green line) or F(ab’)2 
mouse gamma globulin (blue line), then stained with OMCP tetramers. BaF/huFcγRI 
stained with 400 ng OMCP tetramers without blockade shown in red shading, control 
stained with 400 ng DIII tets in blue shading. Representative histograms from 3 
independent experiments. 
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Figure 22: WT B6 BMDMs, BaF/muFcγRI, and BaF/huFcγRI express FcγRI and bind 
OMCP tetramers.  
 (A) Bone marrow isolated from C56BL/6 femurs were cultured for 7 days in M-CSF 
containing media. Unactivated bone marrow derived macrophages were then stained 
for FcγRI expression (top panel, green line). (Bottom panel) Unactivated BMDMs were 
stained with 400 ng of OMCP labeled tetramers (red line), a WNV-DIII labeled control 
tetramer (blue line) and streptavidin only control (gray shading). For comparison see 
results from similar experiments with BaF/muFcγRI (B) and BaF/huFcγRI (C) 
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Figure 23: OMCP vs D132R staining on NKG2D, FCRL5, and FcγRI expressing cells.  
 The appropriate cell lines or primary cells were stained with 400ng of fluorescent OMCP 
tetramers (red line), D132R tetramers (blue line), DIII tetramers (orange line), or 
streptavidin control (green line). Note that NKG2D binding is completely lost with the 
D132R mutation, while binding to FCRL5 expressing cells (BaF/FCRL5 and WEHI231) 
and BaF/huFcγRI is retained. There is a moderate loss of binding of D132R to murine 
BMDMs.  
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Figure 24: OMCP titration on WT BMDMs and human CD14+ monocytes  
 Bone marrow isolated from C56BL/6 femurs were cultured for 7 days in M-CSF 
containing media to generate bone marrow derived macrophages. Unactivated bone 
marrow derived macrophages were then stained for OMCP binding ability. Human blood 
was drawn from a healthy donor, and leukocytes were ficoll purified.  M-CSF cultured 
BMDMs or fresh human PBMCs were stained with the indicated concentrations of 
labeled OMCP tetramer. There is a dose dependent increase in OMCP binding in both 
mouse macrophage and human monocyte subsets.  
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Figure 25: OMCP still binds to FcRI (CD64) knockout mice 
 Bone marrow was isolated from wildtype C56BL/6 mice or FcRI (CD64) knockout mice.  
Bone marrow was cultured for 7 days in M-CSF containing media. Unactivated bone 
marrow derived macrophages were then stained for FcγRI (CD64) expression and 
OMCP tetramer binding. Note that OMCP tetramer binding is unaffected in FcRI 
knockout mice, despite the loss of FcRI receptor expression.  
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Figure 26: Anti-mFcRI antibody blockade does not block OMCP binding to BMDMs 
 Murine BMDMs obtained from a wildtype C57BL/6 mouse were stained with 100 ng of 
APC OMCP or DIII control tetramers, or preincubated with a large excess of unlabeled 
anti-mFcRI antibody or control antibody for 1 hour on ice prior to staining with 100 ng 
APC OMCP tetramers. The anti-mFcRI antibody blockade was performed in the 
presence of 2.4G2 (anti-mFcRII/ anti-mFcRIII) supernatant from antibody producing 
hybridomas. Note that combined blockade with anti-mFcRI, anti-mFcRII, and anti-
mFcRIII antibodies does not reduce OMCP tetramer binding. 
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Figure 27: OMCP binds to murine FcRI (CD64), murine FcRII (CD32), and human 
FcRI (CD64) 
 Mouse FcγRI, FcγRIIb, FcγRIII, and FcγRIV and human FcγRI, FcγRIIa and FcγRIIIa 
were cloned and retrovirally transduced into BaF/3 cell lines. Clones with highest 
receptor expression were sorted and expanded. Each receptor expressing cell line was 
tested for binding to 800ng APC labeled OMCP tetramer or DIII control. Binding of 
OMCP tetramers was observed in only the BaF/mFcγRI, BaF/mFcγRII, and 
BaF/huFcγRI cell lines.  
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Figure 28: OMCP binding to mCD32 displays multiple peaks, despite uniform 
expression of the CD32 receptor  
 BaF/mFcγRII (CD32) was stained for expression of the FcγRII receptor using the PE 
2.4G2 antibody. Note there is a uniform distribution of FcγRII expression in the 
polyclonal cell line. BaF/mFcγRII was stained for binding of the indicated concentrations 
of labeled OMCP tetramer. Note the unusual, reproducible multi-peaked binding pattern.  
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Figure 29: OMCP binding to murine BMDMs does not require expression of the adaptor 
molecules Dap10, Dap12, or FcRγ 
 BMDMs were generated from wildtype C57BL/6 mice, Dap10/Dap12 double knockout 
mice, or FcR gamma chain knockout mice. Cells were stained for binding to OMCP 
tetramers or DIII control. Note that there is unreduced binding of OMCP tetramers to the 
Dap10/Dap12 double knockout mice and FcR gamma chain knockout mice compared to 
wildtype. Experiments were performed independently, each wildtype control is 
presented.   
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Figure 30: New batches of OMCP protein do not bind BaF/huFcγRI 
 Three separate OMCP inclusion body preparations (11/8/11 at 0.74 mg/mL, 11/23/11 at 
0.37 mg/mL, and 5/1/12 at 0.48 mg/mL) have consistently bound to NKG2D and 
huFcγRI expressing cells (2nd column). A new batch of protein generated in our lab 
(11/9/12 at 0.14 mg/mL, 3rd column) was refolded and purified from inclusion bodies, 
and demonstrated binding to NKG2D, but not huFcγRI. An independently generated 
fully glycosylated OMCP batch made from mammalian 293F cells (1/15/13 EL at 0.25 
mg/mL, 4th column) binds to NKG2D, but not huFcγRI by flow cytometry or SPR (Eric 
Lazear). Initial FcR binding was not reproduced with protein batches purified after 
5/11/12. 
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Figure 31: Characterization of OMCP binding using 293F derived protein  
 Mammalian derived OMCP protein produced by expression in 293F cells does not show 
binding to huFcγRI or any FcR tested. This batch of OMCP does demonstrate 
consistently high binding to NKG2D and FCRL5 expressing cells. Protein generated by 
Eric Lazear (Fremont lab).  
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Figure 32: Comparison of mouse FCRL and FcR family members.  
 Extraceullular Ig domains are color-coded according to phylogenetic relationships as 
determined by Ig domain amino acid sequence alignments. Cytoplasmic ITIMs or ITAMs 
are represented by red or green boxes, respectively. Activating FcR family members are 
shown in complex with the FcεRg1 adaptor subunit. FcεR1a is also shown associated 
with FcεR1b/MS4A2. (Note the domain homology between FCRL5 and FcγR1). Figure 
from [13] 
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Figure 33: The three N-terminal Ig domains of FCRL5 are necessary and sufficient for 
OMCP binding.  
 293T cells transfected with Thy1.1 or the indicated FCRL5-Thy1.1 fusion construct 
domain truncations were stained with negative control DIII tetramers (line 1), OMCP 
tetramers (line 2), isotype control mAb (line 3), or anti-Thy1.1 mAb (line 4). Results are 
representative of three independent experiments.  Figure from [8]): 
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APPENDIX 2: CrmD binding to FcRs   
Introduction:  
Cowpox virus has evolved an arsenal of immunomodulatory proteins with specificities 
for virtually all known innate and adaptive immune pathways. In addition to OMCP, 
cowpox encodes a family of chemokine binding proteins known as the cytokine 
response modifying (Crm) family (CrmA, CrmB, CrmC, CrmD, and CrmE). CrmA is a 
viral caspase inhibitor developed to inhibit apoptosis of infected cells [83].  The 
members CrmB, CrmC, CrmD, and CrmE have been identified as viral TNF receptor 
homologs [84]. CrmB and CrmD also have additional anti-chemokine activity. Here we 
focus on the multifunctional cowpox immunevasin CrmD.  
 
CrmD is a 46 kDa secreted glycoprotein that is composed of a distinct N-terminal 
domain and C-terminal domain [85]. The N-terminal of CrmD is homologous to the TNF 
receptor superfamily, and has been shown to bind TNFα. The independent C-terminal 
domain has been identified to bind to diverse chemokines, and recent investigation has 
identified binding of the C-terminal domain to Fc receptors. Full length CrmD can bind 
TNFα and FcRs simultaneously, and can also bind FcRs in the presence of chemokine, 
suggesting that these three binding sites are independent of each other.  
 
C terminal CrmD is sufficient for FcR binding on macrophages, and this binding is 
blocked by soluble FcR blockade (M. Epperson, unpublished data). Surface plasmon 
resonance experiments have determined that CrmD is capable of binding to all tested 
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human and mouse FcRs, with the highest affinity for FcγRIII (CD16) and the lowest 
affinity for FcγRI (CD64). Preliminary crystal structure of CrmD in complex with FcγRIII 
suggests that CrmD is binding at the “elbow” region of the FcR, in close proximity to 
where endogenous IgG binds (M. Epperson, unpublished data). These observations 
suggest that CrmD has the capacity to bind to Fc receptors on macrophages, and is 
positioned in such a way as to block FcR recognition of IgG on opsonized virus.  
 
To test this hypothesis, we used Ba/F3 cell lines that had been transduced to stably 
express mouse or human Fc receptors on their surface. We tested for CrmD’s ability to 
block binding of soluble IgG as well as heat aggregated IgG to simulate immune 
complexes.  
 
Experimental Methods: 
Cells and Cell Lines 
Ba/F3 cells were retrovirally transduced as described previously in Appendix 1. Ba/F3 
cells expressing murine FcγRI (CD64), murine FcγRIIb (CD32), murine FcγRIII (CD16), 
murine FcγRIV (CD16-2), human FcγRI (CD64), human FcγRIIa (CD32), human 
FcγRIIIa (CD16), FCRL5-FLAG, and FCRL5-His, as well as a mock transduced Ba/F3 
control were used in these experiments.  
 
Staining and Blockade  
For protein blockade experiments, Ba/F3 cells were incubated with a vast excess (8ug) 
of non biotinylated CrmD, OMCP, or DIII control on ice for 1 hr. Cells were stained with 
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400ng APC labeled OMCP tetramers on ice for 1 hr. Cells were washed x3 with sorting 
buffer, then analyzed by FACS.  
 
For IgG blockade experiments, Ba/F3 cells were incubated with vast excess (1ug -8ug) 
of CrmD, OMCP, or DIII control for 30 min on ice. Cells were then incubated with 
(200ng - 11.2ug) of mouse gamma globulin (Talecris Biotherapeutics, Research 
Triangle Park, NC), for an additional 30 min on ice. Cells were washed, then stained 
with either PE goat anti-mouse (BD Pharmingen, San Jose CA) or APC goat anti-mouse 
F(ab’)2 (R&D Systems, Minneapolis MN) secondary antibodies. Cells were washed, 
then analyzed by FACS.  
 
For dual label experiments, Ba/F3 cells were blocked with excess cold CrmD, OMCP or 
DIII control for 1 hr, then incubated with APC-labeled OMCP tetramers and mouse 
gamma globulin for 1 hr on ice. Cells were washed, then stained with PE goat anti-
mouse secondary for 30 min on ice.  
 
Heat aggregated IgG 
To produce heat aggregated IgG, purified concentrated mouse gamma globulin was 
heated in water bath at 63oC for 1 hr. Aggregates were diluted prior to use.  
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Results: 
CrmD blocks monomeric IgG from binding FcRs  
Because CrmD is expected to bind in close proximity to the IgG binding site on Fc 
receptors, we were interested to see if CrmD is able to prevent IgG binding on FcR 
bearing cells. We preincubated cells with 2-8 ug of CrmD, OMCP, or DIII control, then 
incubated with a vast excess (11.2 ug) of mouse gamma globulin. We stained cells 
using a PE goat anti-mouse secondary antibody or APC goat anti-mouse F(ab’)2 
fragments.  
 
Our results showed that excess OMCP is not able to block FcR binding of mouse 
gamma globulin. However, CrmD clearly is able to block IgG binding to mouse FcγRIIb 
(CD32) and FcγRIII (CD16) (Fig 34), even at the lowest concentrations of CrmD tested 
and in the presence of 5x excess of IgG. CrmD can also partially block IgG binding to 
mouse FcγRI (CD64) under these conditions (Fig 34). This partial blockade is not 
unexpected, as FcγRI is the high affinity Fc receptor with the highest IgG affinity, yet 
CrmD has low affinity for FcγRI compared to the other FcRs.  
 
The IgG blocking results were repeated using APC goat anti-mouse F(ab’2) fragments 
to avoid issues with using Fc bearing antibodies as a secondary stain. These 
experiments were also repeated using varying concentrations of protein and mouse 
gamma globulin, and we consistently see very efficient blocking of IgG binding with 
monomeric CrmD. Monomeric OMCP is unable to block IgG binding to Fc receptors 
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even in cases of high OMCP concentration (16ug) with much lower mouse gamma 
globulin (200ng).  
 
CrmD blocks heat aggregated IgG binding to FcRs  
Because of these striking results demonstrating complete blockade of IgG binding when 
cells are preincubated with monomeric CrmD, we subsequently made our experiments 
more rigorous by challenging CrmD with heat aggregated IgG. Soluble IgG is heated at 
63oC for 1 hr to form larger aggregated complexes that mimic immune complexes. We 
preincubated FcR bearing cells with CrmD for 1 hr, then incubated with soluble mouse 
gamma globulin or heat aggreagated mouse gamma globulin, and stained with PE goat 
anti-mouse. Of note, the MFI of heat aggregated IgG binding to FcRs is higher than 
soluble IgG in all cases, consistent with the increased avidity of the complexed IgG.  
 
Our experiments with heat aggregated IgG demonstrated that CrmD is capable of 
complete blockade of aggregated IgG on mouse FcγRIIb (CD32) and FcγRIII (CD16) 
bearing cells (Fig 35). There was a partial blockade on human FcγRI (CD64) and 
mouse FcγRI (CD64) bearing cells, which is consistent with the very high affinity these 
FcRs have for IgG. CrmD was unable to block heat aggregated IgG binding to human 
FcγRIIa (CD32a), but was able to block soluble IgG to huFcγRIIa (CD32a) (Fig 35). This 
is consistent with the fact that CrmD has low affinity for the FcγRII receptor. These 
results demonstrate that CrmD is capable of blocking not only monomeric IgG from 
binding to FcRs, but also the higher avidity aggregated IgG from binding to the tested 
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Fc receptors, which may be more meaningful in the context of immune complex 
formation during viral infection.  
 
Determination of EC50 values for CrmD blocking activity on each FcR 
The previous experiments clearly showed that CrmD is very effective at blocking IgG 
and immune complex binding to all of the FcRs tested. To further assess this blocking 
ability, we sought to determine the EC50 values for CrmD’s IgG blocking activity for 
each FcR.  
 
We preincubated cells with 1ng - 8000ng of CrmD, then incubated with 200ng mouse 
gamma globulin, and used a PE goat anti-mouse secondary stain to determine the 
amount of IgG that was able to bind the FcR bearing cells. We tested 1, 10, 25, 50, 125, 
250, 500, 1000, and 8000 ng CrmD blockade on BaF3 cells expressing human FcγRI, 
FcγRIIa and FcγRIIIa, and mouse FcγRI, FcγRIIb, FcγRIII, and FcγRIV. By plotting 
CrmD concentration vs MFI, we were able to determine the concentration of CrmD at 
half maximal inhibitory response and extrapolate the EC50 of this binding assay (Fig 36). 
The EC50 values determined by flow compare well against the KD of the CrmD-FcR 
affinity as determined by SPR (Table 1). However, the EC50 value determined by this 
flow assay also takes into account the affinity of each FcR for mouse gamma globulin, 
which is another factor in determining how easily CrmD is able to displace or prevent 
IgG binding to the FcRs. The affinity of each FcR for IgG also varies based on isotype of 
IgG. Here we did not use IgG purified by isotype, but rather mixed mouse gamma 
globulin from normal mouse serum.  
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CrmD preincubation successfully blocks OMCP binding FcRs 
OMCP had initially been identified to bind to the high affinity FcγRI Fc receptor on both 
mouse and human cells as well as mouse FcγRIIb (Appendix 1). CrmD is known to bind 
to all tested Fc receptors with varying affinities. We therefore tested whether CrmD 
preincubation of Ba/F3 cells expressing FcRs is sufficient to block OMCP binding and 
determine if OMCP and CrmD bind to the same location on Fc receptors.  
 
In these experiments, we incubated BaF3/FcR cells with a vast excess (8000 ng) of 
nonbiotinylated CrmD, OMCP, or DIII control monomers, then stained with 400ng of 
APC labeled OMCP tetramers and analyzed binding by flow cytometry. CrmD 
preincubation was successful in blocking OMCP binding to mouse FcγRIIb and human 
FcγRI expressing cells, but not FCRL5 expressing cells (Fig 37). The almost complete 
abrogation of OMCP tetramer binding on BaF/mFcγRIIb and BaF/huFcγRI by CrmD 
preincubation suggests that CrmD has a higher affinity for the FcRs than OMCP and 
can directly compete with OMCP for binding. On the control BaF/FCRL5 cells, CrmD 
blockade is ineffective, which is as expected since CrmD is not known to bind to FCRL5, 
whereas OMCP blockade partially blocks OMCP tetramer binding on FCRL5 bearing 
cells (Fig 37).  
 
The crystal structure of CrmD in complex with the human FcγRIIIa Fc receptor suggests 
that CrmD is binding in the region of the FcR where IgG binds. This suggests that both 
viral proteins may be targeting the same region of the Fc receptor, which is likely the 
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functional Fc binding site. However CrmD appears to bind with higher affinity and is 
successful in preventing simultaneous IgG binding.  
 
CrmD blocks OMCP tetramer binding and IgG binding simultaneously  
Our previous experiments suggested that CrmD binds FcRs at its functional IgG binding 
site and is sufficient to block IgG and aggregated IgG binding to FcRs. Additionally, we 
saw that CrmD can effectively block OMCP binding to FcRs, suggesting both viral 
proteins bind in the same vicinity. Here, we tested whether CrmD can block OMCP 
tetramer binding and IgG binding simultaneously to further validate our hypothesis that 
both proteins interact with FcRs at the IgG binding site.  
 
In these experiments, we preincubated BaF3/FcR cells with unlabeled CrmD tetramer, 
OMCP tetramer, or DIII tetramer. We then dual labeled the cells with APC labeled 
OMCP tetramers and the PE goat anti-mouse secondary antibody. We saw that OMCP 
tetramers and mouse IgG are able to bind FcR bearing cells at the same time (Fig 38). 
The OMCP tetramer block showed that OMCP can block OMCP binding, but not IgG 
binding. However, CrmD can completely block OMCP binding as well as partially block 
IgG binding on FcγRI (Fig 38). Blocking with DIII control monomers had no effect on 
OMCP tetramer binding or IgG binding, as expected. These experiments were repeated 
on BaF3 cells expressing huFcγRI, mFcγRI, and mFcγRIIb, and confirm that CrmD is 
very effective in preventing both OMCP and IgG from binding to classical Fc receptors.  
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Discussion: 
CrmD is clearly a multifunctional immunoevasion protein produced by cowpox. In 
addition to its established roles as a TNFα sink and chemokine sequestration, our 
results show that CrmD is capable of blocking IgG binding to Fc receptors. The 
effectiveness of this CrmD blockade depends on both the affinity of CrmD with the FcR, 
with stronger blockade on FcγRIII and less effective blockade on the FcγRII receptor, as 
well as the affinity of IgG for the FcR, with less effective blockade on the high affinity 
FcγRI receptor.  
 
This ability to bind to Fc receptors and prevent IgG and immune complex binding, is a 
simple yet effective method to avoid immune detection. Viral particles opsonized by 
antibodies may be unable to be recognized and removed by macrophages and other 
FcR bearing cells in the context of excess secreted CrmD which bind with high affinity to 
FcRs, preventing simultaneous binding and recognition of IgG or immune complexes.  
 
Preliminary studies have also demonstrated that CrmD induces internalization of the 
FcRs on macrophages (M. Epperson). This activity, combined with the TNFα and 
chemokine sequestration of the N-terminal portion of CrmD, may result in a situation 
where N-terminal CrmD binds TNFα and chemokines, while C-terminal CrmD binds 
FcRs at the IgG binding domain. This may trigger internalization of the complex and 
degradation of inflammatory TNFα and chemokines required for the full activation of the 
antiviral response. In this context, CrmD binding to FcRs acts as a trigger for 
 123
endocytosis, and the exclusion of simultaneous IgG binding was evolved to avoid 
unwanted immune complex internalization.  
 
Our other staining experiments demonstrated that CrmD binding precludes OMCP 
tetramer binding. This suggests that CrmD and OMCP are binding to the same site on 
FcRs, likely the functional IgG binding site. However, CrmD is able to completely 
abrogate IgG binding to FcRs, whereas even a vast excess of OMCP tetramers is 
unable to compete with IgG binding. This may be because OMCP binds most strongly 
to FcγRI, but may be unable to compete with the very high affinity that the FcγRI 
receptor has for IgG. Conversely, CrmD has highest affinity binding to human FcγRIIIa, 
which is a weaker affinity IgG receptor, where IgG is more easily displaced.  
 
To supplement the discourse begun in Appendix 1 on the possible source of 
inappropriate binding of FcR seen in early batches of OMCP protein, we note that in the 
experiments described above, OMCP behaves similarly to IgG. Namely, CrmD is 
capable of blocking OMCP binding (Fig 38) as effectively as it can block IgG binding to 
FcRs (Fig 34). This supports the possibility that inappropriate OMCP binding of FcRs 
may have be due to contamination of biotinylated antibody.  
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Figures: 
 
   
Figure 34: CrmD blocks monomeric IgG from binding FcRs 
 BaF/3 cells expressing human CD64, mouse CD64, or mouse CD32 (huCD32a, 
huCD16, muCD16, muCD16-2 not shown) were preincubated with OMCP monomer, 
CrmD monomer, or DIII monomer for 1 hr on ice. Concentrations of protein used varied 
from 1000 ng to 16000 ng in independent experiments. After preincubation with blocking 
protein, cells were incubated with mouse gamma globulin (concentrations tested varied 
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
OMCP block
CrmD block
DIII block
Baf/huCD64 Baf/mCD32Baf/mCD64
20120813_Baf-huCD64.004 87.220120813_Baf-huCD64.002 86.3
20120813_Baf-huCD64.003 87.620120813_Baf-huCD64.005 86.6
20120813_Baf-huCD64.002 5.9220120813_Baf-huCD64.003 2396
20120813_Baf-huCD64.007 104220120813_Baf-huCD64.006 205
20120813_Baf-huCD64.002 5.9220120813_Baf-huCD64.003 2396
20120813_Baf-huCD64.008 165920120813_Baf-huCD64.009 1829
20120813_Baf-mCD64.012 6.5620120813_Baf-mCD64.013 1363
20120813_Baf-mCD64.014 117120120813_Baf-mCD64.015 1290
20120813_Baf-mCD64.012 6.5620120813_Baf-mCD64.013 1363
20120813_Baf-mCD64.017 14720120813_Baf-mCD64.016 19.1
20120813_Baf-mCD64.012 6.5620120813_Baf-mCD64.013 1363
20120813_Baf-mCD64.018 92520120813_Baf-mCD64.019 890
20120813_Baf-mCD32.022 64.320120813_Baf-mCD32.023 601
20120813_Baf-mCD32.024 47620120813_Baf-mCD32.025 474
20120813_Baf-mCD32.022 64.320120813_Baf-mCD32.023 601
20120813_Baf-mCD32.026 18.320120813_Baf-mCD32.027 22.9
20120813_Baf-mCD32.022 64.320120813_Baf-mCD32.023 601
20120813_Baf-mCD32.028 43520120813_Baf-mCD32.029 436
Baf/3
FL1-H, SSC-H subset
% o
f Ma
x
2 5.93 2396
4 1 301733
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
20120813_Baf-3.032 4.6620120813_Baf-3.033 49
20120813_Baf-3.034 35.120120813_Baf-3.035 34.2
FL1-H, SSC-H subset
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
20120813_Baf-3.032 4.6620120813_Baf-3.033 49
20120813_Baf-3.038 3320120813_Baf-3.039 30.5
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
FL1-H, SSC-H subset
20120813_Baf-3.032 4.6620120813_Baf-3.033 49
20120813_Baf-3.036 5.0320120813_Baf-3.037 5.83
all stained with PE goat anti mouse
no mouse gamma globulin200ng mouse gamma globulin
8000ng OMCP block16000ng OMCP block
no mouse gamma globulin200ng mouse gamma globulin
500ng CrmD block8000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
8000ng DIII block16000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
8000ng OMCP block16000ng OMCP block
no mouse gamma globulin200ng mouse gamma globulin
500ng CrmD block8000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
8000ng DIII block16000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
8000ng OMCP block16000ng OMCP block
no mouse gamma globulin200ng mouse gamma globulin
500ng CrmD block8000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
8000ng DIII block16000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
8000ng OMCP block16000ng OMCP block
no mouse gamma globulin200ng mouse gamma globulin
500ng CrmD block8000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
8000ng DIII block16000ng DIII block
 125
from 200ng to 11000 ng). Cells were washed, then stained with PE goat anti-mouse 
secondary antibody or an APC goat anti-mouse F(ab1)2 (not shown) to assess amount 
of IgG bound to cells. Cells were washed twice and analyzed by flow cytometry. 
Representative results from three independent experiments.  
 
 
  
 126
 
   
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
100 101 102 103 104FL2-H: PE goat anti mouse
0
20
40
60
80
100
% o
f Ma
x
1000ng CrmD block
1000ng DIII block
1000ng CrmD block
1000ng DIII block
200ng heat aggregated mouse gamma globulin
200ng mouse gamma globulin
Baf/huCD64 Baf/huCD32a Baf/mCD16-2 Baf/mCD16 Baf/mCD32 Baf/mCD64 Baf/3
no mouse gamma globulin200ng mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng mouse gamma globulin
1000ng DIII block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng CrmD block
no mouse gamma globulin200ng heat agg mouse gamma globulin
1000ng DIII block
 127
 
Figure 35: CrmD blocks heat aggregated IgG from binding FcRs  
 BaF/3 cells expressing human CD64, CD32a, CD16, or mouse CD64, CD32, CD16, or 
CD16-2 were preincubated with 1000 ng CrmD monomer or DIII monomer for 1 hr on 
ice. After preincubation with blocking protein, cells were incubated with 200ng mouse 
gamma globulin (top two rows) or 200ng heat aggregated mouse gamma globulin 
(bottom two rows). Cells were washed, then stained with PE goat anti-mouse secondary 
antibody to assess amount of IgG bound to cells. Cells were washed twice and 
analyzed by flow cytometry. Representative results from two independent experiments. 
Heat aggregated IgG was made the day of each experiment by incubating concentrated 
monomeric IgG (11.2 mg/mL) at 63oC for 1 hr. Heat aggregated IgG was diluted prior to 
use in sterile PBS.  
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Figure 36: Determination of EC50 values for CrmD blocking activity on each FcR 
 BaF/3 cells expressing human CD64, CD32a, CD16a, or mouse CD64, CD32, CD16, or 
CD16-2 were preincubated with 1ng, 10ng, 25ng, 50ng, 125ng, 250ng, 500ng, 1000 ng, 
or 8000ng of CrmD monomer for 1 hr on ice. After preincubation with CrmD protein, 
cells were incubated with 200ng of mouse gamma globulin for 1 hr on ice. Cells were 
washed, then stained with PE goat anti-mouse secondary antibody to assess amount of 
IgG bound to cells. Cells were washed and analyzed by flow cytometry and MFI of PE 
goat anti-mouse was recorded. CrmD concentration was plotted against MFI, and the 
EC50 concentration at half maximal was extrapolated using Graphpad Prism software.  
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 EC50  mIgG blockade activity (ng) 
KD  CrmD–FcR binding affinity by SPR (nM) 
BaF/huCD16a 28.10 3.33 
BaF/mCD16-2 51.03 N/A 
BaF/mCD16 64.70 3.29 
BaF/huCD32a 75.47 8.78 
BaF/mCD64 117.1 22 
BaF/mCD32 148.2 4.19 
BaF/huCD64 769.5 24 
  
Table 1: Comparison of the EC50 by flow against the KD of CrmD-FcR affinity by SPR 
 CrmD concentration was plotted against MFI of PE goat anti-mouse, and the EC50 
concentration at half maximal was extrapolated using Graphpad Prism software as 
described. This table lists the EC50 values determined by the flow cytometry assay 
compared to the equilibrium dissociation constant KD values determined by surface 
plasmon resonance (Megan Epperson) for each of the human and murine Fc receptors.  
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Figure 37: CrmD preincubation successfully blocks OMCP binding FcRs 
BaF/3 cells expressing human CD64 or mouse CD32 (human CD32a, CD16a, mouse 
CD64, CD16, or CD16-2 not shown) were preincubated with 8000ng of CrmD monomer, 
OMCP monomer, or DIII monomer for 1 hr on ice. After preincubation with protein, cells 
were incubated with 400ng of APC labeled OMCP tetramers for 1 hr on ice. Cells were 
washed x3, then analyzed by flow cytometry to assess amount of OMCP binding. 
Tetramers were made fresh prior to each experiment by incubating 400ng of OMCP-
biotin with APC-streptavidin in a 4:1 ratio for 10 min at room temperature prior to dilution 
for staining. 
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Figure 38: CrmD blocks OMCP tetramer binding and IgG binding simultaneously  
 BaF/3 cells expressing human CD64 (mouse CD64 and mouse CD32 not shown) were 
preincubated with 8000ng of cold CrmD-neutravidin tetramers, OMCP tetramers, or DIII 
tetramers for 1 hr on ice. After preincubation with protein, cells were dual stained with 
400ng of APC labeled OMCP tetramers and 200ng of mouse IgG for 1 hr on ice. Cells 
were washed, then incubated with PE goat anti-mouse secondary. Cells were washed 
x3, then analyzed by flow cytometry to assess amount of OMCP binding and IgG 
binding. Labeled APC tetramers were made fresh prior to each experiment by 
incubating 400ng of OMCP-biotin with APC-streptavidin in a 4:1 ratio for 10 min at room 
temperature prior to dilution for staining. Cold unlabeled tetramers were made the same 
manner, except using unlabeled neutravidin instead.  
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 APPENDIX 3: Sex Differences in IFN signaling  
Introduction:  
Sex differences in autoimmune disease and response to infection 
There are many well documented examples of sex differences in humans. Autoimmune 
diseases in general disproportionately affect females, as exemplified by the 9:1 female 
to male ratio in systemic lupus erythematosus. Females also have notably higher 
incidences of other autoimmune diseases including rheumatoid arthritis, myasthenia 
gravis, scleroderma, Sjogren’s syndrome, and multiple sclerosis [86, 87]. Additionally, 
there are well characterized sex differences in adaptive immune responses, some of 
which have been attributed to the influences of estrogen [88]. Evidence of sexual 
dimorphism in the innate immune response has been accumulating [89, 90], and there 
is evidence that men and women differ in their innate and adaptive responses to viral 
vaccines [91-93]. In general, females respond to infection, vaccination, and trauma with 
increased antibody production [94, 95]. There are some reports that men are more 
susceptible to infection, have more severe inflammation, and increased mortality upon 
infection [96]. In fact, men with sepsis have a significantly higher hospital mortality rate 
(70%) compared to that of women (26%) matched for age, cause, and severity of sepsis, 
despite identical surgical and intensive care management in one hospital study [97].  
Generally, estrogens appear to increase the immune response whereas testosterone 
acts to decrease the immune response, however, gender specific susceptibility depends 
strongly on the identity of the microbe causing the infection [98]. The mechanisms 
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leading to the sex bias in immune and autoimmune susceptibility are still not fully 
understood.  
 
Enhanced immunoreactivity in women compared to men is thought to be the basis of 
this autoimmunity bias, as women appear to mount stronger cellular and humoral 
immune responses against viral infections [98]. Hypotheses to explain this difference 
include the effect of sex steroids [99], the roles of X chromosome microRNAs [100] and 
Y chromosome non-testis determining genes [101], and fetal microchimerism [102]. 
Some studies have also suggested that the dosage effect of X chromosome genes may 
impact the differential immune response between sexes [103, 104].  
 
Sex differences in systemic HSV infection 
In a model of murine systemic HSV infection, our lab observed a striking difference in 
mortality between female and male C57BL/6 mice, with a 28 fold higher LD50 in males 
compared to females [105]. In our model, we saw no sex differences in serum 
proinflammatory cytokines (IL-1β, IL-2, IFNγ, and TNFα), suggesting that mortality in 
females was not due to an overwhelming inflammatory response. In fact, these 
observations suggested that male viral defense may be more effective than female in 
keeping virus in check. Importantly, the difference in survival between sexes is nearly 
completely abrogated when we infected IFNαβR deficient mice. 
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Importance of IFNαβR signaling in mediating sex differences 
Infection of IFNαβR haploinsufficient mice demonstrates a strong role for IFNαβR 
signaling. Survival of IFNαβR haploinsufficient males remained unchanged compared to 
WT males, indicating that half the amount of receptors is sufficient to protect males from 
HSV infection. However, IFNαβR haploinsufficient females were substantially more 
susceptible than WT females. There were no differences in the serum levels of IFNα in 
males and females, and no difference in the level of IFNαβR on cells following HSV 
infection [105]. These results together suggest that signaling events downstream of the 
IFNαβ receptor plays a central role in mediating sex differences in survival in this 
systemic virus model.  
 
Given that serum Type I IFN levels and IFNαβR receptor levels are the same in male 
and female mice, we hypothesized that there are differences in Type I IFN pathway 
downstream signaling or downstream target gene transcription that account for the large 
sex difference in susceptibility to HSV.  
 
Type I IFN and differential ISG expression in mediating sex differences  
It has been shown that the production of IFNα (a type I IFN) by plasmacytoid dendritic 
cells is significantly higher in women compared to men in response to HIV-1 antigens 
[106]. Type I IFNs induce the transcription of thousands of interferon-stimulated genes 
(ISGs), which play crucial roles in the host defense against pathogens. One recent 
study reported sex-dependent differences in the expression of some ISGs in HIV-1 
infected human plasmacytoid dendritic cells (pDCs), after controlling for viral load [107]. 
 137
This increased IFNα production and ISG expression in females may contribute to the 
stronger immune response and faster disease progression in chronic HIV female 
patients compared to males.  
 
Our lab hypothesized that sex-dependent differences in interferon-stimulated gene 
(ISG) expression following type I IFN stimulation in human macrophages might partially 
explain this large sexual dimorphism. We are interested in analyzing the sex differences 
in IFNαβR signaling in males and females and assessing any differential upregulation of 
downstream interferon stimulated genes. Differences in ISG expression may help 
explain the large sex differences seen in response to viral infections and autoimmunity. 
We planned to investigate sex differences in both humans and mouse models.  
 
Experimental Methods: 
Cytokines 
Type I IFN responses were evaluated using a panel of interferons, including mouse IFN-
α1, IFN-α4, IFN-α11, IFN-α13, and IFN-β. Mouse IFN was purchased from PBL 
Interferon Source (Piscataway, NJ). This would allow us to assess responses to Type I 
IFNs with high (IFN-β, IFN-α11), intermediate (IFN-α4, IFN-α13), and low (IFN-α1) 
activity [108]. 
 
We have an extensive panel of human interferons including human IFN-α1, IFN-α2, 
IFN-α5, IFN-α8, IFN-α10, and IFN-β1a. This panel includes several low activity (IFN-α1, 
IFN-α2), intermediate activity (IFN-α5), and high activity (IFN-α8, IFN-α10, IFN-β1a) 
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interferons with a broad range of antiviral activity. Human IFN were all purchased from 
PBL Interferon Source (Piscataway, NJ). Human recombinant IFN-γ was purchased 
from Novoprotein (Shanghai, China). Human GM-CSF was purchased from Gold 
Biotechnology (St Louis, MO).  
 
In vitro generation of murine bone marrow derived macrophages 
Male or female 8 week old mice were sacrificed by CO2 euthanasia. The long bones 
(tibia and femur) of the hind leg are harvested and cleaned of muscle and tendons. The 
ends of each bone are snipped open to access bone marrow. Marrow is flushed or 
centrifuged out of the bone, and resuspended in DMEM with 20% L929 cell supernatant, 
10% FBS, 1% L-glutamine, 1% Na pyruvate, 1% P/S. Marrow from one mouse (4 
bones) can be plated in 5x 10 cm tissue culture petri dishes. Incubate at 37oC, 5% CO2 
for 7 days. On Day 5, add fresh L929 supplemented media. BMDMs ready for use 
between day 7 to day 14. Note – L929 cell line produces murine M-CSF. Supernatant 
from L929 cells in log phase growth is filtered and used for BMDM media. L929 
supernatant can be replaced with recombinant murine M-CSF.    
 
In vitro generation of monocyte-derived M1 macrophages 
The study was approved by the Institutional Review Board at Washington University in 
St Louis, and subjects gave written, informed consent. We obtained peripheral blood 
samples from healthy, age- and race-matched male and female donors. Monocytes 
were purified from buffy coats of four healthy, age and race-matched donors using a 
Ficoll-Paque density gradient. Platelets were discarded by washing 2X in 10% FBS 
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media. Monocytes were seeded in DMEM 10% FBS, 1% L-Glutamine, 1% Pen/Strep, 
100 ng/ml GM-CSF at a concentration of 5 x 105 cells/ml in 12-well tissue culture treated 
plates for a total of 10 days to drive differentiation of monocytes into macrophages. 
Media was replaced every 3-4 days, and non-adherent cells were removed on day 6. 
On day 7, 100 ng/ml LPS and 20 ng/ml HuIFN-γ were added to the media for 24 hours 
to drive activation to produce M1 polarized macrophages. Monocyte-derived 
macrophages were then incubated in LPS-free and IFN-γ-free media for 48 hours. On 
day 10, macrophages were replated on 12-well tissue culture treated plates at a 
concentration of 6 x 104 c/ml to 1.2 x 105 c/ml. The polarized M1 macrophages 
appeared as a mixture of fibroblast-like cells and round cells Changes in cell 
morphology were assessed by bright field microscopy (Nikon TS100) on day 10.  
 
IFN stimulation and gene expression analysis 
Murine BMDMs were used between 7-14 days old. Macrophages were activated with 
IFN at the specified dose (1000 U/mL or 200 U/mL) for 24 hours.  
 
Human macrophages were used at 10 days old, and were stimulated with 1000 U/ml 
IFN-A for 6 hours. IFN stimulation was initiated after a 48 hour rest period following 
activation by LPS and IFN-γ. This 48 hour delay was intended to minimize changes in 
gene expression due to downstream responses to LPS and IFN activation, therefore 
allowing gene upregulation due solely to stimulation by IFN-αA to be adequately 
assessed.  
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RNA was isolated from the cells using Trizol (Invitrogen), followed by Qiagen RNeasy 
kit, according to manufacturers’ instructions. RT-PCR was performed on purified RNA 
using Superscript III RT kit (Invitrogen), according to manufacturer’s instructions. 
Relative quantitation of cDNA levels was performed by qPCR, using beta-actin as a 
reference gene. Taqman Universal PCR Master Mix (Applied Biosystems) was used, 
and PrimeTime Standard qPCR assay 5’ Nuclease primer-probe combinations were 
obtained from IDT.  
 
Results:  
We attempted to test the hypothesis that sex differences in immune response may be 
evident at the level of IFN target genes, namely that there is differential upregulation of 
interferon stimulated genes (ISGs). To address this, we evaluated expression of ISGs in 
response to Type I Interferon stimulation in male and female primary cells by qPCR. We 
have identified 7 mouse ISGs and their human analogs of particular interest because 
they are very highly upregulated following viral infection. We have evaluated expression 
of these ISG targets (ISG15, ISG54, ISG56, IRF7, MX1, Oas1a, and Viperin) by qRT-
PCR using primary BMDMs from male and female mice, followed by stimulation with a 
mouse IFN panel (eg IFNβ, IFNα4) for 24 hours. Activated cells were harvested, and 
RNA extracted using Trizol/chloroform extraction. Total RNA was then converted to 
cDNA using Invitrogen Superscript III reverse transcriptase. Target gene expression 
was determined using qRT-PCR with TaqMan Universal PCR Master Mix and unique 6-
FAM/IBQ probes.  
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Preliminary experiments have provided evidence of some clear sex differences between 
female (n=5) and male (n=5) mouse bone marrow derived macrophages (Fig 39). Our 
results suggest that ISG expression in male C57BL/6 mice is on average higher than 
expression in female mice across all of the tested ISGs (Fig 39). This difference was 
higher in BMDMs than in BMDCs when activated with 1000 U IFN-α4 for 24 hours (data 
not shown). The male dominant expression of ISGs was present when BMDMs were 
activated with 1000 U IFN-β or 1000 U IFN-α4 for 24 hours. This data suggests that 
there are indeed sex differences downstream of IFNαβR signaling that is evident at the 
gene transcript level. This global increase in ISG expression in males is also consistent 
with our initial observations of significantly enhanced male survival during systemic HSV 
infection.  
 
There are 13 subtypes of IFN-α and a single subtype of IFN-β in mammals, which may 
have differential regulation and be secreted by different cell types during different 
stages of infection in different locations [109]. All of these type I IFN proteins bind to the 
same IFNαβR receptor with varying affinities. We were interested in determining 
whether the ISG response in males and females differed with activation by select IFN-α 
or IFN-β subtypes. We purchased type I IFN subtypes that demonstrated a wide range 
of IFNαβR binding affinity (highest affinity - IFN-β > IFN-α11 > IFN-α4 > IFN-α13 > IFN-
α1 – lowest affinity) [108, 110]. In a preliminary experiment, we assessed the response 
of two ISGs (ISG15 and ISG56) to stimulation using high or low concentrations of a high 
affinity interferon IFN-β, a medium affinity IFN-α4, and a low affinity IFN-α1 (Fig 40). 
Interestingly, there was differential response with stimulation by high or low affinity 
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interferon. For both ISG15 and ISG56, expression in male cells was higher when cells 
were stimulated with high affinity IFN-β, while expression in female cells was higher 
when stimulated with low affinity IFN-α1 (Fig 40). The medium affinity IFN-α4 case was 
intermediate, with slightly higher expression of ISG15 but lower expression of ISG56 in 
males. This preliminary data suggests that there is a continuum of stimulation with type I 
IFNs in the inflammatory milieu, and the amount of activation may determine the 
magnitude and direction of the sex difference between males and females. This may 
explain observations that males are more susceptible to certain infections, while 
females are more susceptible to other pathogens [98], if individual pathogens activate 
type I IFNs to varying degrees.  
 
To follow up our promising mouse data, we were also interested in assessing sex 
differences in upregulation of interferon stimulated genes in healthy human donors. We 
initially selected eight genes which have previously been reported to be highly 
upregulated upon interferon stimulation [111]. These human ISGs (ISG15, IFIT1, IFIT2, 
IRF7, OAS1, MX-1, RSAD2) were probed in IFN stimulated human monocyte derived 
M1 macrophages generated from peripheral blood from healthy male and female 
donors. We used fully differentiated M1 macrophages for Type I IFN stimulation using a 
panel of human interferons. Activated cells were harvested, RNA extracted and 
converted to cDNA similar to the protocol described for mouse. Target gene expression 
was determined using qRT-PCR with TaqMan Universal PCR Master Mix and 6-
FAM/IBQ probes unique for the human homologs of the ISGs of interest. Based on our 
initial experiments in mouse, we expected to find increased ISG transcription in male 
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cells compared to female cells under conditions of high stimulation.   
 
Our preliminary experiment used a small sample of two age- and race- matched female 
and male Chinese-American healthy volunteers. Peripheral blood was drawn, and 
human monocyte derived macrophages generated by long term culture of peripheral 
blood monocytes in GM-CSF containing media. Using qRT-PCR, we were able to 
identify clear differences in upregulation of eight ISGs between the male and female 
samples. We found that six of the eight ISGs had a higher fold change in gene 
expression in females than in males upon IFN-A2a stimulation (Fig 41). Of these six 
genes, MX1 and ISG15 had also been previously reported to be more highly expressed 
in females compared to males in HIV-infected CD4+ and CD8+ T cells [107]. This 
preliminary experiment suggests that sex-dependent differences in ISG expression can 
be detected and could help explain the sex disparities in immune response between 
males and females in both humans as well as mice. The largest sex differential that we 
observed was in IFIT1, in which females had on average 10 times higher gene 
expression than males. This differential ISG upregulation between female and male 
macrophages may partially contribute to the consistent sex bias in autoimmunity, and 
may help explain the overall sex bias in immune responses. 
 
In our preliminary human experiment we found that six of the eight ISGs tested (IFIT1, 
MX1, OAS1, ISG15, RSAD2, IRF7) were significantly more upregulated in females than 
in males. In this experiment we stimulated with an intermediate strength IFN-A2a in our 
human macrophage experiments. The mixed results were somewhat consistent with our 
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experiment using stimulation by the intermediate affinity IFN-α4 in mice which also 
showed mixed results with higher ISG56 expression in females, and slightly higher 
ISG15 expression in males. This is in contrary to our findings that stronger stimulation 
with IFN-β in mice appear to consistently more highly upregulate ISG expression in 
males. Although the responses of males and females are clearly different from each 
other in both species, significant inter-species variability may also be present. 
Additionally, there appears to be very different responses to high, medium, and low 
affinity type I IFN, as well as strong dose dependence. These factors may explain 
discrepancies in ISG upregulation trends, and emphasize the need for a large scale 
systematic investigation of type I IFN responses in this model.  
 Discussion:  Our results from these qPCR experiments show hundreds- to thousands-fold 
differences in the expression of certain genes between males and females. However, 
the sample sizes for each of these experiments is too small to extrapolate meaningful 
conclusions. Additional murine bone marrow derived macrophages and human 
peripheral monocyte derived macrophages from additional age matched individuals will 
need to be tested to confirm our initial studies and conduct statistical tests on the data. 
Our preliminary experiments investigated only M1 macrophages activated by LPS and 
IFN-γ, and stimulated by only a few subtypes of interferon. Further experiments may 
focus on other important cell types known to be involved in a Type I IFN response, 
including dendritic cells and myeloid cells, and systematically investigate the effect of 
different subtypes of IFN- and IFN-β. We suspect that the magnitude and direction of 
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the sex difference is highly dependent on the strength of activation through the IFNβR 
receptor. This hypothesis remains to be tested.  
  
If the expression of certain interferon-stimulated genes proves to be consistently higher 
in one sex, it would be crucial to establish a connection between gene expression 
differences and sex disparities in immune response. A thorough review of ISGs may 
identify certain genes of particular interest. Knockdown experiments may then be 
conducted to determine the requirement of certain ISGs in establishing the immune sex 
bias, and knock-in experiments may be conducted to determine their sufficiency.  
 
In addition to the handful of ISGs we have identified through literature review as being 
highly upregulated following viral infection, we are also interested in performing a non-
biased microarray screen of all ISGs to evaluate global differences in expression 
between sexes. We are particularly interested in assessing differential upregulation of 
ISGs encoded on the X chromosome. There are 77 identified ISGs encoded on the X 
chromosome in humans (Table 2).  It is possible that incomplete X inactivation in 
females results in increased expression of some or all of these X chromosome ISGs. If 
true, this may strongly impact immune regulation in humans and mice. Once a 
mechanism for sex disparities in immune responses is identified, we may be able to 
better understand the sex bias in infection and autoimmune disorders. 
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Future Experiments:  We have obtained some promising initial findings that demonstrate a reproducible sex 
difference in male and female primary cells following Type I IFN stimulation. Although 
we investigated only a handful of select ISGs, we have identified a strong sex 
dependent difference in upregulation in the interferon pathway. These findings deserve 
future follow up, and here we propose some additional experiments to validate and 
explore this difference in sensitivity of the Type I IFN pathway.  
 
Assess differential phosphorylation of murine IFNαβR signaling intermediates in vitro 
and ex vivo 
To further assess the difference in male and female IFNαβR responses, we propose to 
analyze the activation of signaling intermediates immediately downstream of the IFNα/β 
receptor.  We will focus on phosphorylation of intermediates such as STAT1, STAT2, 
STAT3, Tyk2, JAK1, and IRF9. The STAT1 pathway has been shown to be important in 
protection of the CNS from HSV infection [112-114], which may explain the high HSV 
brainstem titers we have observed in female mice compared to males. We plan to 
screen bone marrow derived macrophages, bone marrow derived dendritic cells, and 
murine embryonic fibroblasts for differential Type I IFN responses using a panel of 
interferons, including mouse IFN-α1, IFN-α4, IFN-α11, IFN-α13, and IFN-β. This will 
allow us to assess responses to Type I IFNs with high (IFN-β, IFN-α11), intermediate 
(IFN-α4, IFN-α13), and low (IFN-α1) activity [108]. In this assay, we will generate 
primary cells from male and female mice, stimulate with our Type I interferon panel for 
various amounts of time (5, 10, 20, 30, 60 min), then quantify the amount and 
 147
phosphorylation status of downstream signaling intermediates by flow cytometry or 
immunoblot. Stronger signaling in one sex may be possible if there exists a higher basal 
level of important signaling intermediates. Therefore, it will be important to assess the 
levels of total STAT1, STAT2, JAK1, etc in males and females as well as the 
phosphorylation status of each signaling intermediate. Enhanced male survival during 
HSV infection may be due to enhanced IFNαβR signaling. We expect that this approach 
will identify differential phosphorylation of signaling intermediates in male and female 
primary cells in response to Type I IFN stimulation and/or differential basal amounts of 
regulatory signaling molecules.  
 
Assess differential phosphorylation of human IFNαβR signaling intermediates in vitro 
and ex vivo 
The IFNαβR signaling pathway in humans is similar to that of mouse. Using phospho-
antibodies against the signaling intermediates STAT1, STAT2, JAK1, and TYK2, we will 
also probe the human Type I IFN pathway by flow or immunoblot. We will generate 
human monocyte derived macrophages from healthy male and female donors. PBMCs 
purified by Ficoll centrifugation will be plated on tissue culture treated plates and 
incubated for 1hr at 37oC, 5% CO2 to allow adherence of monocytes. Non-αdherent 
cells will be washed away, and the plates enriched for monocytes will be incubated in 
media supplemented with 50ng/mL hGM-CSF for 7 days. Media will be replaced on day 
3. Cells should be fully differentiated M1 macrophages on day 7 and ready for Type I 
IFN stimulation [115, 116]. We have an extensive panel of human interferons including 
human IFN-α1, IFN-α2, IFN-α5, IFN-α8, IFN-α10, and IFN-β1a. This panel includes 
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several low activity (IFN-α1, IFN-α2), intermediate activity (IFN-α5), and high activity 
(IFN-α8, IFN-α10, IFN-β1a) interferons with a broad range of antiviral activity tested 
against HSV, VSV, and SFV [117, 118]. After stimulation with different interferons for a 
variable amount of time (5, 10, 20, 30, 60 min), we will quantify the amount and 
phosphorylation status of downstream signaling intermediates by flow cytometry or 
immunoblot. We expect that this approach will identify differential phosphorylation of 
signaling intermediates in male and female primary cells in response to Type I IFN 
stimulation and will correlate with our initial mouse observations.  
 
Assess sensitivities of male and female MEFs to a panel of IFNs by protection from 
HSV cytopathic effect 
Any differences in IFNαβR signaling or differences in ISG gene transcription between 
male and female mice will manifest as differences in the antiviral, antiproliferative, and 
immunomodulatory effects in male and female cells. We are most interested in the 
antiviral role of Type I IFNs, so we plan on examining IFN induced resistance to viral 
cytopathic effect and IFN induced protection against viral growth. These experiments 
would allow us to determine whether differences in Type I IFN responses leads to a cell 
intrinsic resistance to viral challenge.  
 
Our working hypothesis is that male and female cells exhibit different sensitivities to 
Type I IFN, which manifests as a cell intrinsic difference in resistance to HSV viral 
challenge.  
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We would like to assess whether male and female cells are differentially sensitive to the 
development of the Type I IFN induced antiviral state. We will assay for antiviral state 
induction by modifying a bioassay developed for detection of interferon activity [119]. In 
this assay, we will use primary mouse MEFs that are highly susceptible to HSV 
cytopathic effect [120]. We will sacrifice a pregnant mouse at day 13.5 post coitum and 
harvest the uterine horns. Each embryo will be processed separately, and part of the 
embryo saved for sex genotyping. We will preincubate fully cultured MEFs with serial 
dilutions of IFN for 24 hours, followed by a viral challenge with 0.5 MOI HSV for 48 
hours. Cells will be stained with crystal violet to determine cell death. Unprotected MEFs 
will easily lift off the plate and not be stained by crystal violet. The dye can be 
solubilized with 70% methanol, and absorbance read using plate reader at 590nm. 
Using serial dilutions of a panel of Type I IFN, we can determine the amount of each 
IFN required to protect male and female MEFs from HSV cytopathic effect. We expect 
that males will be more sensitive to the effects of IFN, needing less IFN stimulation to 
become resistant to HSV.  
 
Assess permissiveness of male and female cells to HSV viral growth 
If male and female cells are differentially sensitive to the induction of an antiviral state 
by Type I IFN, it follows that they may be differentially permissive to HSV viral growth 
and replication. We will test this by performing HSV growth curves in male and female 
BMDMs, BMDCs, or MEFs in the presence and absence of Type I IFN. We will plate 
5x105 cells per well in a 12 well plate and harvest in duplicate. Following infection with a 
low MOI of 0.1 HSV, we will collect the culture supernatant at 6hr, 12hr, 24hr, 48hr, 72hr, 
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and 96hr post infection. We will determine viral loads in the supernatant using qPCR for 
the HSV thymidine kinase gene. Given our observations of male resistance to HSV and 
increased male global ISG levels, as well as increased HSV titer in female brainstems, 
we might expect to see virus replicate more readily in primary female cells.  This would 
be consistent with papers describing the importance of IFNα and the STAT1 pathway in 
limiting progression of HSV to the CNS [112, 121], limiting replication in the cornea 
[113], and controlling the acute replication of HSV [122].  
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Figures:  
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Figure 39: qRT-PCR of the interferon stimulated genes ISG56, ISG54, Osa1a, Mx-1, 
Viperin, and IRF7 
 BMDMs were generated from  n=5 male and n=5 female mice. Cells were stimulated 
with 1000U/mL IFN-β (top Figure) and 1000U/mL IFN-α (bottom Figure) for 24 hours, 
and qRT-PCR of ISGs performed. Comparisons were made by the comparative Ct 
method, with β-actin serving as the comparator. Data are presented as fold change 
relative to naïve unstimulated mice.  
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Figure 40: Effect of high, medium, and low affinity IFN stimulation of ISG expression 
 Mouse bone marrow derived macrophages were generated by long term culture in M-
CSF. BMDMs were stimulated with 1000U/mL (hi) or 200 U/mL (lo) dose of high affinity 
IFN-β, medium affinity IFN-α4, or low affinity IFN-α1 for 24 hours.  qRT-PCR of the 
interferon stimulated genes ISG15 (top panel) and ISG56 (bottom panel) in n=2 male 
and n=2 female mice was performed. Comparisons were made by the comparative Ct 
method, with β-actin serving as the comparator. Data are presented as fold change 
relative to naïve unstimulated mice. 
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Figure 41: Effect of IFN-α2A stimulation on male and female human MDMs 
 Higher expression of some ISGs in female macrophages compared to males following 
IFN-α2A stimulation. IFIT1, IRF7, ISG15, MX1, and OAS1 were more highly 
upregulated in female macrophages than males. Day 10 macrophages were stimulated 
by IFN-αA for 6 hours, and gene expression was measured by qPCR. Gene expression 
changes were normalized to beta-actin. The graphs show data for 2 females and 2 
males. The middle bar represents the mean. (Experiment performed by Carol Liu)  
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Table 2. ISGs located on the X chromosome. 
 A database of IFN regulated genes (Inferferome [123]) was cross referenced against a 
genomics database. Interferon regulated genes that are located on the X chromosome 
were identified and categorized as above.  (Table compiled by Carol Liu)  
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APPENDIX 4: Sex Differences in HSV infection 
Introduction:  
There are well established reports of sex differences in the outcome of a variety of viral 
infections. HIV infection (without antiretroviral therapy) is associated with shorter 
survival in women than men [124]. There are reported differences in viral 
encephalomyocarditis [125], vesicular stomatitis [126], and coxsackie virus B3 infection 
[127]. Females have twice the risk of severe congenital CMV meningitis compared to 
males, and the memory T helper response to CMV is higher in females than males [128]. 
There exists a wide body of literature setting precedence for a large and clinically 
significant difference in outcome between males and females in the setting of a variety 
of viral infections.  
 
Sex differences in HSV infection in humans 
There are two types of herpes simplex virus (HSV) that infect humans. HSV-1 is 
typically acquired during childhood, usually mild, and produces most cold sores. HSV-2 
is primarily acquired as teenagers or adults as a sexually transmitted infection and 
produces most genital herpes. However, there is overlap, and both types can infect oral 
and genital areas. There is some sex difference in distribution of HSV-2 with the virus 
more common in women than men [129, 130], however since it is a sexually transmitted 
infection, acquisition depends strongly on anatomy, and this may not indicate an 
intrinsic difference in susceptibility to HSV between the sexes. There are, however, 
reports of increased incidence of HSV-2 meningitis with females accounting for 75-80% 
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of cases [131-133], which may suggest a real increased susceptibility to HSV in human 
females, which proves consistent with our findings in mice.  
 
HSV is a neurotropic and neuroinvasive virus that establishes latency in the cell bodies 
of neurons in the dorsal root ganglia. HSV infection in humans is characterized by 
lifelong latency with sporadic reactivation. Immune system control is the major factor 
affecting reactivation, and both HSV-1 and HSV-2 infection can be severe in infants with 
limited immune response and individuals with compromised immune systems due to 
AIDS, cancer, severe burns, or immunosuppressant medication.  
 
Sex differences in HSV infection in mice 
Our lab has previously reported a striking difference in mortality between C57BL/6 mice 
of different sexes following infection with several systemic DNA viruses, including HSV, 
MCMV, and VV [105]. This difference in mortality was particularly striking with systemic 
(intraperitoneal) HSV-1 infection, with a 28 fold higher LD50 in males compared to 
females [105]. Female mice also demonstrated 100 fold higher HSV brainstem titers 
than males day 6 post infection. However there were no sex differences in serum 
proinflammatory cytokines (IL-1β, IL-2, IFNγ, and TNFα), suggesting that mortality in 
females was not due to an overwhelming inflammatory response. These observations 
suggest that there exist differences in viral defense, viral transit, and/or viral replication 
in the CNS between males and females that manifests as a very large difference in 
mortality and brainstem titers.  
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Properties of Neuroinvasive HSV  
HSV-1 is thought to gain access to the CNS through the adrenal glands after peripheral 
infection [134]. Adrenalectomy prior to infection proved that the virus reached the spinal 
cord via the adrenals [134]. Virus can be isolated from the adrenal glands as early as 1 
hr post infection [135], and by day 3 virus can be isolated from the brainstem of mice. 
Additionally, there has been reported extensive virus replication in the adrenal cortex 
with some involvement of the medulla [134, 136].  These reports all implicate the 
adrenal glands as the major gateway for HSV entry into the CNS.  
 
Neuroinvasive HSV strains were shown to replicate to high titers in adrenal glands and 
ovaries, migrate to spinal cord, then migrate to the brain. Conversely, nonpathogenic 
HSV strains were shown not to replicate in adrenal glands [137] or had only transient 
detection in adrenal glands [138]. However, both neuroinvasive and noninvasive 
variants are highly neuropathic after direct intracranial injection [139].  
 
We hypothesize that there is a difference in the ability of HSV to replicate in or traverse 
the adrenal glands in male and female mice. The difference may be due to poor 
localization or homing of HSV to the adrenals in male mice, poorer replication in the 
adrenals in males, better peripheral control by the immune system in males, or poor 
virus crossing from the adrenals to the spinal cord through peripheral nerves in males.  
 
Although our intraperitoneal mouse model does not accurately reflect the route of HSV 
infection in humans, the information obtained from this study may prove valuable in 
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understanding sex differences in immune control or neural permissiveness. This has 
important clinical significance since there is evidence of a sex bias in the rate of HSV 
meningitis [131-133]. A greater intrinsic ability to enter the female brain or increased 
permissiveness of neural cells to viral growth in females may be identified in this mouse 
model. Outside of HSV virology, this work on immune control and CNS entry may be 
pertinent to the study of multiple sclerosis, which also has a strong female 
predominance, with CNS access a major limitation.  
 
Experimental Methods:  
Mice 
Female C57BL/6 mice were ordered from NCI (Frederick, MD) at 6-7 weeks old.  They 
were housed in a specific pathogen free facility (4th Floor CSRB) at Washington 
University in St. Louis until they reached 8 weeks of age, when they were used for 
majority of the experiments.  
 
Four Core Genotype Mice breeding stock were originally ordered from Jackson Labs 
(Bar Harbor, Maine). They were then bred on site in a specific pathogen free facility 
(SRF) at Washington University in St. Louis. Mice were individually genotyped to 
determine their sex chromosome complement. Mice were used between 8-12 weeks of 
age, and transferred to 4th Floor CSRB for infection.   
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Virus and Intracranial Infection 
HSV strain 17 was a kind gift from David Leib (Dartmouth Medical School, Lebanon NH). 
HSV was propagated in and titered using Vero cells (ATCC) following established 
protocols [140]. HSV was diluted in sterile DMEM for intraperitoneal infections, or 
diluted in sterile PBS for intracranial infections.  
 
For intracranial infections, mice were heavily anesthetized with ketamine/xylazine short 
acting sedative. Diluted HSV was drawn up into a 29.5 gauge insulin syringe. The 
syringe needle was inserted through a plastic stopper cut at a height to allow adequate 
penetration of about 4mm into the cortex through the skull, while preventing inserting 
too deep. Mice were injected with a 10uL volume of diluted HSV into the cortex at the 
midline. Control mice were injected with an equal volume of sterile PBS.  
 
Antibiotic Treatment  
Some cohorts of mice were put on long term trimethoprim-sulfamethoxazole treatment 
for certain experiments. Sulfamethoxazole and Trimethroprim oral suspension, USP 
200mg sulfamethoxazole / 40 mg trimethoprim per 5mL, Grape flavor was purchased 
from Hi-Tech Pharmacal Co, Inc (Amityville, NY). Approximately ½ tablespoon of well 
shaken antibiotic suspension was added to the drinking water. New antibiotic was 
added each time the water was changed, on a schedule of twice per week water 
changes over a course of 8 week treatment. Antibiotic treatment was continued as 
described after HSV infection, until mice were sacrificed 28 days p.i.  
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Radiation mediated Bone Marrow Transplant  
Bone marrow transplants were performed with female recipients and male or female 
bone marrow donors. Recipient 5 week old female Ly5.1 mice were placed on antibiotic 
water for 1 week prior to gamma irradiation at 6 weeks old. Food was removed the night 
before irradiation. The recipients were irradiated with 950 rad of gamma radiation over 
the course of about 20 min. Bone marrow cells were prepared from male or female 
Ly5.2 donors. Donors were culled with CO2, femurs and tibias were removed, and bone 
marrow harvested by centrifugation. Cells were diluted in sterile HBSS, and 2x107 donor 
bone marrow cells were retroorbitally injected per recipient mouse. Recipients were 
maintained on Trimethoprim-sulfamethoxazole in the drinking water for 8 weeks. 
Peripheral blood of each bone marrow chimera and controls were analyzed week 7 post 
irradiation. Mice were bled via retroorbital bleed with the contralateral eye, and 
peripheral blood was confirmed as having >97% donor reconstitution in the T cell, B cell, 
and myeloid cell compartments. At 8 weeks post radiation (recipients are 14 weeks old), 
mice were infected with 1x107 pfu HSV intraperitoneally. Survival and weight loss was 
monitored and antibiotic water was maintained out to 28 days post infection.  
 
Busulfan mediated Bone Marrow Transplant  
Bone marrow transplants were performed with female recipients and male or female 
bone marrow donors using the chemotherapy drug Busulfan, to avoid irradiating mice 
and avoid long term antibiotic treatment. 6 week old Ly5.1 recipient B6 females were 
toe tagged and individually weighed prior to buslfan administration. Busulfan is made 
fresh each day and administered based on the individual mouse’s weight. To make a 2 
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mg/mL busulfan suspension, 100 mg of busulfan (Sigma B-2635) is weighed out and 
added to 1mL of DMSO preincubated in a 55oC water bath. Once dissolved, the 
busulfan-DMSO mixture is added to 49 mL of sterile PBS preincubated at 55oC. The 
solution is kept warm in a beaker of 55oC water en route to the mouse facility. 50 mg/kg 
(or 40 mg/kg) of busulfan is taken up in a 29.5 gauge insulin syringe and allowed to cool 
before injecting into the mouse intraperitoneally. First dose is given 3 days prior to 
transplant, followed by a second dose (50 mg/kg or 40 mg/kg) 2 days prior to transplant. 
Mice are allowed 1 day of rest on the day immediately prior to transplant.  
 
On the day of bone marrow transplant, donor male or female Ly5.2 mice were sacrificed, 
femurs and tibias removed, and bone marrow harvested by centrifugation. Cells were 
diluted in sterile HBSS, and 2x107 donor bone marrow cells were retroorbitally injected 
per recipient mouse. Recipients were allowed to reconstitute their hematopoietic 
compartment for 8 weeks, without antibiotic treatment. Peripheral blood of each bone 
marrow chimera and controls were analyzed week 7 post-transplant. Mice were bled via 
retroorbital bleed with the contralateral eye, and peripheral blood was confirmed as 
having >97% donor myeloid cells, but only >80% reconstitution in the B cell 
compartment, and only >75% reconstitution in the T cell compartment. At 8 weeks post-
transplant (recipients are 14 weeks old), mice were infected with 1x107 pfu or 3x107 
HSV intraperitoneally. Survival and weight loss was monitored out to 28 days post 
infection. Controls were not busulfan treated, not transplanted, and had no antibiotic 
exposure.  
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Results: 
HSV entrance into the CNS is the limiting step in systemic HSV model  
We sought to answer whether a sex dependent difference in blood brain barrier 
permeability or entrance to brain exists in this HSV model; and whether the sex 
difference is due to cells of the hematopoetic compartment. To determine whether 
entrance into the brain is the limiting step in our model, we infected male and female 
mice with HSV directly into the cortex via the intracranial route of infection. Interestingly, 
there is no difference in survival between males and females when infected with 100 pfu 
HSV intracranially (Fig 42). This suggests that the virus is equally virulent in both sexes 
when it arrives at its final destination in the brain, and rules out the possibility that virus 
is cleared faster in the brain or replicates poorer in the brain of males compared to 
females. This finding implicates a step prior to entry to the brain as being a limiting step 
in males.  
 
Murine Survival Differences during Systemic HSV infection is not dependent on 
Sex Chromosome Complement  
Female mice are more susceptible than male mice to a variety of DNA viruses, including 
HSV, CPX, and MCMV [105]. Data in ovarectomized females, castrated males, and 
castrated males given exogenous estrogen demonstrates that less than half of the 
survival difference between males and females can be attributed to the presence of 
estrogens [105]. Androgens have no effect on survival. Therefore the majority of the 
almost 80 fold difference is susceptibility due to a hormone independent effect. We 
hypothesized that part of the female susceptibility to viral infection is due to sex 
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chromosome complement. The X chromosome contains a number of genes important 
for immune function, including TLR7, TLR8, CD40L, FOXP3, BTK, IL-2 receptor 
common gamma chain, and many other genes with direct and indirect roles in immune 
function [141].  Additionally, there is a disproportionately high number of microRNAs 
located on the X chromosome compared to the autosomes, while there are no miRNAs 
present on the Y chromosome [142]. Processes such as skewing of X chromosome 
inactivation and the unequal expression of X chromosome microRNAs may be partially 
responsible for sex differences in autoimmunity, immunity, and cancer. Female 
susceptibility to HSV and other viral infections may be due in part to their XX sex 
chromosome complement.  
 
To test whether sex chromosome complement affects murine survival after HSV 
infection, we used the Four Core Genotype (FCG) mouse model. The FCG mice have a 
deletion of the testes determining gene Sry from the Y chromosome, and an insertion of 
an Sry transgene onto an autosome [143].  This allows production of four genotypes, 
XX(Sry-) Females, XY-(Sry-) Females, XX (Sry+) Males, and XY-(Sry+) Males. Analysis 
using this mouse model allows one to draw conclusions based on X gene dosage, Y 
gene dosage, and X gene imprinting independent of gonadal sex and gonadal 
hormones.  We monitored survival over 28 days with 3x107 pfu HSV/mouse, weight loss, 
and brainstem HSV titers.  
 
We had expected that mice with the XX chromosome complement (XX F, XX Sry+ M) 
would have been more susceptible than mice with the XY chromosome complement, if 
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susceptibility were due to a gene localized on the X chromosome. However, in our 
experiments with FCG mice infected with 1x107 pfu HSV (Fig 43A) or 3x107 pfu HSV 
(Fig 43B), we did not see an increased susceptibility in XX bearing mice. In female mice, 
we paradoxically observed an increased susceptibility in XY- females compared to XX 
females (Fig 43). We saw no statistical difference in susceptibility between XX (Sry+) 
males and XY- (Sry+) males (Fig 43). Additionally, the large survival difference we 
usually see between normal XX Females and XY Males was greatly reduced in these 
mice. This may indicate a greater underlying difference in response between mice 
obtained from Jackson Labs (FCG) and mice obtained from NCI (wildtype B6) that will 
need to be further evaluated.  
 
The unexpected reversal of susceptibility with the XX F and XY-F may suggest that sex 
chromosome complement is not the main driving factor for the original sex susceptibility 
difference. Alternatively, the effect of hormones may be masking any effect of sex 
chromosomes, as the mice used in these experiments had not been gonadectomized 
prior to puberty.  
 
Determine the sex dependence in the hematopoietic compartment using male-
female bone marrow chimeric mice 
To confirm a role of the sex chromosome complement in protection against viral 
challenge, we generated bone marrow chimeric mice from Ly5.1 male or female mice 
reconstituted into irradiated Ly5.2 recipients, followed by challenge with 3x107 pfu HSV. 
If the sex difference in survival is due to the sex chromosome complement or differential 
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responsiveness of male and female hematopoetic cells, we would expect greater 
mortality in chimeric mice generated with female bone marrow compared to those 
generated with male bone marrow. We hypothesized that the sex susceptibility 
phenotype was due to a cell intrinsic difference in the Type I IFN response of the 
hematopoietic compartment. If so, male resistance and female susceptibility to HSV can 
be transferred to irradiated recipients by transfer of bone marrow.  
 
To determine whether the sex differences between male and female mice are 
dependent on the hematopoietic compartment, we studied male/female bone marrow 
chimeric mice. Bone marrow from wt Ly5.1 female or male mice was used to 
reconstitute irradiated Ly5.2 male recipients. Chimerism was evaluated by flow 
cytometry of peripheral mononuclear cells at 6 weeks post reconstitution. Systemic 
infection with 1x107 pfu HSV was performed at 8 weeks post reconstitution. We 
expected that reconstitution with male bone marrow would rescue the susceptibility of 
female mice, and conversely female bone marrow would increase mortality in male mice 
following HSV infection. Preliminary data from an experiment where male bone marrow 
was reconstituted into female mice showed promising results with 7/7 mice surviving a 
3x107 pfu dose of HSV, a dose at which about 20% of female mice normally survive 
(data not shown).  
 
In a follow-up experiment, recipient female mice were irradiated with 950 rad, then given 
a bone marrow transplant from male or female donors. They were then given 
trimethoprim-sulfamethoxazole antibiotic in the drinking water for 8 weeks prior to 
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infection with 1x107 pfu HSV. A cohort of control females were age matched, but not 
irradiated, and not given antibiotic water. Interestingly, both the Male BM  Female 
recipient and Female BM Female recipient groups were highly resistant to HSV 
infection (Fig 44). However, the age matched female controls had about 80% lethality, 
consistent with previous survival data for female mice. The fact that the Female BM  
Female recipient group did not phenocopy Female controls, but rather the Male BM  
Female recipient group, suggests that there is something in bone marrow chimera 
procedure itself that is making these mice unexpectedly resistant to HSV. The two main 
differences between the experimental groups and the control group are exposure to 
radiation and long term antibiotic use.  
 
Determine the effect of long term antibiotic use on HSV susceptibility  
To test whether exposure to antibiotics affects HSV susceptibility, we treated B6 
females with trimethoprim-sulfamethoxazole in the drinking water for 8 weeks, or age 
matched controls with no antibiotic exposure, then infected mice with 1x107 pfu HSV. 
The antibiotic treated mice appeared to be protected from HSV with higher survival and 
lost less weight than controls (Fig 45). However the survival in the control group was 
also higher than expected in this experiment, so definitive conclusions unfortunately 
cannot be drawn, and this experiment needs to be repeated. 
The bone marrow chimera experiment was repeated a second time, with female B6 
mice irradiated with 950 rad, then given a bone marrow transplant from male or female 
donors. This time, both the bone marrow female recipients and the age matched control 
female mice were given antibiotics in the drinking water for 8 weeks before HSV 
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infection. The results from this experiment showed that all three groups were protected 
from HSV (Fig 46), and notably there was no statistical difference between mice given 
male bone marrow or female bone marrow. This may suggest that exposure to long 
term antibiotics alone may improve survival from HSV viral infection.  
One hypothesis is that the existing female gut flora makes mice more susceptible to 
certain infections including HSV, compared to males. Antibiotic treatment may be 
altering commensal gut flora composition by converting the female microbiome to a 
more “male” or more protective microbiome. This remains to be tested.  An alternative 
explanation is that older mice are more resistant against acute HSV infection. We have 
previously infected female or male B6 mice at 8 weeks old in our initial characterization 
of the sex difference during acute infection. However, mice used in the radiation 
experiments were irradiated at 6 weeks old and infected at 14 weeks old. Mice in the 
antibiotic experiments were treated starting at 6 weeks old and infected at 14 weeks old. 
However, we routinely have controls that are aged along with the radiated mice that 
show the expected high mortality, so we consider resistance secondary to aging to be 
less likely.  
Determine the effect of radiation using non irradiative busulfan BMT 
Additionally, we wanted to test whether radiation accounted for the initial result seen in 
Fig 44. To test whether radiation alone was responsible for the unexpected protection in 
both the Male BM Female recipient and Female BM  Female recipient cohorts, we 
decided to perform bone marrow chimeras using a non-irradiative method. Busulfan is a 
chemotherapy drug used to treat leukemias, lymphomas, and other myeloproliferative 
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disorders, and also routinely as a conditioning agent prior to bone marrow 
transplantation in humans and mice [144]. Female recipients were given a split dose of 
Busulfan (100 mg/kg) to ablate the stem cell niche in bone marrow. On day 4, the mice 
were given a bone marrow transplant from female donors. They were then allowed to 
reconstitute for 8-10 weeks with no antibiotic treatment prior to infection with 1x107 pfu 
HSV.  The female mice given female bone marrow appears to be similarly susceptible 
to female controls (Fig 47A). Unfortunately the controls showed much higher survival 
than expected so the dynamic range of this experiment is limited. Since these age-
matched controls did not receive busulfan, radiation, or antibiotics, we would have 
expected them to match the 80% lethality rate of previous experiments in B6 females, 
instead we observed only 20% lethality. In this experiment, however, we observed a 
high level of toxicity at the 100 mg/kg split dose of busulfan, with several mice dying 
following the second dose of busulfan. The surviving mice were well reconstituted with 
donor marrow, with 85% T cells, 92% B cells, and >97% myeloid cells donor derived.  
 
This busulfan bone marrow chimera experiment was repeated with a lower dose of 
busulfan (80 mg/kg split dose) and a higher innoculum of HSV (3x107 pfu) to obtain 
more reliable and reproducible survival data with fewer deaths due to busulfan.  We saw 
minimal protective effect with male BM that was not significant with the number of mice 
used (Fig 47B).  However, there was a trend of increased survival in the male BM 
recipients compared to female controls.  At the lower dose of busulfan, we did not 
observe any deaths due to busulfan toxicity. However, there is some mixed chimerism 8 
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weeks post bone marrow transplant, with 75% T cells, 80% B cells, and >97% myeloid 
cells donor derived.  
 Discussion:  This recent work has opened up several new avenues of investigation. The finding that 
HSV is equally virulent in males and females when given intracranially strongly 
suggests that the block is downstream of entering the CNS, possibly at the level of the 
adrenal glands. The experiments with the Four Core Genotype mice imply that sex 
chromosome complement is probably not the driving factor for female susceptibility, but 
this must be investigated in a cleaner gonadectomized model. Other additional 
experiments have introduced the gut microbiome and antibiotic treatment as possible 
factors involved in resistance and susceptibility to acute HSV. Finally, busulfan treated 
bone marrow chimeras evaluated the hypothesis that protection is at least partially due 
to components of the hematopoietic system.  
 
HSV enters CNS through adrenal glands 
Our results with intracranial infections of male and female mice clearly demonstrate that 
HSV is equally lethal when CNS entry is bypassed (Fig 42), whereas a very significant 
sex difference exists when virus is given intraperitoneally [145]. Via intraperitoneal 
infection the sex difference in CNS entry is demonstrated by the greatly increased 
brainstem titers in females compared to males [105]. According to extensive literature 
research, HSV-1 is thought to gain access to the CNS through the adrenal glands after 
peripheral infection. Via all peripheral routes of infection (footpad, intranasal, 
intraperitoneal, intravenous), virus appears to spread preferentially to adrenals and 
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ovaries [146]. Adrenalectomy prior to infection proved that virus reaches the spinal cord 
through the adrenals [134]. Virus can be isolated from the adrenal glands as early as 1 
hour post infection [135], and there is extensive virus replication in the adrenal cortex 
with some involvement of the medulla after around 1 day post infection [134]. By day 2, 
virus can be detected in the lower thoracic spinal cord, and virus can be isolated from 
the brainstem by day 3, indicating a quick progression to the CNS though an adrenal 
gland entry.  
 
There are neuroinvasive strains of HSV and noninvasive strains of HSV. We expected 
that by identifying their differences, we would be able to identify what regulates HSV 
entry into the CNS. Neuroinvasive HSV strains were shown to replicate to high titers in 
adrenal glands and ovaries (testes are not colonized), migrate to spinal cord, then 
migrate to the brain [146]. Conversely, nonpathogenic HSV strains were shown not to 
replicate in adrenal glands [137] or had only transient detection in adrenal glands [138]. 
However, both neuroinvasive and noninvasive variants are highly neuropathic after 
direct intracranial injection [139], paralleling our intracranial infection results between 
males and females. We hypothesize that there is a difference in the ability of HSV to 
replicate in or traverse the adrenal glands in male and female mice.  
 
The Adrenal Medulla  
The adrenal medulla is of ectodermal origin, and derives from neural crest cells that 
migrated during embryonic development. The medulla is highly innervated with a very 
rich nerve supply. A large proportion of fibers projecting to adrenal gland are destined to 
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innervate chromaffin cells, which are considered modified post-ganglionic 
neuroendocrine cells. Importantly, chromaffin cells are innervated by preganglionic 
neurons (not postganglionic neurons) that synapse in the medulla to directly innervate 
the chromaffin cells. There are no intermediate cells between the adrenal glands and 
CNS, indicating that this is a very direct pathway into the CNS.  
 
The adrenal cortex mainly produces cortisol, aldosterone, and androgens, while the 
medulla chiefly produces epinephrine and norepinephrine. In contrast to the direct 
innervation of the medulla, the cortex is regulated by neuroendocrine hormones 
secreted from the pituitary gland which are under the control of the hypothalamus, as 
well as by the renin-angiotensin system.  
 
Necropsy reports after acute HSV infection implicates adrenal glands 
The hypothesis that HSV enters through the adrenals is consistent with our previous 
necropsy reports on mice at 6 days pi with 3x107 pfu HSV (Dr Suellen Greco). Three 
independent reports indicated that there was extensive adrenal necrosis involving both 
the cortex and medulla, with moderate to severe lesions in the medulla and mild to 
moderate lesions in the cortex. There was also necrosis of peripheral nerves noted in 
the vicinity of the adrenal and kidney. Other notable features included presence of 
intranuclear inclusion bodies, centrilobar hepatocellular degeneration, lymphoid 
necrosis in the white pulp of spleen and lymph nodes, leucopenia, and lymphopenia. 
There was little inflammatory infiltrate noted in the organs of these mice; such changes 
in inflammatory cell populations were noted primarily in the spleen and lymph nodes. 
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Females showed elevations in transaminases and there were particularly notable 
differences in the medullary necrosis, with often severe lesions in the females and none 
in the males. Illness in these mice is thought to be certainly related to sequelae of 
adrenal necrosis, and may have been further complicated by hepatocellular 
degeneration. These necropsy reports strongly implicate the adrenal medulla in the sex 
differences in viral susceptibility, given the extensive necrosis seen in females 
compared to males.  
 
Sex differences in adrenal gland morphology 
Given that this information suggested a block at the level of the adrenal glands, we 
investigated the obvious differences between male and female adrenal glands. There 
are some dramatic anatomic differences. Notably, female adrenal glands are much 
larger (size and weight) than age matched males. There is an increased volume of both 
the adrenal cortex and medulla. At 9 weeks old, female adrenal glands are about two 
fold heavier than males [147]. Females also have a unique X zone in the adrenal cortex 
that is not present in males at the age ranges used in our experiments. The X zone is 
thought to be a remnant of the fetal adrenal zone, and degenerates after puberty in 
male mice, whereas the X zone persists until first pregnancy in female mice.  
 
This literature review and preliminary work suggests a block in HSV access to the CNS 
in males at the level of the adrenal glands. This may be due to poor localization of HSV 
to the adrenals in male mice, poorer replication in adrenals in male mice, better 
peripheral control by the immune system in male mice, or poorer virus crossing from the 
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adrenals to the spinal cord through peripheral nerves in males. This model will need 
further study to fully evaluate these hypotheses.  
 
Effect of antibiotic treatment on HSV mortality 
Although we have only very preliminary evidence, our experiments involving antibiotic 
treatment suggest that there may be some protective effect of antibiotics against HSV 
mortality. The parallel observation that C57BL/6 mice purchased from NCI have a very 
large sex phenotype between males and females, while Four Core Genotype mice 
obtained through Jackson Labs does not replicate this sex difference phenotype 
between XX Females and XY Males, also supports the idea that some gut microbiome 
differences may be playing a role. Although clearly there are genetic differences 
between C57BL/6 mice and Four Core Genotype mice that have yet to be ruled out, 
these two lines of evidence may suggest that male and female murine gut flora would 
also be of interest for future study as mice bred in different facilities would theoretically 
have distinct microbiome compartments. If this holds true under further testing, then we 
might hypothesize that female gut flora is distinct from male gut flora, and female gut 
flora somehow allows susceptibility to HSV, while male gut flora is protective. It is 
possible that antibiotic treatment in previous experiments converts the female 
microbiome to a more “male” microbiome, although these suppositions have yet to be 
substantiated and require extensive further investigation.  
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Future Experiments:  A substantial amount of preliminary work has been completed in the investigation of the 
sex difference phenotype following systemic HSV infection, but it has raised more 
questions than it has solved. This work has led us to several important avenues, 
including the possibility of a barrier to CNS entry at the level of the adrenal glands, a 
possible dependence on antibiotic treatment or normal flora variation in mice housed in 
different facilities, as well as the possible contribution of sex chromosomes. Additional 
experiments to address these questions should be completed in the future. Here we 
have outlined a series of experiments designed to follow up on our preliminary findings.  
 
Adrenal gland titers in males and females 
Adrenal glands, spleen, liver, ovaries/testes, spinal cord, brainstem, and cortex have 
already been harvested from male and female mice infected with 1x107 pfu HSV ip. We 
have frozen organs from 5 males and 5 females each on day 1, day 3, and day 6 post 
infection. We would expect to see higher adrenal titers in females than in males. We 
also expect virus to enter the CNS earlier in females and reach a higher titer in spinal 
cord, brainstem, and cortex in females. The frozen organs are ready to be tittered.  
 
Adrenal gland histology in males and females  
Adrenal glands from males and females infected with 3x107 pfu HSV should be 
obtained for H&E sections at day 1 and/or day 3 pi. Adrenal gland sections would be 
assessed for presence of lesions or intranuclear inclusion bodies, necrosis of cortex and 
medulla, necrosis of peripheral nerves, and presence of inflammatory infiltrate. We 
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expect more medullary destruction in females, with possible necrosis of peripheral 
nerves. We expect very mild lesions if any in males.  
 
Adrenalectomy prior to acute HSV infection  
Plans should be made to adrenalectomize male and female mice 4 weeks prior to 
infection with 3x107 pfu HSV. Mice will be anesthetized with a ketamine/xylazene short 
acting sedative and surgically prepared. Adrenal glands will be bilaterally removed using 
a 1.5 cm dorsal midline incision over the 13th rib. Adrenal glands located in the fat pad 
that covers the cranial portion of the kidney will be removed. Incisions will be closed 
with absorbable suture, and skin incisions closed with stainless steel wound clips. 
Staples will be removed 7-10 days post-operatively. Adrenalectomized animals will be 
maintained with 0.9% sodium chloride drinking water, and may require a corticosteroid 
added to drinking supplement to increase survivability. Mice will be allowed 4-6 weeks 
to recover from surgery prior to infection with HSV. Adrenalectomized mice will be 
infected and monitored for survival and weight loss. Other cohorts will be sacrificed at 
specific times post infection to assess organ titers. We expect adrenalectomy to be 
protective in both sexes. Adrenalectomy may prevent HSV entry into the CNS as 
assessed by viral plaque assay of spinal cord, brainstem, and cortex.  
 Repeat 8 week antibiotic experiment  
Plans should be made to repeat the previous antibiotic experiment, using a cohort of 10 
mice placed on trimethoprim-sulfamethoxazole in drinking water for 8 weeks prior to 
infection with 3x107 pfu HSV (higher dose). Control cohort of 10 mice will be on normal 
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water, housed in same facility, and age matched for 8 weeks prior to infection. This 
experiment will confirm whether antibiotics alone are protective.  
 
Compare Jackson mice vs NCI mice (males and females) 
To compare mice housed in different facilities, we will obtain 10 female/5 male C57Bl/6 
mice from NCI (normal vendor for wildtype B6 mice) and 10 female/5 male C57Bl/6 
mice from Jackson Labs (original vendor for Four Core Genotype mice). We will infect 
these mice at 8 weeks old with 3x107 pfu HSV. We have consistently seen a very 
dramatic difference in survival between males and females from NCI. This experiment 
will confirm whether the survival difference between XX F and XY M are minimized in 
Jackson mice, as suggested by the preliminary Four Core Genotype mice survival data. 
If so, this may point to the gut microbiome as a possible contributor to the observed sex 
difference in male and female B6 mice from NCI.  
 
Ovariectomize and castrate Four Core Genotype mice prior to HSV infection  
To further evaluate the effect of sex chromosomes in the absence of hormonal 
influences, we will castrate males and ovariectomize females prior to HSV infection. 
Male mice (XX M, XY M) will be castrated at 3 weeks old, prior to onset of puberty. Mice 
will be anesthetized with a ketamine/xylazene short acting sedative and surgically 
prepared. A midline incision will be made in the scrotum, then an incision in the tunica 
albuginea of the first testicle. The testes, vas deferens, and attached testicular fat will be 
pulled out of the incision. The blood vessels supplying the testes will be cauterized, and 
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testes and vas deferens severed. The procedure will be repeated on the contralateral 
testicle. The scrotum incision will be closed using sterile tissue glue.  
Female mice (XX F, XY F) will be ovariectomized at 3 weeks old, prior to onset of 
puberty. Females will also be anesthetized with ketamine/xylazene and prepared under 
sterile operating conditions. A dorsal midline skin incision will be made caudal to the 
posterior border of the ribs. The peritoneum will be cut to enter the abdominal cavity. 
The ovary and periovarian fat will be lifted out, and the fallopian tube will be clamped. 
The ovary is removed by cutting above the clamped area, and the blood vessels will be 
cauterized. The uterine horn is returned into the abdomen, and the peritoneum closed 
with absorbable suture. The skin incision is closed using wound clips. The procedure is 
repeated on the contralateral side.  
Mice will be followed for post-operative care and watched for signs of dehydration, 
weight loss, and proper wound healing. Analgesics will be used post operatively as 
needed. Wound clips will be removed 1 week after surgery. At 8 weeks old, male and 
female mice will be infected with 3x107 pfu HSV and monitored for survival and weight 
loss. This experiment will determine if there is any sex chromosome effect in absence of 
any masking effect due to hormones.  
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Figures:   
 
Figure 42: Male and Female B6 mice are equally susceptible to HSV via direct 
intracranial infection 
 
B6 males (blue line) and B6 females (red line) were infected with 100 pfu HSV 
intracranially. Mice were followed for survival out to 28 days post infection. There is no 
statistical difference between survival after intracranial infection in male and female 
mice.  
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Figure 43: XX sex chromosome complement does not increase HSV susceptibility  
 Four Core Genotype mice were infected with (A) 1e7 pfu HSV  or (B) 3e7 pfu HSV 
intraperitoneally. XX Female (red solid), XY Female (red dashed), XX male (blue 
dashed), XY Male (blue solid). Note that there is no statistical difference between Four 
Core Genotype XX Females (red solid) and XY Males (blue solid) at either dose, 
contrary to the large sex difference seen in C57BL/6 mice obtained from NCI. There 
also is no increased susceptibility in XX bearing mice, contrary to expectations.  
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Figure 44: Irradiated mice on antibiotic treatment are resistant to systemic HSV 
infection  
Recipient female Ly5.1 mice were irradiated with 950 rad, then given bone marrow from 
male (blue dashed) or female (red dashed) Ly5.2 donors. Recipients were given 
Trimethoprim-sulfamethoxazole in the drinking water for 8 weeks prior to infection with 
1e7 pfu HSV intraperitoneally. Control females were age matched, but not irradiated, 
and not given antibiotic water (black solid). Note that Female BM into Female recipient 
mice unexpectedly does not phenocopy nonirradiated, non antibiotic treated Female 
controls.  
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Figure 45: Long term Antibiotic treatment maybe protective against systemic HSV 
infection  
 
B6 females were treated with trimethoprim-sulfamethoxazole in the drinking water for 8 
weeks (blue) or left untreated (black), then infected with 1e7 pfu HSV intraperitoneally. 
This may suggest some protective effect due to long term antibiotic treatment. This 
should be repeated.  
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Figure 46: Irradiated mice on antibiotic treatment are resistant to HSV; non-irradiated 
controls on antibiotic treatment are also resistant to HSV  
 Recipient female Ly5.1 mice were irradiated with 950 rad, then given bone marrow from 
male (blue dashed) or female (red dashed) Ly5.2 donors. Recipients were given 
Trimethoprim-sulfamethoxazole in the drinking water for 8 weeks prior to infection with 
1e7 pfu HSV intraperitoneally. Control females were age matched and also given 
antibiotic water, but not irradiated (black dashed). Compare to Figure 44, where non-
irradiated controls were not given antibiotic water. All groups exposed to long term 
antibiotic treatment are highly resistant to systemic HSV in this model. 
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Figure 47: Effect of Busulfan mediated bone marrow transplant on HSV susceptibility  
 (A) Recipient female Ly5.1 mice were given 100 mg/kg busulfan split dose (50 mg/kg 
day 1, 50 mg/kg day 2), rested on day 3, and transplanted with bone marrow from 
female Ly5.2 donors on day 4. Mice were allowed to reconstitute for 8 weeks with no 
antibiotic treatment, then infected with 1e7 pfu HSV intraperitoneally. (B) Same protocol 
was followed, except recipient female mice were given 80 mg/kg busulfan split dose (40 
mg/kg day 1, 40 mg/kg day 2), and following 8 weeks of reconstitution, mice were 
infected with 3e7 pfu HSV intraperitoneally. In both experiments, controls were not 
busulfan treated and not transplanted, and had no antibiotic exposure. 
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